Effects of maternal high fat diet and pharmacological intervention on the developmental origins of metabolic &amp; cardiovascular disease by Elahi, Maqsood M.
University of Southampton Research Repository
ePrints Soton
Copyright © and Moral Rights for this thesis are retained by the author and/or other 
copyright owners. A copy can be downloaded for personal non-commercial 
research or study, without prior permission or charge. This thesis cannot be 
reproduced or quoted extensively from without first obtaining permission in writing 
from the copyright holder/s. The content must not be changed in any way or sold 
commercially in any format or medium without the formal permission of the 
copyright holders.
  
 When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given e.g.
AUTHOR (year of submission) "Full thesis title", University of Southampton, name 
of the University School or Department, PhD Thesis, pagination
http://eprints.soton.ac.uk 
 
  
 
 
 
Effects of Maternal High Fat Diet and 
Pharmacological Intervention on the Developmental 
Origins of Metabolic & Cardiovascular Disease 
by 
Maqsood Manzoor Elahi 
Thesis Submitted for the Degree of Doctor of Philosophy 
June 2011 
Faculty of Medicine Health & Life Sciences 
School of Medicine 
Maternal, Fetal and Neonatal Physiology 
Supervisors: Mark A. Hanson & Sunil K. Ohri 
 
 
 
 
for my parents;  
 
Dr Sheikh Manzoor Elahi & Mrs Fehmida Sultana 
 
who always advised me "Maqsood search yourself". 
 
 At the time, I did n't realize what I am aiming for but I carried on. Hence in search of 
me, I discovered Truth. In search for Truth, I discovered Love. In search for Love,  
I discovered GOD. And in GOD, I have found Everything! 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
I've met men who are sensitive  
and caring  
and men who are cruel and calculating. 
 
I've known women who are sincere  
and honest 
 and women who are jealous and hateful. 
 
I've seen smiles filled with lies 
and tears  
wet with truths. 
 
I've shared time with those who have 
needed me, 
and I've been by myself  
when I was in need. 
 
I've been associated with people who 
are dreamers but not doers  
and with people who make promises, 
but never keep them. 
 
I've found myself learning how to 
understand all these personalities 
and to  
avoid those that cause my life sadness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
My soul yearns for those who 
still believe in life's truths  
of honesty, of sincerity, of compassion  
and of true friendship 
.  
But most of all, I long to know those 
 few people  
who really know what love is 
and 
 how to be a loving person 
 
I long for a place where people can  
get together  
and talk to one another about the things 
that matter,  
like being friends and caring about 
dreams  
that we all believe in.  
 
I long for a time when friendship 
 and love  
are important and the best parts of our 
lives! 
 
 
 
 
 
 
 
 
 
 
I put these thoughts together on my 
seven days tracking and hiking 
expedition to Mount Wellington in 
Tasmania from Oct 23to Oct 30, 2010. 
 
Signed:................................................. 
 
 
I have known many different kinds of people in my life... 
 
 Abstract 
  I 
UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
FACULTY OF MEDICINE, HEALTH & LIFE SCIENCES;  
SCHOOL OF MEDICINE 
 Doctor of Philosophy 
EFFECTS  OF  MATERNAL  HIGH  FAT  DIET  AND  PHARMACOLOGICAL 
INTERVENTION ON THE DEVELOPMENTAL ORIGINS OF METABOLIC AND 
CARDIOVASCULAR DISEASE.  
by Maqsood M Elahi  
A  high  fat  (HF)  diet  leads  to  hypercholesterolemia  and  predisposes  the 
individual to developing cardiovascular disease (CVD). We hypothesised that mother‘s 
HF diet before and during pregnancy and lactation can also influence predisposition to 
CVD in offspring fed a similar diet. The thesis sets out to investigate whether (1) the 
effects of long-term consumption of a HF diet by the mother predisposes her offspring 
to  developing  a  CVD/  metabolic  syndrome  in  adult  life  and  (2)  pharmacological 
intervention using statin alleviates the detrimental effects of maternal HF diet on the 
health of the dams and their offspring.  
     Female C57BL/6 mice were fed either a HF diet (45% kcal fat) or standard chow 
(C; 21% kcal fat) from weaning through pregnancy and lactation. Pregnant C57/BL6 
mice on HF diet were further given pravastatin in the drinking water (5 mg/kg of body 
weight per day) either short-term (2
nd half of pregnancy and during lactation) or long-
term  (from  weaning  through  to  pregnancy  and  lactation)  to  lower  cholesterol  and 
improve post-weaning maternal blood pressure. Weaned female offspring from each 
group were then fed either a HF or C diets to adulthood. Body weight, blood pressure, 
plasma  cholesterol,  C-reactive  protein  (CRP)  and  bone  marrow  derived  endothelial 
progenitor cells (EPC) were measured at 24, 28 and 36 weeks post-weaning in different 
experiments.  Histology of the liver and kidneys were performed.  
     Offspring  from  hypercholesterolemic  mothers  on  HF  diet  were  significantly 
obese  (bodyweight  in  grams;  17.2+4.2  vs.  13.8+4.7;  P<0.05),  hypertensive  (SBP 
mmHg; 134+4.2 vs. 117+3.4; P<0.001), less active (distance in cm; 312 + 31 vs. 563 + 
45; P<0.001), demonstrated increased lipid laden vacuoles in liver and kidneys; and 
showed reduced expression of EPC (P<0.05) than offspring from C dams independent 
of their postnatal nutrition respectively. Pravastatin therapy in HF mothers resulted in 
abrogation  of  these  variables  in  offspring  independent  of  post  weaning  nutrition 
(P<0.05). The effects were more permanent when the dams were given long-term statin 
treatment.  
   The  study  demonstrates  that  long-term  maternal  HF  feeding  from  weaning 
through pregnancy and lactation predisposes offspring to hypertension, raised plasma 
lipids, fatty liver, kidney disorders, raised CRP and inhibition of EPC numbers and 
expression in offspring. Pravastatin treatment of these dams inhibits these effects on the 
offspring  and  may  reduce  their  risk  of  later  cardiovascular  pathophysiology.  The 
findings  may  have  implications  for  understanding  the  effects  of  the  ‗nutritional 
transition‘ to higher dietary intake of fat which could lead to increased cardiovascular 
disease in many societies.  
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=8-10/group). Bars with different letters are significantly different 
(p<0.05)  from  each  other  (by  the  Tukey-Kramer  comparisons 
test).  
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and female (right panels) offspring from control fed mothers that 
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HF)  or a chow diet (HF-C). Values are means ± SEM (n =8-
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(p<0.05)  from  each  other  (by  Duncan‘s  Multiple  Range  Test). 
Bars with different letters are significantly different (p<0.05) from 
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              Figure 3.5:   Comparison  of  total  cholesterol  (a,  b)  and  C-reactive  protein 
(CRP) levels (c, d) in male (left panels) and female (right panels) 
offspring from control fed mothers that were then fed a chow diet 
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Duncan‘s  Multiple  Range  Test).  Bars  with  different  letters  are 
significantly different (p<0.05) from each other (by the Tukey-
Kramer comparisons test).  
 
              Figure 3.6:   Liver histology in female offspring from control fed mothers that 
were then fed a chow diet (C-C) or a high fat diet (C-HF) and 
from high fat fed mothers that were then fed a high fat diet (HF-
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observed  within  hepatocytes  of  the  C-HF,  HF-HF  and  HF-C 
offspring.  Staining  with  haematoxylin  and  eosin;  magnification 
x20; bar scale = 40 m. 
 
Figure 3.7:   Schematic  representation  of  the  effect  of  pregnancy  on 
carbohydrate, lipid, and amino acids metabolism. Arrows with (+) 
markings  are  those  pathways  enhanced  during  late  pregnancy; 
arrows  with  (-)  markings  are  those  reduced.  In  general,  these 
metabolic  shifts  are  more  enhanced  in  obese  than  in  normal-
weight women. Part A shows the response in a post absorptive 
state; part B depicts a postprandial state. FFA, free fatty acids; 
VLDL,  very-low-density  lipoproteins;  LPL,  lipoprotein  lipase. 
From Herrera.
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regulate  pravastatin-induced  pleiotropic  activities.  Pravastatin 
diminishes  proinflammatory  effects  and  promote  anti-
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chemokine-,  cytokine-,  and  acute  phase  reactant-induced 
intracellular  signalling  pathways  in  several  cell  types  (such  as 
leukocytes,  vascular  cells,  adipocytes,  and  hepatocytes).  In 
particular,  the  inhibition  of  ERK  1/2,  rho,  JAK/STAT3,  or 
mevalonate pathways is crucial to reduce inflammation. On the 
other hand, statins directly activate AMPK and PI3K/Akt/NFkB 
pathways, thus, increasing cell survival, endothelial, and neuronal 
protection. (Adapted from references
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Figure-4.2:    Flow diagram of the experimental protocol.  
Figure-4.3:   The  mammalian  mevalonate  pathway;  PP,  pyrophosphate. 
Adopted from Corsisni et al
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Figure-4.4:   Chemical structures of the statins
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Figure 4.5:   Time scheduled chromatogram of a standard solution of statin. 
Figure-4.6:   Statin  treatment  in  hypercholesterolemic  mothers  during  late 
pregnancy and lactation has beneficial effects on the cholesterol 
profile, blood pressure and locomotor behaviour in their offspring. 
(a) Body weight gain, (b) systolic blood pressure (c) locomotor 
activity, (d) serum cholesterol, (e) serum LDL and (f) serum HDL 
in offspring from mothers on standard chow (C), high fat-high 
cholesterol  (HF) diet or HF diet and treated with  statin during 
pregnancy and lactation (HF-S). Weaned offspring were then fed  
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either  HF  or  C  diets  to  adulthood,  thus  generating  the 
dam/offspring dietary groups: HF/HF, HF-S/HF and C/C (n = 8 
per group).  
Figure-4.7:   Overall  maternal–fetal  transfer  likely  encompasses  an 
"uptake/influx" component for maternal lipoproteins and/or their 
cholesterol  into  the  syncytiotrophoblast  (STB),  transport  of 
lipoprotein-derived cholesterol (C) to the basal side of the STB, 
subsequent release into the villous core for passage through the 
extracellular  matrix  (ECM),  uptake  into  ECs,  and,  finally,  an 
efflux component by which cholesterol is released from ECs into 
the fetal circulation. To date, only the uptake and degradation of 
LDL and HDL in cultured trophoblasts have been described
533-535 
However, other lipoproteins and their respective receptors have 
not  been  analyzed,  and  the  subsequent  intraplacental  transport 
steps are still uncharacterized.  
 
Chapter 5 
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Figure-5.2:    Long-term  statin  treatment  in  hypercholesterolemic  mothers  has 
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offspring from mothers on standard chow (C), high fat-high cholesterol 
(HF)  diet  or  HF  diet  and  treated  with  statin  during  pregnancy  and 
lactation (HF-S). Weaned offspring were then fed either HF or C diets 
to adulthood, thus generating the dam/offspring dietary groups: HF/HF, 
HF-S/HF and C/C (n = 8 per group).  
Figure-5.3:    Long-term  statin  treatment  in  hypercholesterolemic  mothers  has 
beneficial effects on total cholesterol and CRP in their offspring. (a) 
Total cholesterol levels in males, (b) Total cholesterol levels in female 
(c) CRP levels in male (d) CRP levels in female offspring from mothers 
on standard chow (C), high fat-high cholesterol (HF) diet or HF diet and 
treated  with  statin  during  pregnancy  and  lactation  (HF-S).  Weaned 
offspring  were  then  fed  either  HF  or  C  diets  to  adulthood,  thus 
generating the dam/offspring dietary groups: HF/HF, HF-S/HF and C/C 
(n = 8 per group).  
  
  XV 
Figure 5.4:   Representative  photomicrographs  of  Oil  Red  O  stained  renal 
sections from (a) HF/HF and (b) HF+S/HF mice. The sections 
were counterstained with haematoxylin and eosin. Lipid droplets 
appeared as red spots that revealed the accumulation of neutral 
lipids in the glomerular and tubulointerstitial cells and showed an 
increase in HF/HF compared with HF+S/HF (n=8) 
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Figure 6.1:   Experimental protocol for Study-I 
Figure-6.2:   Statin treatment in hypercholesterolemic mothers during late pregnancy 
and  lactation  has  beneficial  effects  on  the  cholesterol  profile,  blood 
pressure and CRP in their offspring. (a) Body weight gain, (b) systolic 
blood pressure (c) serum LDL-cholesterol, (d) serum CRP, (e) serum 
total cholesterol in offspring from mothers on standard chow (C), high 
fat-high cholesterol (HF) diet or HF diet and treated with statin during 
pregnancy  and  lactation  (HF+S).  Different  letters  indicate  p<0.001 
except  between  bars  with  different  letters  and  asterisks  (*)  where 
p<0.05, showing the level of significance. 
Figure 6.3:   Pravastatin  treatment  in  hypercholesterolemic  mothers  during  late 
pregnancy  and  lactation  has  beneficial  effects  on  (a)  the  positively 
stained mononuclear cells (MNCs) and (b) the number of double stained 
colonies in offspring from mothers high fat-high cholesterol (HF) diet.  
Different letters  indicate  p<0.001 except  between  bars  with  different 
letters and asterisks (*) where p<0.05, showing the level of significance. 
Figure- 6.4:   Expression  of  endothelial  markers  on  EPCs.  Representative 
photomicrographs  of  EPC  colonies  stained  for  endothelial 
markers  Dil-Ac-LDL  (red)  and  lectin  (green).  EPC  colonies 
demonstrate reduced staining in HF/HF vs. C/C. Statin treatment 
to HF-fed dams abolished these effects in their offspring.  
 
Figure-6.5   Correlation between the number of EPCs from HF/HF offspring with 
hypercholesterolaemia  and  total  cholesterol  (A)  and  LDL-cholesterol 
(B) levels 
Figure 6.6:    Long-term statin treatment in hypercholesterolemic mothers increased 
circulating  endothelial  progenitor  cells  (a)  number  of  stained  EPC 
colonies (b) percentage of mononuclear cells that are FITC labelled. 
Weaned offspring were then fed either HF or C diets to adulthood, thus 
generating the dam/offspring dietary groups: HF/HF, HF-S/HF and C/C 
(n = 8 per group).  
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Figure-6.7:   The plot shows the linear regression results in HF/HF offspring. The 
solid  line  illustrates  that  increase  in  plasma  CRP  levels  in  plasma 
correlates  with  decrease  in  number  of  bone  marrow  derived  EPC 
colonies  expression  in  adult  offspring.  Asterisks  (*)  where  p<0.05, 
shows the level of significance. 
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  Figure-7.1:   Adapted from Gluckman & Hanson.
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Figure 7.2:   The plot shows the linear regression results in female HF/HF offspring. 
The solid line illustrates that increase in total cholesterol correlates with 
increase in systolic blood pressure in 28 weeks old offspring. Similarly 
the dotted line demonstrates the correlation curve between the rises in 
cholesterol  levels  to  increase  in  C-reactive  protein  values  in  same 
offspring  (n=8).  Asterisks  (*)  where  p<0.001,  show  the  level  of 
significance. 
Figure-7.3:   Scheme  for  dysfunctional  activation  of  Kupffer  cells  in  NAFLD. 
Pattern recognition receptors of Kupffer cells such as TLR4 may be 
increasingly  exposed  to  exogenous  and  endogenous  danger  signals 
(e.g.,  LPS,  excess  fatty  acids,  modified  lipoproteins)  via  the  portal 
circulation,  enhanced  by  lack  of  hepatocellular  clearance.  Pattern 
recognition  pathways  may  intensify  due  to  altered  sorting  and 
signalling,  impaired  inhibitory  circuits,  or  amplification  of  redox-
sensitive signalling loops. Adipokine imbalance may contribute to these 
events  including  low  adiponectin  levels  that  fail  to  suppress 
intracellular ROS generation. Fat-laden hepatocytes may compromise 
sinusoid microcirculation leading to entrapment of inflammatory cells. 
Finally,  steatosis  may  shift  away  Kupffer  cells  from  alternative 
activation.  Solid  lines,  pro-inflammatory  effects;  dotted  lines,  anti-
inflammatory  mechanisms.  Malfunction  at  one  or  more  steps  may 
promote  ‗second  hit‘  responses,  while  cellular  targeting  of  these 
checkpoints has the potential for identifying novel treatment strategies 
in NAFLD. 
Figure 7.4:   Hypercholesterolaemia plays a crucial role in the development of 
atherosclerotic diseases in general and CVD in particular. Statin, 
converts  HMG-CoA  to  mevalonate.  Inhibition  of  HMG-CoA 
reductase  by  statins  decreases  intracellular  cholesterol 
biosynthesis,  which  then  leads  to  transcriptionally  upregulated 
production of microsomal HMG-CoA reductase and cell surface 
LDL receptors. This resets intracellular cholesterol homeostasis in 
extrahepatic tissues. The liver is the target organ for the statins,  
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since it is the major site of cholesterol biosynthesis, lipoprotein 
production  and  LDL  catabolism,  inhibits  CRP  metabolism  and 
exerts a healthy effect on the bone marrow derived endothelial 
progenitor cells in the circulation. The beneficial effects of statin 
in offspring from HF dams on long term treatment may depend in 
part upon the degree to which statin act on extrahepatic tissues. 
508-510,516,522,526,537,592-594 
Figure 7.5:   Hypothesized  “Hypercholesterolemic-mediated  Teratogenesis” 
model originating from this thesis. This model demonstrates on 
one extreme (right side) the risk of adult disease and on the other 
extreme (left side) range of postnatal physiological settings for 
survival fitness. At the x-axis (bottom) five different quality of 
prenatal environments from very poor to very rich are presented. 
The  red  line  curve  represents  the  environment  that  the  fetus 
anticipates  postnatally  judged  from  the  nutritional  and  related 
signals it receives from the mother through the placenta. Provided 
that the postnatal environment matches the range for which the 
fetus  has  set  its  postnatal  physiology  by  the  processes  of 
predictive adaptive responses, the disease risk is low. However, 
when  it  lies  outside  that  range  then  the  postnatal  environment 
turns  bad  (indicated  by  the  red  arrow)  and  the  disease  risk 
increases.  The  fetus  perceives  the  more  restricted  environment 
and  predicts  a  poorer  postnatal  survival.  But  maternal  high-fat 
dietary  stress  worsens  the  situation.  Overnutritional  high  fat 
environment  prenatally  and  postnatally  shifts  the  postnantal 
survival associated with increased disease risk further to the upper 
limit (represented with curve black line). Maternal high fat diet 
causes  hypercholesterolemic  mediated  teratogenesis  with 
deranged lipid profile, increased oxidative stress and decreased 
activity of endothelial progenitor cells in the circulation of the 
offspring. This even further potentiates the CVD risk with early 
manifestation of cardiovascular disease/ metabolic syndrome in 
its own adult life. From an adequate nutritional environment, the 
offspring  then  lies  outside  the  band  of  rich  and  very  rich 
environment  that  can  be  detrimental  to  its  survival  fitness. 
However,  administration  of  statin  to  mothers  on  high  fat  diet, 
even at rich nutritional upper limit, can provide a good safeguard 
from the disease process and maintains the survival fitness even if 
increasing affluence raises the richness of the mature postnatal 
environment.   
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CHAPTER 1 
General Introduction 
 
Cardiovascular disease (CVD) has become a leading cause and contributor of
 morbidity and 
mortality in this present time since the first decade of 21
st century draws to a close.
1-2 The 
World Health Statistics have suggested that at present, the developing countries contribute
 a 
greater share to the global burden of CVD when compared with developed
 countries.
3-4 It is 
reported that 5.3 million deaths
 attributable to CVD occurred in the developed countries in 
1990,
 whereas the corresponding figure for the developing countries
 ranged between 8 to 9 
million (i.e., a relative excess of 70%).
3-5 And that this difference
 would be even higher if the 
term "developed countries" is restricted
 to established market economies only and excludes the 
former
 socialist economies (Table-1.1). 
 
This high, yet inadequately recognized, contribution of developing countries
 to the absolute 
burden of CVD is illustrated by the fact
 that 78% of the 49.9 million global deaths from all 
causes occurred in regions other than the established market
 economies or former socialist 
economies (Table 1.2). In addition, a greater cause for concern
 is the early age of CVD deaths 
in the developing countries compared
 with the developed countries e.g. the proportion
 of CVD 
deaths occurring below the age of 70 years is 26.5%
 in the developed countries compared with 
46.7% in the developing countries
3-4 and even larger
 for Indian subcontinent (i.e. Pakistan, 
India,  Bangladesh  &  Srilanka;  52.2%).
3-4  Therefore,
  the  contribution  of  the  developing   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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countries to the global burden
 of CVD, in terms of disability adjusted years of life lost,
 is 2.8 
times higher than that of the developed countries (Table
 1.1)
1.  
 
Region 
Population, 
millions 
CVD 
Mortality, 
thousands 
Coronary 
Mortality, 
thousands 
Cerebrovascular 
Mortality, 
thousands 
DALYs 
Lost, 
thousands 
Developed 
regions  1144.0  5328.0  2678.0  1447.9  39 118 
Developing 
regions  4123.4  9016.7  2469.0  3181.2  108 802 
Established 
market 
economies  797.8  3174.7  1561.6  782.0  22 058 
Former 
socialist 
economies  346.2  2153.3  1116.3  665.9  17 060 
India  849.5  2385.9  783.2  619.2  28 592 
China  1133.7  2566.2  441.8  1271.1  28 369 
Other Asian 
countries 
and islands  682.5  1351.6  589.2  350.4  17 267 
Sub-Saharan 
Africa  510.3  933.9  109.1  389.1  12 252 
Middle 
Eastern 
Crescent  503.1  992.3  276.6  327.4  12 782 
Latin 
America  444.3  786.7  269.1  224.1  9538 
 
Table 1.1:  Regional Differences in Burden of CVD (1990). DALY indicates disability-adjusted life year. 
(Adopted from  Refs 1 & 4)   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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 Region  All Causes, %  CVD, % 
Established market economies  14  22 
Former socialist economies  8  15 
India  19  17 
China  18  18 
Other Asian countries and islands  11  9 
Sub-Saharan Africa  10  7 
Middle Eastern Crescent  9  7 
Latin America  6  5 
World  100  100 
 
Table 1.2:  Regional contributions to mortality (1990). Values are given as percent of world total. (Adopted from  
Refs 1 & 4) 
Although there are inadequacies
 and imperfections of cause-specific mortality ascertainment
 
methods currently used in many developing countries, the conservative assumptions
 made by 
the analysts suggest that this pattern will become even more pervasive as the CVD epidemic 
accelerates in many developing regions of the world, even as it retains its primacy as the 
leading public health problem in the developed regions.
5-8 A considerable cause for alarm is 
the projected rise
 in both proportional and absolute CVD mortality rates in the
 developing 
countries over the next 25 years.
6-9 Reasons for
 this anticipated acceleration of the epidemic 
include  genetic  factors  as  well  as  demographic  factors  including  lifestyle  changes  and 
nutritional transitions.    
 
1.1 Genetic Factors 
It is increasingly recognized that CVD prevalence is a consequence
 of the interaction between 
the distribution
 of relative genotype frequencies and environmental exposures
 of a particular 
population.
10-11  It  is  suggested  that  distribution  of  such
  relative  frequencies  of  genotypes 
involved in determining the
 distribution of individual susceptibilities to CVD is dependent on 
the  number  of  segregating
  susceptibility  genes,  the  number  of  alleles  of  each  gene,  their   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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relative frequencies, and the correlation between alleles
 of each gene and alleles of different 
genes.
12-14 There are
 hundreds of genes known to have functional allelic variations
 that may 
contribute  to  determining  an  individual‘s  susceptibility
  to  CVD.  But  then  all  functional 
variations in a particular gene are not
 expected to be present in all populations.
10-14 Because 
new DNA variations  arise in  isolation and  their  chance, selection,
  and  migration work as 
"filters"  in  each  population  to  modify
  the  relative  frequencies  of  genetic  variations  in 
evolutionary
 time, different populations will have different combinations
 of DNA variations.
15-
16 Therefore different combinations
 of susceptibility genes will be involved in determining 
CVD risk in different individuals in different families and it is always difficult to relate such 
different combinations
 of susceptibility genes to the CVD risk. However, only few genetic 
studies of common multifactorial diseases recognize
 the importance of this question.
17-18 
In 2004, the INTERHEART study
19 examined the influence of nine risk factors for CVD and 
reported that smoking, diabetes, hypertension, obesity, diet, inactivity, alcohol intake, ApoB : 
ApoA1 ratio and psychosocial factors accounted for 90-94% of population-attributable risk. 
Based on this model, the authors
19 suggested that populations with all these risk factors are 
337 times more likely to suffer cardiac disease than populations with none. In addition to these 
risk  factors  (which  may  themselves  be  genetically  determined),  a  positive  family  history 
increases coronary artery disease (CAD) and myocardial infarction (MI)  risk to 2-3.9 fold.
20  
 
Until recently, such attempts to identify the genetic associations used either candidate gene or 
linkage  studies.  The  former  examines  variations  in  a  low  number  of  known,  plausibly 
associated  genes  in  affected  cases  and  controls,  and  while  linkage  studies  assess  affected 
families/sibling pairs using microsatellite markers to define a genomic region linked to the 
phenotype.  So  far,  these  approaches  have  been  applied  with  great  success  to  identifying 
causative  mutations  in  monogenic  cardiovascular  diseases,  such  as  hypertrophic 
cardiomyopathy  and  long  QT  syndrome.
21-24  However,  the  complex  interplay  between 
environment  and  genetics  demonstrated  in  INTERHEART  made  it  clear  that  similar 
approaches were unlikely to identify the poorly penetrant and multiple causative genes that 
accounted  for  non-Mendelian  diseases,  such  as  CVD.  Although  CVD  can  also  rarely  be   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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inherited in a Mendelian fashion (predominantly in conditions leading to elevated LDL), this 
only  accounts  for  a  small  proportion  of  incident  cases,
25  most  of  which  are  likely  to  be 
polygenic. Linkage studies of non-Mendelian CVD have provided some biased associations, 
26-34  conspicuously  lacked  reproducibility  between  cohorts,  suffered  from  poor  statistical 
power and lacked detailed genomic mapping provided by conventional microsatellite markers. 
 
Recent technological advancement, coupled with greater understanding of the structure of the 
human genome derived from genome sequencing projects,
35-37 now make unbiased whole-
genome  association  studies  (GWAS)  possible.
38  The  International  Haplotype  Mapping 
project
39 identified hundreds of thousands of single nucleotide polymorphisms (SNPs) and 
assessed their degree of linkage disequilibrium (the degree to which a SNP predicts the DNA 
flanking it). It is reported that genotyping 0.008% of an individual's nucleotides (250 000-350 
000 in total) is able to identify an individual genome.
40 This technological advance led the 
Wellcome  Trust  Case  Control  Consortium  and  others  to  perform  SNP-based  GWAS  on 
patients with CAD compared with matched controls.
41 For example the most reproducible 
locus conferring increased risk of CAD is situated on chromosome 9 (locus 9p21.3)
42-44 and 
increases risk by approximately 1.2 for a single copy (1.5 in the 25% of the population who 
carry two copies).
45 Interestingly, unlike other regions associated with surrogate risk factors 
for CAD, such as C-reactive protein (CRP),
46 adiposity
47 and left ventricle (LV) mass,
48 the 
9p21.3 locus does not affect such risk factors, suggesting that it promotes CAD in a non-
canonical  manner.  However,  studies  are  suggesting  that  SNP-based  GWAS  knowledge 
provides no additional benefit
49 despite the availability of genotyping via the internet. This 
may be first because loci such as 9p21.3 confer effects by altering the regulatory region of 
DNA
42; second the involved region that overlaps a non-coding RNA named ANRIL, is only 
conserved in primates and not other mammals or lower organisms; and third the associations 
of some loci (e.g. 9p21.3 locus) are also present in conditions such as dementia
50 and stroke,
 51 
rather  than  specifically  CAD.  Therefore,  incorporation  of  risk-conferring  alleles  such  as 
9p21.3 and others into a CAD prediction algorithm is still not clear and thus remains to be   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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substantiated  in  terms  of  its  true  importance  under  the  current  models  and  on  clinical 
parameters.
52   
 
1.2 Demographic Factors 
There was a major surge in life expectancy experienced by most developing countries in the 
second
 half of the twentieth century.
53 For example, the life expectancy
 in India rose from 41.2 
years in 1951–1961 to 61.4 years
 in 1991–1996 as reported by Reddy & Yusuf
1. The authors
1 
further explained that this is due to a decline in
 deaths occurring in infancy, childhood, and 
adolescence.  This  was  also
  related  to  more  effective  public  health  responses  to  perinatal, 
infectious,
 and nutritional deficiency disorders and to improved economic
 indicators such as 
per-capita income and social indicators such
 as female literacy in some areas
1. Although much 
remains to be done in these areas, the demographic
 shifts have augmented the ranks of middle-
aged and older adults.
 The increasing longevity provides longer periods of exposure
 to the risk 
factors of CVD resulting in a greater probability
 of clinically manifested CVD events.
54 The 
concomitant decline
 of infectious and nutritional disorders (competing causes of death)
 further 
enhances the proportional burden due to CVD and other chronic
 lifestyle-related diseases. This 
shift, representing a decline
 in deaths from infectious diseases and an increase in those due
 to 
chronic diseases, is often referred to as the modern epidemiological
 transition.
8-9  
 
It is reported that the ratio of deaths due to pretransitional diseases (related
 to infections and 
malnutrition) to those caused by post-transitional diseases
 (e.g., CVD and metabolic disorder) 
varies  among  regions  and  between  countries,
  depending  on  factors  such  as  the  level  of 
economic development
  and literacy as well as  availability and access to health care
1.
 The 
direction  of  change  towards  a  rising  relative  contribution
  of  post-transitional  diseases  is, 
however, common to and consistent among
 the developing countries.
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urban China, in
 which the proportion of CVD deaths rose from 12.1% in 1957 to
 35.8% in 
1990, is illustrative of this phenomenon.
56 
 
The United Kingdom itself is a diverse society with 7.9% of the population from minority 
ethnic groups (Africa, Middleast, Indian Subcontinent, South America and Chinese region)
57. 
The causes of the excess CVD and metabolic disorder morbidity and mortality in minority 
ethnic groups are incompletely understood by socio-economic factors. However, the role of 
classical  CVD  risk  factors  is  clearly  important  despite  the  patterns  of  these  risks  factors 
varying  significantly  by  ethnic  group.  Moreover,  the  CVD  epidemiology  of  African 
Americans  does  not  represent  well  the  morbidity  and  mortality  experience  seen  in  black 
Africans and black Caribbeans,  both  in Britain  and in  their native  African  countries
58.  In 
particular, atherosclerotic disease and CAD are still relatively rare in the latter groups. This is 
unlike the South Asian Diaspora, who has prevalence rates of CVD in epidemic proportions 
both in the Diaspora and on the subcontinent
55-57. 
 
Data  for  population  surveillance  of  CVD  and  metabolic  disorders  are  limited  in  many
 
countries. The World Health Organization (WHO) has set up a range
 of projects aimed at 
improving the amount and quality of relevant
 data. The Surveillance of Risk Factors (SuRFs) 
project, launched
 in 2003, presents chronic disease risk factor profiles from
 170 WHO member 
states. These data include patterns of physical inactivity, low fruit/vegetable intake,
 obesity, 
blood pressure, cholesterol, and diabetes.
58 The most
 recent report SuRF2 enables country 
comparisons  for  these  data
59-60.  Figure-1.1  shows  data  on  the  percentage
  of  adults  in  the 
different countries of Southeast
 Asian nations with body mass index (BMI) >30 kg/m
2.
 The 
variation is marked and it is interesting to note that two of the poorest countries
 in the region, 
Laos and Myanmar, have severe obesity rates comparable
 with some of the wealthiest. On the 
other hand, Singapore, the most developed
 country in the region does not suffer from obesity 
epidemic.     M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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Figure 1.1:  Use of WHO web Global InfoBase.
58-59 Obesity (BMI > 30 kg/m
2) in the Association of Southeast 
Asian Nations in 2002 
Although the biological determinants  of  CVD and metabolic disorders  in  low and middle 
income countries are likely
 to be similar to those in affluent countries,
60 the drivers
 of these 
determinants are likely to differ. For example, rural–urban
 migration may be an important 
factor in promoting the adoption
 of Western dietary habits and activity patterns, leading to
 an 
increased CVD risks.  
 
Similarly, socioeconomic patterns of CVD disease
 risk, though well established in affluent 
countries, are more complex
 in some low and middle income countries.
60-62 For example It has 
been  the  historical  experience  of  the  developed  countries  that  the  CVD  epidemic  usually 
commences in members of the higher social classes, who are the first to change from a low-
risk  to  a  high-risk  lifestyle,  which  is  characterized  by  diets  rich  in  fat  and  calories, 
sedentariness, and smoking. But today, the risk permeates across the social spectrum, affecting 
all classes. The higher-social classes are, again, the first to respond to the knowledge of risk 
factors and the message of prevention. The CVD rates begin to decline in them, with the 
present pattern of higher CVD rates among the lower social classes becoming increasingly 
established. In most developing countries, there has been an initial preponderance of CVD in   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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the higher socioeconomic strata. However, the pattern observed in the developed countries, in 
which the burden of disease shifts progressively to the lower social classes, is likely to be 
replicated  as  the  epidemic  advances
1,60-61.  Indeed,  recent  reports  from  India  (described  in 
reference  55),  based  on  community  surveys  and  case-control  studies,  suggest  that  poor 
educational  or  economic  status  is  associated  with  higher  risk  of  CHD  in  some  regions.
55 
Hence, with the complete reverse of the social gradient, progressively larger numbers of poor 
individuals will become its victims and will be unable to obtain the necessary health care.  
 
New opportunities
 to use large demographic surveillance projects as tools to study
 CVD and 
metabolic disorders are  emerging rapidly as  part  on the work of INDEPTH (International
 
Network  of  field  sites  with  continuous  Demographic  Evaluation
  of  Populations  and  their 
Health in developing countries).
63-64 Even with such studies, the understanding of determinants
 
for rising CVD/ metabolic disorder epidemic and explaining such differences as to how rural–
urban migration increases risks
 of obesity, diabetes, and CVD will still be not possible. One 
important caveat to looking at such data
 is to study the role
 of impaired early growth, resulting 
from fetal and infant nutrition operating at different stages of the life course,
64-65  an issue that 
particularly applies when defining the causality of this problem.  
 
1.3 Nutritional Transition and Life Style Changes 
Another concern is that if population levels
 of CVD risk factors rise as a consequence of 
adverse lifestyle
 changes accompanying industrialization and urbanization, the
 rates of CVD 
mortality and morbidity could rise even higher
 than the rates predicted solely by demographic 
changes. It is suggested that both
 the degree and the duration of exposure to CVD risk factors
 
would increase due to higher risk factor levels coupled with
 a longer life expectancy. An 
increase in body weight (adjusted
 for height), blood pressure, and cholesterol levels in Chinese
 
population samples aged 35 to 64 years, between the two phases
 of the Sino-MONICA study 
(1984 to 1986 and 1988 to 1989) and
 the substantially higher levels of CVD risk factors in   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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urban
 population groups compared with rural population groups in Indian subcontinent
 provide 
evidence of such trends.
54-55,66-67 A cross-sectional survey
 of urban Delhi and its rural environs 
revealed a
 higher
 prevalence of CAD in urban Delhi.
 54 This is reported to be associated with 
higher levels of body mass index, blood
 pressure, fasting blood lipids (total cholesterol, ratio 
of
 cholesterol to HDL cholesterol, triglycerides), and diabetes.
54 The increasing use of tobacco 
in a number of developing countries
 also translates into higher mortality rates of CVD, CAD 
and other tobacco-related diseases.
68-70 
 
As reviewed by Drewnowski and Popkin,
71 the global
 availability of cheap vegetable oils and 
fats has resulted in
 greatly increased fat consumption among many countries.
 The transition 
now  occurs  at  lower  social  classes  than  previously  and  is  further  accelerated  by  rapid
 
urbanization. For example, the proportion of upper-income
 persons who were consuming a 
relatively high-fat diet (>30%
 of daily energy intake) rose from 22.8% to 66.6% between 1989
 
and 1993 in China. The lower- and middle-income classes also showed a
 rise (from 19% to 
36.4% in the former and from 19.1% to 51.0%
 in the latter).
68 These countries, with a diet that 
is
 traditionally high in carbohydrates and low in fat, have shown
 an overall decline in the 
proportion of energy from complex carbohydrates
 along with the increase in the proportion of 
fat.
71 The globalization
 of food production and marketing is also contributing to the
 increasing 
consumption of energy-dense foods poor in dietary
 fibre and several micronutrients.
71 
 
1.4 The Complexity of the Problem 
The prior discussion in sections 1.1-1.3 hence shows that CVD has a complex multifactorial 
aetiology  leading  to  a  reappraisal  of  the  ways  in  which  three  key  factors—genome, 
development  and  environment—influence  the  adult  phenotype,  including  the  individual‘s 
susceptibility  to  disease.    Neither
  genetic
  makeup  nor  exposures  to  adverse  environments 
predict  with
  certainty  the  onset,  progression,  or  severity  of  CVD.  Disease
  develops  as  a 
consequence  of  interactions  between  the  "initial"
  conditions,  coded  in  the  genotype,  and   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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exposures  to  environmental
  agents  indexed  by  time  and  space
72-74  that  are  integrated
  by 
dynamic, regulatory networks at levels above the genome.
75  
 
The interaction of an individual‘s environmental experiences
 with her/his genotype determines 
the history of her/his multidimensional
 phenotype, beginning at conception and continuing 
through adulthood (Figure1.2).  
 
Figure 1.2: From Sing et al.
  77 with permission. At a particular point in time, each genotype has a range of 
possible phenotypes determined by the range of possible environmental histories. The phenotype of an individual 
to  react  to  contemporary  environments  in  a  particular  environmental  niche,  at  a  particular  point  in  time,  is 
influenced by the phenotype produced by previous genotype-phenotype combination. The figure illustrates this 
relationship, by collapsing an individual‘s phenotype into single dimension, showing two of the many possible 
phenotype histories for a given genotype. 
  
The
 consequence of these interactions with exposures to environmental
 agents indexed by time 
and space is that many individuals who
 have a genotype that predicts an increased risk of CVD 
will
 remain healthy because of exposures to compensatory environments.
 The converse will 
also be true: individuals who have a genotype
 that has a low risk of CVD might develop 
disease because
 of an adverse environmental history.    M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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CVD research has revealed
 tens of high-risk environmental factors and hundreds of genes,
 
each with many variations that influence disease risk. The phenotypic measures
 of health are 
constantly being shaped, changed, and transposed
 as a consequence of epigenetic mechanisms 
of cellular and organismal
 dimensions that change over the lifetime of the individual.
 At the 
level of the cell, these mechanisms influence DNA methylation
 and repair; they also serve to 
organize coordinated responses
 to heat-shock, oxygen deprivation, and other environmental 
changes.
77  The  relationships  between  these  subsystems  influence  the  trajectory
  of  an 
individual‘s phenotype to influence the expression of the participating genes
78-80 (Figure 1.3).  
 
 
 
Figure 1.3: From Sing et al.
77 with permission. A model for an individual‘s propensity to develop CVD such as 
coronary artery disease. This figure shows how a particular multigene genotype is connected to the domain of 
potential CVD phenotypes through the primary biochemical and physiological subsystems. The important role 
that biochemistry and physiology play in
 the connections between the genome and disease phenotypes brings
 into 
question the utility of the overused, simplistic view that
 the genome produces an independent, isolated, and fixed 
one-way
 flow of information from genome to phenotype.   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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However,  how  differences  in  neonatal  human  epigenotype  may  be  linked  to  a  functional 
outcome in later life is still in its infancy. Yet, it suggests that the developmental componenet 
of phenotype determination is very important in humans and provides mechanistic proposal to 
explain  the  variable  risk  of  individuals  living  in  obsegenic  world.  Given  the  epigenetic 
changes  are  both  reversible  and  can  be  influenced  by  maternal  stste,  the  potential  for 
interventions  during  early  development  to  reduce  the  risks  of  metabolic  and  CVD  in  the 
modern obsegenic envoirnment warrents greater attention.  
 
 
Studies have suggested that different ethnic groups that live in the same geographic areas and 
share similar environmental risks have different profiles of disease markers and prevalence, 
which may propose a genetic cause for differences in disease susceptibility.
81-82 Yet, with 
some notable exceptions,
83 few ancestry-specific alleles have been discovered that can explain 
particular pathologies. Other explanations of both inter-individual and ethnic differences in 
disease risk, therefore, need to be considered. Of note, high incidences of metabolic disease 
are found in those ethnic groups in which the average birth weight is low
84 or the rates of 
gestational diabetes and maternal obesity are high.
85  
 
 
Untangling  the  effects  of  genes  from  those  of  environmentally  determined  developmental 
processes is not straightforward. Importantly, fetal nutrition does not equate to maternal food 
intake,  but  rather  is  dependent  on  maternal  metabolism,  cardiovascular  function  and, 
particularly, placental function.
86 The long-lasting changes in developmental trajectory that 
underpin  altered  susceptibility  to  disease  may  arise,  at  least  in  part,  from  epigenetically 
mediated  alterations  in  gene  expression.  Whereas  compelling  evidence  supports  both  the 
developmental  origins  of  health  and  disease  and  the  underlying  epigenetic  mechanisms,
87 
many  features  of  the  latter  remain  insufficiently  understood.  These  elements  include  the 
differences among epigenetic mechanisms across species and between patterns of epigenetic 
modifications  on  paternal  and  maternal  genomes,  the  mechanisms  that  regulate  the 
establishment,  stability  and  flexibility  of  epigenetic  changes,  and  the  precise  connection   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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between an epigenetic change, altered gene expression and the resultant phenotype for CVD 
epidemic in countries
72-80.  The hypothesis is currently recognised as "Developmental origins 
of Health and Disease‖ (DOHaD) and requires particular understanding before  proceeding 
further with the subject. 
 
1.5 Developmental Origins of Health and Disease 
DOHaD hypothesis states that
 adverse intrauterine influences such as poor maternal nutrition 
lead
 to impaired fetal growth, resulting in low birth weight, short birth
 length, and small head 
circumference. These adverse influences are
 postulated to also induce the fetus to develop 
adaptive  metabolic
  and  physiological  responses.  These  responses,  however,  may  lead  to 
disordered reactions to environmental
 challenges as the child grows, with an increased risk of 
glucose
  intolerance,  hypertension,  and  dyslipidaemia  in  later  life  and
  adult  CVD  as  a 
consequence.
88-94 Although some supportive evidence
 for the hypothesis has been provided by 
observational studies,
95-99 it awaits further evaluation for a causal role. If
 it does emerge as an 
important risk factor for CVD, the populations
 of developing countries will be at an especially 
enhanced risk
 because the vast numbers of poorly nourished infants who
 have been born in the 
past several decades now suffer a threat through an over-nourished rich environment. The 
steady improvement
 in child survival will lead to a higher proportion of such infants
 surviving 
to adult life, when their hypothesized susceptibility
 to vascular disease may manifest itself
100-
109. 
1.5.1 Origins of the hypothesis- Historical perspective  
The "early or fetal‖ origin of adult disease hypothesis was originally put forward by David 
Barker
 and colleagues in Southampton
89. The authors suggested that environmental factors, 
particularly nutrition, act in early
 life to program the risks for the early onset of cardiovascular
 
and metabolic disease in adult life and premature death
89,93-94,110-112. Before
 the fetal origins 
hypothesis was articulated, an association
 between early life events and later CVD had
 been 
proposed on more than one occasion. In 1934, Kermack et
 al
113 demonstrated that death rates   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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from all causes in the
 United Kingdom and Sweden fell between 1751 and 1930. The authors 
concluded that this was the result of better childhood living
 conditions during this period. 
Subsequently, Forsdahl
114 reported that there was a correlation within different geographical
 
regions of Norway between coronary heart disease in 1964–1967
 and infant mortality rates 
some 70 years earlier. Forsdahl
114 postulated that poverty may act through a nutritional
 deficit 
to result in a life-long vulnerability to disease with a more affluent
 adult life-style. In 1985, 
Wadsworth et al.
115 in the United
 Kingdom reported that adult blood pressure was inversely 
related
  to  birth  weight  in  men  and  women  born  in  1946.  In  1986,  Barker
  and  colleagues 
suggested
 that poor health and physique of mothers were important determinants
 of the risk of 
stroke in their offspring
94. Soon afterwards,
 it is proposed that environmental influences, that 
impair growth
 and development in early life, result in an increased risk for
 CVD
87-93;95-112. This
 
then led to a worldwide series of epidemiological studies
 that extended the initial observations 
on  the  association  between
  pre-  and  postnatal  growth  and  CVD  to  include
  associations 
between  early  growth  patterns  and  an  increased
  risk  for  hypertension,  impaired  glucose 
tolerance, non-insulin-dependent
 or type-2 diabetes, insulin resistance, and obesity in adult
 
life
115-124.   
1.5.2.  The  thrifty  phenotype  hypothesis,  developmental  plasticity  and  predictive  adaptive 
responses  
To explain the biological basis of the associations
 observed between early growth patterns and 
health outcomes in the epidemiological
 studies, number of mechanistic frameworks such as 
―thrifty
 genotype‖ 
125-126 and then "thrifty phenotype"
 127 derived from thrifty genotype, were 
proposed.  ―Thrifty genes‖ were proposed to be selected during evolution at a time when
 food 
resources  were  scarce  and  they  resulted  in  a  "fast
  insulin  trigger"  and  thus  an  enhanced 
capacity  to  store  fat,
  which  placed  the  individual  at  risk  of  insulin  resistance  and
  type-2 
diabetes
126.  In  contrast  the  thrifty  phenotype  hypothesis  suggested  that  when  the  fetal 
environment is poor, there is
 an adaptive response, which optimizes the growth of key body
 
organs  to  the  detriment  of  others  and  leads  to  an  altered  postnatal
  metabolism,  which  is 
designed to enhance postnatal survival
 under conditions of intermittent or poor nutrition
128-129.   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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It  was  proposed
  that  these  adaptations  only  became  detrimental  when  nutrition
  was  more 
abundant in the postnatal environment, than it had
 been in the prenatal environment
127.  
 
Lucas suggests that that
 there are embryonic and fetal adaptive responses to a suboptimal
 
intrauterine  environment  which  result  in  permanent  adverse  consequences
  either  via  the 
induction,  deletion,  or  impaired
  development  of  a  permanent  somatic  structure  or  the 
physiological system.
130 Infact closing the critical window early in development allows the 
preservation of maternal strategy in offspring phenotype, which in humans benefits the mother 
by  constraining  offspring  demand  after  weaning.  The  offspring  gains  by  being  buffered 
against environmental fluctuations during the most sensitive period of development, allowing 
coherent adaptation of organ growth to the state of the environment. The critical window is 
predicted to close when offspring physiology becomes independent of maternal physiology, 
the timing of which depends on offspring trait
130-133.
 All this highlight the relationship between 
intrauterine nutritional experiences
 and subsequent health outcomes
134-135  
 
Researchers  working  with  humans  and  animal  models  of  human  diseases  often  view  the 
effects  of  early  life  events  as  the  developmental  plasticity.  This  embodies  the  idea  that 
developmental  plasticity  is  the  ability
  of  a  single  genotype  to  produce  more  than  one 
alternative form
 of structure, physiological state, or behaviour in response to
 environmental 
conditions
136-138. Consistent
 with this, it is thought that CVD may be
 a consequence of fetal 
adaptations to undernutrition that are
 beneficial for short-term survival, even though they are 
detrimental
 to health in postreproductive life
112.
 Although some effects of nutrition may be 
direct  consequences
  of  alterations  in  substrate  availability,  McCance  and  Widdowson 
demonstrated that early undernutrition had a permanent
 effect on the subsequent growth of 
rats, whereas later undernutrition
 only had a transient effect
139.  
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It is clear from a range of diverse fields including evolutionary
 ecology and molecular biology 
that  a  given  genotype  can  give
  rise  to  different  phenotypes,  depending  on  environmental 
conditions
139-141.
  There  are  many  different  species  where  the  impact  of  an  environment
 
experienced  by  one  generation  determines  the  development  and
  behaviour  of  the  next 
generation.  Female  birds  are  able  to  alter
  many  aspects  of  the  composition  of  the  egg  in 
response  to  a
  range  of  environmental  factors  including  food  availability,
  levels  of  sibling 
competition, and the quality of their mates
140. Such maternal effects can result in the effects of 
a
 specific environmental factor persisting across several generations
136-137,141. If the effects of 
the  past  conditions  produce  mismatches
  with  current,  changed  conditions,  however,  then 
developmental
 plasticity may have a detrimental effect on survival and reproductive
 success
142. 
Thus Bateson et al. 
142 proposed that for individuals
 whose early environment has predicted a 
high level of nutrition
 in adult life and who develop a large phenotype, the better
 the postnatal 
conditions the better will be their adult health.
 For individuals whose conditions in fetal life 
predicted poor
 adult nutrition and who develop a small phenotype, the expected
 outcomes may 
vary, although they are predicted to be worse off
 when there is a relative excess of nutrition in 
postnatal life. There has also been a proposal to separate those homeostatic
 responses that 
represent fetal adaptations to changes in the
 intrauterine environment and that may have long-
term consequences,
 from those which need not confer immediate advantage but are
 induced in 
the expectation of future adaptive changes
143; this
 latter group of responses has been defined as 
"predictive adaptive"
 90,92,137,141. In this model of predictive adaptive response, selection across 
generations  operates
  to  favour  protection  of  those  predictive  adaptive  responses  that
  aid 
survival to reproductive age. The programmed or plastic
 responses made during development 
that have immediate adaptive
 advantage might also act to limit the range of postnatal adaptive
 
responses to a new environment and would be considered to be
 "inappropriate" predictive 
adaptive  responses.  This  general
  model  is  therefore  consistent  with  the  original  thrifty 
phenotype
 hypothesis which stated that fetal adaptations to a poor intrauterine
 environment 
may have adverse consequences if there is a relative
 excess of nutrition available in adult life.
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The use of the term ―predictive adaptive response‖ (PAR) must be clarified because it is used 
in two very different ways in the literature. In a physiological context it refers to adjustments 
made by an individual in response to current conditions. For example, in conditions of severe 
intrauterine  deprivation,
  there  is  the  capacity  to  lose  structural  units  such  as  nephrons,
 
cardiomyocytes,  or  pancreatic  β-cells  within  developing  organ
  systems.  Such  decreases  in 
structural and hence the life-long
 functional capacity of an organ system may be an inadvertent
 
consequence of a decrease in energy supply across the placenta
 or a selective trade off to 
maintain the development of more
 important tissues, such as the brain
144-146. 
 
In an evolutionary context it refers to changes in the characteristics of populations or species 
resulting from natural selection, mainly promoting Darwinian fitness and  adaptive according 
to the evolutionary criteria of enhancing survival or reproductive success
147. In case of fetal 
origins of disease, this would require that environmental conditions present early in life are 
predictive  of  the  conditions  the  individual  will  encounter  in  the  future  over  a  range  of 
timescales (Figure 1.4).  
 
 
Figure 1.4: From Gluckman et al.
137 with permission. Modes of human adaptability. 
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immediate challenge. Then, stressors or exposures during critical developmental periods can 
affect  growth,  tissue  differentiation,  and  physiological  set-points,  affecting  responses  to 
environmental challenges for life. New evidence suggests that epigenetic mechanisms could 
contribute  to  such  challenges
148-149.  On  a  long  timescale,  the  genomes  of  populations  can 
change over many generations as a result of selection or drift, and there are many examples of 
responses  to  environmental  change  becoming  integrated  into  the  human  genome
141,150-152. 
Clinical  medicine  and  public  health  research  have  focused  largely  on  causation  and 
intervention  at  the  short-term  end  of  this  spectrum.  In  this  context  consideration  of  the 
outcomes  of  developmental  plasticity  acting  over  the  intermediate  timescale  is  now 
important
141. In humans, development plasticity  can induce responses that have short-term 
benefits for the mother or the fetus but on longer term reduced fitness and increased disease 
process
152-153. It is suggested that when environmental conditions change strikingly between 
conception and adulthood, as has happened in most current human populations, the potential 
for a substantial  mismatch is  especially  great,  and this  difference  contributes  to  increased 
disease risk
135.  
 
1.5.3 Environmental cues affecting human development 
 
These broad considerations are relevant to understanding of some critical variations such as 
developmental
 adaptations that permanently change structure, physiology, and
  metabolism, thereby 
predisposing individuals to cardiovascular,
 metabolic, and endocrine disease in adult life. 
154-155. The 
human baby responds to undernutrition, placental dysfunction and other adverse influences by 
changing the trajectory of his or her development and slowing growth. Although the fetus was 
thought to be well-buffered against fluctuations in its mother's condition, a growing body of 
evidence suggests that the morphology and physiology of the human baby is affected by the 
state  of  the  mother
156-157.  It  is  possible  therefore,  that  human  development  may  involve 
induction of particular patterns of development by cues that prepare the developing individual 
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adversely if the environmental prediction provided by the mother and the conditions of early 
infancy prove to be incorrect
113.  
 
Thus, people whose birth weights were towards the lower end of the normal range and who 
subsequently grows up in affluent environments are at increased risk of developing CAD, 
type-2 diabetes and hypertension
39-40,156,158. Those born as heavier babies and brought up in 
affluent environments enjoy a much reduced risk. The long-term influences may arise from 
cues acting from before conception to infancy
159. The ill effects of being small, which in the 
short term include high death rates and childhood illness, are usually treated as yet another 
inevitable  consequence  of  adversity.  However,  a  functional  and  evolutionary  approach 
suggests that the pregnant women in poor nutritional condition may signal to her unborn baby 
that help it to cope with a shortage of food. When sufficiently high levels of nutrition are 
available after the development of a small phenotype has been initiated, marginal benefits of 
rapid growth may offset the costs
160, but they may also trigger the health problems arising in 
later life. This concept is illustrated in Figure 1.5. 
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Figure 1.5 The hypothetical relationship between adult health and nutritional level during later development for 
two extreme human phenotypes that were initiated by cues received by the fetus. From Bateson et al.
142 with 
permission. 
 
Although adaptive responses may explain some variation in human development, it would be 
implausible to argue that all responses to the environment should be explained in these terms. 
Undernutrition,  stress  or  hypoxia  may  impair  normal  development.  Babies  with  low  birth 
weight have a reduced functional capacity and fewer cells
161. The latter may be part of a 
general reduction in cell numbers or a selective trade-off in the development of tissues that are 
less important to the baby, such as the kidney
162. Reduced numbers of nephrons at birth is a 
life-long deficit, as all nephrons are formed during a sensitive period of development in late 
gestation. The resulting increased functional demand on each individual nephron, for example 
by increased blood flow through each nephron, may lead to acceleration of the nephron death 
that accompanies normal ageing, with a consequent rise in blood pressure
163-165. 
 
The diversity in past and present ecological conditions of humans is also likely to introduce 
complexity into the relationship between developmental prediction and later health outcome. 
For  example,  some  populations  may  have  adapted  genetically  to  conditions  of  nutritional 
stress, especially seasonal food shortages, over a long time span, while others will have been 
buffered  from  such  local  evolutionary  effects.  The  sharp  increase  in  glucose  intolerance 
leading to type-2 diabetes might arise from genetic differences between populations
166-167. The 
possibility of a thrifty genotype well adapted to harsh conditions is not incompatible with the 
plastic  induction  of  thrifty  phenotypes  from  a  pool  of  uniform  genotypes.  However,  the 
hypothesis that differences in susceptibility to diabetes are explained by genetic differences 
would not readily account for the evidence from the Dutch famine of 1944–45 that glucose 
intolerance is induced by maternal malnutrition during the final three months of pregnancy
167. 
However, persisting into adult life, insulin resistance leads to increasing blood glucose and 
type-2 diabetes develops, especially in people who have become overweight. 'Thrifty' handling 
of sugar becomes maladaptive if undernutrition in the womb is followed by excess in later   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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life
168.  Conversely,  individuals  with  large  bodies  may  be  particularly  at  risk  in  harsh 
environments such as prison camps or during famines.
153,168 Especially striking is the evidence 
from a famine-exposed Ethiopian population, where the incidence of rickets was nine times 
greater in children who had been reported as having high birth weights than in age-matched 
control children
169. No such differences were found in children with normal birth weights. 
 
1.6 DOHaD Approach to Cardiovascular Disease  
Lower birth
 weight and weight at 1 year of age were associated with an increased
 risk of death 
from CVD and stroke
170-171. Early criticisms of the association of death rate
 from CVD with 
lower birth weight raised questions
 about completeness of follow-up
172-173. This criticism was 
largely answered in a Swedish study of 15,000 men and women with a 97%
 follow-up over a 
period of more than 50 yr. The study suggested that death rates from ischemic heart disease 
(IHD) were increased in individuals
 in the lower quartiles of birth weight compared with those 
in
  the  highest  quartile
174.  Also  of  note  was  the  Nurses  Study
  in  the  United  States  which 
includes 121,700 women who have been
 followed since 1976. In one retrospective study of 
more than
 70,000 women from this group, there were strong negative trends
 between self-
reported birth weight and nonfatal coronary heart
 disease and stroke
175. The association of 
cardiovascular
 death and birth weight has now been reported in many studies
176-179 and this 
raises the importance of developmental environmental influences. 
 
It has also been shown that cardiovascular disorders may be greatest in males born to mothers 
who were obese
179.
 Short birth length of female infants followed by increase in
 height was also 
associated with increased risk of death from
 coronary heart disease
180. These women tended to 
have  tall
  mothers
181,  which  suggests  that  prenatal  growth  of  these
  female  infants  was 
constrained. Thus the most adverse cardiovascular
 disease risk profile is found in men and 
women who were small
 at birth but became obese in adult life
182, and the effects
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on high blood pressure, type-2 diabetes, and insulin
 resistance were greater in individuals of 
low birth weight
181. Whatever the mechanisms, the possibility of a biological
 link between 
birth weight and adult body mass index (BMI) complicates interpretation
 of studies that link 
birth weight and adult BMI to other adult
 outcomes such as CVD, hypertension, and metabolic 
syndrome.  
 
Soon afterwards, the association between low birth weight
 and high blood pressure in adult life 
was  extended  to  include
  the  normal  range  of  birth  weight
183.  In  addition  to  raised
  blood 
pressure at age 10, children living in areas with higher
 rates of death from CVD also had high 
resting
 pulse rates. The children and their mothers were shorter than
 those living in areas with 
low  cardiovascular  mortality,  raising
  the  possibility  of  environmental  or  inherited/genetic 
effects.
 A small number of studies have also examined the contribution of
 the placenta to the 
association between size at birth and CVD later in life. In cohorts in Preston in the United
 
Kingdom and in Adelaide in Australia, blood pressure increased
 with decreasing birth weight 
and increasing placental weight
184-185. In the Adelaide cohort, however, the effect of placental
 
weight was no longer apparent when the blood pressure was measured
 and when the subjects 
were nearly 20 yr of age. In this group, the amplification
 of blood pressure from 8–20 yr of 
age was greatest in
 those with lower birth weights
185. No support for an effect
 of placental size 
or birth weight was found in the New Zealand
 cohort followed from birth to 18 yr of age or for 
other
 indices of fetal or placental growth in 8-yr-old Australians
186.
  
 
During the past two decades there has been a marked increase
 in the global prevalence of adult 
and childhood obesity, and
 currently >50% of all adults in the United States and the
 United 
Kingdom are overweight, i.e., have a BMI of >25 kg/m
2 
187-189. An increase in the prevalence 
of  obesity
  (BMI  >30  kg/m
2)  is  associated  with  an  increase  in  a  range
  of  co-  morbidities 
including type-2 diabetes, high blood pressure,
 and CVD
190-193. A range of epidemiological
 
studies have shown that there is a relationship between increased BMI (obesity) in childhood 
and CVD in adult life
190-191. In this context it is of particular interest
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clinical, and experimental studies have
 shown that there is a relationship between the prenatal 
nutritional
 environment and patterns of postnatal growth and adult adiposity including CVD 
and  dyslipidemia
191-193.  There  is  also  an  interaction  between  lesser  prenatal  growth  and 
postnatal weight gain
189. Thus, the risk of developing CVD is greatest in those who are small 
or thin at birth and who then develop relative obesity postnatally. Individuals at greatest risk 
have an earlier pre-pubertal adiposity rebound and gain weight faster in the late pre-pubertal 
period
190-192.  The  weight  of  epidemiological  evidence  is  substantial,  though  controversial 
because  the  studies  were  criticized  as  retrospective,  confounded  by  other  variables  (e.g. 
socioeconomic  status)  and  as  biologically  implausible.  Critics  questioned  the  size  of  the 
relationship between birth weight and surrogate measures of cardiovascular disease risk (e.g. 
blood pressure). However, stronger and robust relationships exist between birth size and the 
incidence  of  clinical  disease  (e.g.  heart  disease  or  clinical  hypertension).  Furthermore, 
prospective clinical and experimental observations demonstrate clear relationships between 
measures of the fetal environment and risk of developing CVD. It is, therefore important to 
consider in populations of the world that are undergoing the nutritional and epidemiologic 
transition to Western styles of diet, sedentary behaviour and obesity, the ominous pattern that 
Baker et al., identified- lower birth weight followed by excess weight gain in childhood- is 
both  common  and  liable  to  persist  for  the  foreseeable  future
191-192,194-195.    It  is  these 
environmental factors that induce change in metabolic and cardiovascular development in our 
changing  world.  Several  models  have  been  developed  to  explain  these  effects
195-200. 
Experiments  in several  species show that it is easy to  induce insulin  resistance and other 
manifestations  of  the  CVD,  including  hypertension  and  endothelial  dysfunction,  by 
manipulating  maternal  nutrition  or  exposing  the  mother  to  synthetic  glucocorticoids
201-204. 
Following  maternal  under-nutrition  in  rats,  pups  develop  fasting  hyperinsulinemia, 
hyperleptinemia, hyperphagia and have increased lethargy; they also develop central obesity 
and have reduced muscle mass
204-206. In similar experiments, changes in hypothalamic appetite 
regulatory peptides and a preference for fatty food consumption are reported
207-208.
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Relatively,  few  studies  into  the  aetiology  of  the  DOHaD  have  attempted  to  establish  the 
mechanistic basis of this phenomenon. Whereas most research has involved pathways through 
which under-nutrition during development translates into subsequent metabolic disorder and 
ultimately CVD, studies are beginning to focus on the role of excess nutrition, excess exposure 
to  hyperglycaemia  in  utero  and  whose  mothers  are  obese,  at  increase  risk  of  developing 
metabolic  disorders  and  CVD
208-214.  One  possible  mechanism  under  investigation  is  that 
maternal nutrition prior to or during pregnancy can program fetal development and adult CVD 
via heritable epigenetic mechanisms involving additional interactions between non-transcribed 
RNAs and covalent modifications to associated histone proteins (discussed in ref 210). Our 
work  in  animal  models  has  demonstrated  that  the  adverse  effects  of  impaired  early-life 
nutrition and the associated epigenetic changes can be prevented or reversed by nutritional 
interventions  (such  as  folate  supplementation)  or  endocrinological  interventions  (such  as 
neonatal leptin administration)
212, 215. Further support for such a mechanistic base has come 
from  studies  in  rats,  where  Zambrano  et  al  answered  the  question  of  (a)  reversibility  of 
maternal obesity by altered dietary intake commencing before conception and (b) the adverse 
metabolic effects of maternal obesity on offspring metabolic phenotype, and that outcomes 
and reversibility vary by  tissue  affected
216. Other studies  with  rodents  have reported both 
epigenetic  and  phenotypic  effects  in  offspring  of  dams  transiently  exposed  to  endocrine 
disrupting  compounds  during  pregnancy
217-219.  Moreover,  it  is  reported  that  epigenetic 
processes  are  involved  in  some  of  the  immediate  manifestations.  For  example,  decreased 
histone H3 methylation  (an epigenetic marker associated with repression of transcription), 
together with increased expression of proinflammatory genes, has been proposed to underlie 
the  sustained  proinflammatory  phenotype  of  vascular  smooth  muscle  cells  that  is  seen  in 
diabetic  animals  even  after  normalization  of  glycemia
220-225.  Similarly,  transient 
hyperglycemia causes persistent expression of proatherogenic genes, which is underpinned by 
specific changes in histone H3 methylation in vascular endothelial cells
218-219. Whilst such 
phenomena  would not  normally  be  considered in  the  context  of  developmental  origins  of 
CVD,  they  do  serve  to  illustrate  the  environmental  liability  of  acquired  epigenetic 
modifications  induced  by  maternal  over-nutrition  that  may  contribute  to  transgenerational 
amplification of obesity in humans
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The second  possible  mechanism involves  altered tissue differentiation. For example, adult 
nephron numbers are reduced both in humans who are born small and in animals manipulated 
experimentally in utero
227-228. This might be the result of a biological trade-off to conserve 
energy in response to deprivation during a crucial developmental window, having immediate 
but no long-term adaptive value. Alternatively, it might simply be a result of developmental 
disruption  with  no  adaptive  value,  analogous  to  teratogenesis.  Similarly,  in  the  rat,  the 
developing pancreatic islet undergoes a wave of developmental apoptosis during the perinatal 
period, presumed to reflect a transition from a fetal to a postnatal form of islet cell with a 
different regulatory profile
229. The rate of β-cell apoptosis is increased in infant rats whose 
mothers  are  fed  a  low-protein  diet
230,  perhaps  because  of  an  increased  sensitivity  to 
cytokines
231. Inhibition of this apoptosis in the neonatal period prevents the development of 
subsequent diabetes
232.  
 
The third mechanism involves altered homeostatic processes. Offspring of rats fed a low-
protein diet have an altered ratio of periportal to perivenous hepatocytes, leading to an altered 
ratio of phosphoenolpyruvate carboxykinase to glucokinase-enriched cells and greater hepatic 
glucose production
233-234. The expression of enzymes involved in lipid homeostasis, including 
carnitine palmitoyl transferase, is suppressed
235. Skeletal muscle from growth-retarded infant 
rats is relatively resistant to both insulin and insulin-like growth factor I
236.  There is also 
mitochondrial dysfunction and reduced expression of protein kinase C-ζ, which might lead to 
altered  glucose transporter 4  (GLUT-4) mobilization in muscle
236-238. Cardiac muscle  also 
shows reduced synthesis of GLUT-1, GLUT-4 and hexokinase II 
239 in such settings.  
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It is quite clear from the subject presented so far that there is a growing recognition of the 
importance of environmental factors acting on the genotype throughout the life cycle of an 
individual to progressively modify its phenotype, thus leading to metabolic disorder and CVD 
in later life in an unpredicted environment. Several models have been developed to explain 
these effects and are discussed earlier. Clearly there are windows of time in the lifecycle when 
the susceptibility of the genome to such an influence is very high. The periconceptional and 
intrauterine period seem to be the most crucial, when a small change in environment could 
have a large effect on the phenotype. Any preventive intervention will therefore have to start 
in utero, and improving the health of future mothers will be a very important aspect of such an 
approach.  
 
Since the discovery that low birth weight is associated with increased cardiovascular mortality 
rate and the development of type-2 diabetes mellitus and the metabolic syndrome
240, numerous 
epidemiologic  and  experimental  studies  have  confirmed  these  associations.  The  adverse 
effects of low birth weight are increased if it is followed by accelerated weight gain after the 
age of two years 
241-242. These findings have led to the concept that an undernourished mother 
produces  a  small  (thin–fat)  insulin  resistant  baby.  If  this  baby  remains  undernourished  in 
postnatal life, the cycle is propagated. If the thin–fat insulin resistant baby is over-nourished, it 
becomes  obese,  hyperglycaemic  and  possibly  hypercholesterolemic.  An  obese  and 
hypercholesterolemic mother then produces a baby at higher risk of obesity, hyperglycemia 
and dyslepidemia. Thus, this intergenerational cycle of metabolic like syndrome is propagated 
through a girl child. Rapid transition shifts the balance from undernutrition to overnutrition 
and contributes to escalation of the metabolic/ CVD epidemic, a current situation of our new 
world.  Improving  health  of  a  girl  child  is  of  paramount  importance  in  controlling  this 
epidemic. This proposed model is illustrated in Figure 1.6.  
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It is becoming increasingly clear that the evidence from historical and prospective work so far 
published contains major apparent contradictions 
243-256. Whilst some researchers believe that 
fetal and infant undernutrition is key to the developmental induction of adult disease 
202, others 
argue that overnutrition in the very same time periods is fundamental
203. This controversy 
polarises  research  and  detracts  from  the  ability  to  develop  a  more  holistic  model  of 
environmental impacts on disease risk. So far published literature (referenced above) has led 
to controversy driven primarily from inconsistency in research outcomes, terminology, study 
designs  and  the  interpretation  of  statistics.  This  approach  has,  hence,  made  difficult  to 
understand the concept of overnutrition during early life in increasing risk of common set of 
diseases. 
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Figure-1.6: Proposed model of fetal programming in rapid transition. The model shows the interrelationship of 
two major maternal factors (undernutrition and overnutrition) in fetal programming. An undernourished mother 
produces a small (thin fat) baby. If the baby remains undernourished in a postnatal life, the cycle is propagated. If 
the thin fat baby is overnourished, it becomes obese and hyperglycaemic and produce metabolic syndrome like 
phenotype. An obese and metabolic syndrome mother produces a ―macrosomic‖ baby at higher risk of obesity 
and hyperglycemia. Thus the intergenerational cycle is propagated through a girl child. Rapid transition shifts the 
balance from undernutrition to overnutrition and contributes to escalation of the CVD and metabolic epidemic. 
Improving health of a girl child is of paramount importance in controlling this epidemic.
85,88,89,111,112,194 
 
So far the interpretation of associations between maternal overnutrition and later disease risk 
in  offspring  remains  controversial.  This  is  because  the  statistical  significance  for  these 
associations tends to depend on adjustment for adult weight. It has  also been argued that 
change in size between birth and adulthood is the primary determinant of risk, implicating 
postnatal growth rather than in utero development
205. For example, data from some published 
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subsequent metabolic profile 
206, 257-258, paradoxically suggesting increased risk of the same 
diseases that have been associated in observational cohort studies with infant undernutrition.  
 
 
Given the prominence of CVD risk in offspring, it is helpful to begin by exploring the notion 
that adequacy of fetal nutritional supply reflects variability during pregnancy and/or lactation. 
Genetic factors undoubtedly influence fetal growth; however, studies are relatively consistent 
in  attributing  a  minority  to  genetic  factors
207-208,  indicating  that  most  can  be  attributed  to 
environmental factors. Logic behind the Dutch famine data suggests that those individuals 
exposed during the third trimester provide support for the paradoxical ‗U‘-shaped association 
between prenatal environment and subsequent risk of obesity, as categorised by BMI
200, and 
diabetes
209. Nevertheless, a recent study using ultrasound measurements to identify growth 
faltering  in  each  trimester  of  pregnancy  has  revealed  unexpected  findings
259,  that  early 
faltering may result in a degree of catch-up growth in utero and that large birth weight need 
not necessarily indicate a lack of fetal growth faltering. 
 
 
A second critical issue are apparent inconsistencies in the literature reported with different 
outcomes assessed. Several studies have shown that a maternal diet rich in fat and cholesterol 
during  pregnancy  can  induce  obesity,  vascular  dysfunction,  impaired  skeletal  muscle 
development, sedentary behaviour, and gender-specific hypertension in the offspring
213, 217-219, 
246-247,  254.  However,  these  studies  have  been  confined  to  short-term  modifications  in  the 
maternal  diet,  such  as  during  pregnancy  and/or  lactation  periods  only.  This  disparity  in 
research  outcomes  is  a  major  contributing  factor  to  conceptual  confusion,  for  two  related 
reasons.  First,  it  is  difficult  to  integrate  the  different  outcomes  within  a  simple  model  of 
disease. Second, study findings may on occasion conflict drastically, according to the age of 
the participants.  
 
 
Defining  the  fetal  environment  is  complex.  One  in  which  the  offspring‘s  immediate 
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directly exposed to the external environment
260. Organogenesis occurs primarily within the 
first period, hence this critical period of development could be argued to be induced not by the 
external environment but by maternal phenotype
260-261. The duration of this maternal induction 
varies according to the trait in question. During pregnancy maternal and fetal haemodynamics 
interact, generating differential growth of peripheral vs. central organs
111. The offspring can 
respond  adaptively,  but  its  strategy  is  also  open  to  maternal  manipulation 
260,263.  This 
opportunity for direct haemodynamic interaction ceases at parturition. In contrast, offspring 
metabolism remains sensitive to maternal phenotype during the window of lactation, through 
hormonal  effects  on  milk  output  and  composition.  Physiological  traits  such  as  nephron 
number
264, cardiac structure 
265 and pancreatic β-cell mass 
127 are therefore strongly (although 
not necessarily exclusively) associated with fetal experience, whereas insulin metabolism is 
further sensitive to infant experience
266. It has been argued, from an evolutionary perspective, 
that  the  offspring  adapts  to  the  ‗niche‘  of  maternal  metabolism  and  that  the  mother 
manipulates her offspring to optimise her own reproductive strategy
260-261. As many aspects of 
organ phenotype are essentially fixed from birth or early infancy onwards, as a result of the 
majority of rounds of cell division having been achieved
267, aspects of phenotype induced 
during this developmental period track subsequently into adulthood. 
 
 
Thus, reference can be made to the ‗maternal induction‘ of offspring ‗metabolic capacity‘, 
which is closely associated with certain aspects of organ phenotype. The influence of maternal 
phenotype  on  offspring  development  must  inevitably  weaken  with  offspring  age,  but  the 
schedule of this change depends on ecological factors. Until the development of agriculture, 
early postnatal growth would likewise have been strongly influenced by maternal phenotype, 
via lactation. Even after weaning, the tendency for human offspring to be provisioned by their 
mother would maintain a link between maternal phenotype and offspring growth rate 
260. Such 
extended maternal care confers coherence on offspring development throughout the period of 
pregnancy, infancy and childhood
261.  
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Postnatal growth contrasts with prenatal growth by increasingly impacting on tissue size rather 
than fundamental structure, especially from late infancy. Postnatal growth, the sum of both 
size and somatic tissue (lean and fat), may thus be conceptualised primarily as generating 
‗metabolic load‘. The relative magnitude of growth, and the load it imposes, is associated with 
homeostatic  adaptations  in  metabolic  traits.  For  example,  blood  pressure  increases 
systematically during the growth process
267, influenced independently by both somatic size 
(lean mass)
268 and adiposity
269, with each contributing to the total metabolic load. Even weight 
gain in the first 3 months demonstrates such effects on blood pressure by 1 year of age
270. 
These increases in blood pressure have been attributed to larger bodies imposing a greater load 
on the kidneys
267, invoking haemostatic changes in order to maintain renal homeostasis. In 
other  words,  variability  in  blood  pressure  during  childhood  and  adulthood  reflects  the 
normalisation of metabolic load for a given metabolic capacity
268.  
 
 
This process of normalisation, evident for blood pressure is merely one example of a broader 
pattern whereby metabolic traits mediate the impact of growth-generated metabolic load on 
metabolic capacity. For example, insulin resistance and insulin secretion are closely related, 
such that in healthy individuals insulin resistance can be accommodated by increases in insulin 
secretion  to  maintain  glycaemic  control
266.  However,  the  understanding  of  this  remains 
incomplete. 
 
 
The notion that disease is the result of disparity between metabolic capacity and metabolic 
load  was  essentially  described  in  the  thrifty  phenotype  hypothesis
126,  and  this  conceptual 
model remains capable of integrating the findings of diverse developmental origins research 
studies.  What  has  not  been  sufficiently  appreciated  as  yet  is  the  shift  most  notably  in 
industrialised populations, the possible maternal high fat influence to the offspring exposing 
the offspring to stochastic growth patterns as early as 30 weeks post conception in those born. 
It is this coherence in nutritional experience that appears most strongly to predict subsequent 
disease. 
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Differentiating growth into periods targeting high fat metabolic capacity or metabolic load 
clarifies in several ways the apparent controversy between the ‗low birth weight‘ and ‗growth 
acceleration‘  schools.  First,  it  is  easier  to  appreciate  apparent  inconsistencies  relating  to 
outcomes. Birth weight has been associated with risk of diabetes
152, while rapid infant growth 
has been associated with insulin resistance
257. However, since diabetes represents a ‗two hit‘ 
phenomenon,  in  which  insulin  resistance  is  accompanied  by  β-cell  defect  preventing 
compensations in insulin secretion
 236,239241,242, 258, the epidemiology of diabetes need not be 
identical to the epidemiology of insulin resistance. For example, the life-course induction of 
physiology (e.g. β-cell mass, nephron number) differs from that of physiological function (e.g. 
glycaemic control, blood pressure), which in turn differs from that of disease (e.g. diabetes, 
hypertension). Whether the insulin resistance induced by faster infant growth
257 actually leads 
to  diabetes  in  later  life  is  likely  to  be  mediated  by  β-cell  function,  and  hence  by  fetal 
developmental experience. 
 
 
Second, it is possible to resolve apparent inconsistencies relating to statistical models. Studies 
of older adults with CVD show that, holding current weight constant, those with low birth 
weight have an increased disease risk
202, which implicates the induction of metabolic capacity 
in  early  life  through  strong  effects  on  traits  such  as  nephron  number  or  β-cell  mass,  as 
discussed earlier. Studies of younger adults show that rapid infant weight gain is associated 
with increased physiological markers of risk, regardless of birth weight
206,257, which implies 
the environmental induction of increased metabolic load. The greatest risk for metabolic load 
and metabolic capacity occurs in those individuals who are born small and become large, for 
whom the risk of CVD and the metabolic syndrome is greatly increased
241,  271-272. Recent 
studies further suggest that different periods of childhood growth impact differentially on the 
risk of specific diseases
273-274. Each statistical approach may therefore be considered merely to 
emphasise one component of the dynamic process whereby metabolic load is superimposed on 
metabolic capacity.  
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Third, it is beneficial to differentiate between study designs and possible sensitive periods of 
growth. The findings of intervention studies conducted in both preterm and full-term infants 
during  the  immediate  postnatal  period  have  been  used  to  argue  that  postnatal  growth  is 
implicated  as  the  key  ‗critical  window‘  in  which  susceptibility  to  CVD  is  induced
203. 
However, such studies only demonstrate the magnitude of effect of an intervention conducted 
during a specific period. This interpretation does not therefore support the model that CVD is 
essentially induced by undernutrition prenatal and postnatal experience alone, as suggested 
previously
203. Although it is claimed that the hypothesis of ‗undernutrion‘ (being harmful) is 
supported by data from a range of animal species, the vast majority of such animal studies 
describe  catch-up  growth  following  initial  nutritional  insult,  while  the  remaining  studies 
involve genetically variant animals
206 and so cannot attribute adult phenotypic variability to 
early-life environmental variability. Again,  these animal  studies  implicate an inherent  link 
between different growth periods in the aetiology of later disease, one earlier period exerting 
deleterious effects on metabolic capacity and the other imposing an increased metabolic load 
on that capacity. 
 
 
Fourth, it is possible to differentiate alternative pathways whereby public health policies might 
beneficially impact on health. The close association between birth weight and subsequent lean 
mass,
275  and  the  fact  that  organogenesis  is  largely  completed  by  birth,  suggests  that 
interventions on the mother, during her own development or during pregnancy, may represent 
the  optimum  approach  for  benefitting  offspring  metabolic  capacity.  Birth-weight 
supplementation studies tend to have limited efficacy, 
260-261 hence nutritional intervention 
earlier in the maternal life course may be most successful. Animal studies, for example, show 
that maternal  effects  continue to  act  on offspring  phenotype  across several  generations.
276 
Alternatively, during pregnancy maternal metabolic control may represent a better candidate 
for intervention than maternal diet,
260 as it is the nutrient concentration gradients between fetus 
and mother that determine fetal supply. In contrast, postnatal interventions may prove most 
beneficial in preventing the induction of excess metabolic load. 
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Prompted  by  animal  studies,  the  proposed  over-nutrition  model  (section  1.8)  changes 
perspectives on how to intervene in the ―life-style‖ disease epidemic. It shows that lifestyle 
interventions alone may be only partially effective in that those who are most affected by 
inappropriate PAR and may be difficult to manage with life-style interventions in adulthood. 
The proposed model suggests that improving maternal and fetal health will allow humans to 
cope better with current postnatal nutritional conditions—conditions that we do not evolve to 
inhabit. There is increasing focus on the periconceptual period being the critical period when 
programming cues are most effective. If that is the case, then the focus will have to be on the 
health  of  women  before  pregnancy  and  their  nutritional  status  at  conception  and  early 
pregnancy. The DOHaD paradigm is clearly important in these evolution patterns of human 
disease  and  intervention  studies  with  strict  experimental  design  to  test  the  importance  of 
maternal  nutrition  on  offspring  phenotype  need  to  be  initiated.  But  before  discussing  the 
specific hypothesis and overall aims of this thesis, it would be advantageous to elaborate on 
the aetiology of the CVD in the following paragraphs. 
 
1.10 Factors that Promote Early Cardiovascular Disease 
 
The underlying cause of early CVD is characterized by a long lag time between
 onset and 
clinical  manifestation.  The  prodromal  stages  of  CVD
  lesions  are  suggested  to  be  already 
formed during fetal development
277-278.
 Once initiated,
 progression of the CVD is influenced
 
by  classical  risk  factors  that  promote  vascular  inflammation
279-282.  These  inflammatory 
changes  in  vasculature  results  in  remodelling  with  a  well  established  consequence  of 
perturbations in blood pressure or flow. These perturbations are affected by the secretion of 
vascular smooth muscle elastin, reported to occur during development and thus induce effects 
on  vascular  compliance
283.  In  turn,  this  results  in  increased  numbers  of  macrophages
  and 
lymphocytes, release
 of hydrolytic enzymes, cytokines, chemokines, and growth factors
284 that 
could  induce  further  damage  and  eventually  lead  to  focal
  necrosis
285.  Endothelial  cell 
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considered to provide further pro-atherogenic stimulus. It is suggested that poor endothelial 
function  implicated  in  insulin  resistance,  observed  in  metabolic  syndrome;  and  leads  to 
reduced glucose uptake. This impaired vascular growth in the early development is linked to 
prematurely  reduced  compliance  in  adulthood
286  by  a  few  investigators  working  on  CVD 
lesions during fetal development.  
 
1.10.1 Maternal lipid profile  
Napoli  and  co-workers  observed  that  maternal  hypercholesterolemia  was  associated  with 
greatly
  enhanced  fatty  streak  formation  in  human  fetal  arteries
278.  These  results  hence, 
suggested that during the earlier
 stages of pregnancy, maternal hypercholesterolemia promoted
 
lesion formation in the fetus.
278 However, conventional risk factors
 assessed in children and 
their mothers remained unable to explain this
 difference.  
 
Studies  have  so  far  reported  a  direct  evidence  describing  a  correlation  of  maternal 
hypercholesterolemia
  with  the  plasma  concentrations  of  oxidized  fatty  acids  and  lipid 
peroxidation  by-products  in  offspring
  of  hypercholesterolemic  and  cholestyramine-treated 
mothers.
287-290  Fetal  arterial  cells  exposed  to
  significant  oxidized  low  density  lipoprotein 
(OxLDL)  from  maternal  hypercholesterolemia  demonstrated  a  pattern  of  atherogenesis 
distribution similar to that in early lesions
 of adults and animal models.
291-292 In humans, it 
remains  to  be  established  how  much  of  the  accelerated
  atherogenesis  in  offspring  of 
hypercholesterolemic mothers is caused by in utero programming events and how much is due
 
to inherited genetic differences. Nevertheless, numerous signalling pathways downregulated in 
fetuses by increased oxidation of LDL in hypercholesterolemic mothers
293-296 suggested
 that 
fetal pathogenic events increased the postnatal susceptibility
 to atherosclerosis and this led to 
early CVD. 
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1.10.2 Acute phase response- C-reactive protein 
Pregnancy  is  generally  associated  with  an  increase
  in  circulating  cytokine  and  C-reactive 
protein (CRP) concentrations
297 and this increase strongly correlates to the decrease
 in insulin 
sensitivity in pregnancy. 
298 In rodents, it is demonstrated that prenatal exposure to cytokines
 
leads to marked increase in adipose tissue
 mass in male and female offspring.
299 The metabolic 
consequences
 of this excess abdominal fat mass manifests in reduced insulin sensitivity
 in 
male  offspring  and  hyperandrogenism  in  female  offspring.  Hence,  pregnancy-induced 
elevations in cytokines especially CRP may have a role to play in fetal programming.  
 
CRP  is  an  acute-phase  reactant  pathologically  produced  during  infection,
  inflammatory 
disease,  cancer,  and  tissue  injury.
300  It  consists  of  five  identical  nonglycosylated  21-kDa 
subunits that
 are synthesized mainly in the liver
301 and is present at a low
 level (below 10 
µg/ml) in humans under normal conditions. In response
 to acute-phase stimuli, plasma CRP 
concentration can increase
 significantly up to 1,000-fold and return to
 normal levels (<1µg/ml) 
with resolution of the disease.
301 It is reported that in patients at increased risk of CVD, the 
CRP
 levels are elevated and remains elevated
 for many months to years.
302  According to the 
recently  issued  guidelines  for  cardiovascular  risk  assessment,  patients  with  CRP  levels 
between 1 and 3mg/L are considered to be at intermediate risk and those with levels above 
3mg/L at high risk
303.  
 
It  is  suggested  that  CRP  directly  causes  endothelial  dysfunction  through  reducing  the 
expression and bioactivity of endothelial nitric oxide synthase (eNOS), and inhibits in vitro 
angiogenic  functions  as  measured  by  endothelial  cell  migration.
304-305  Increased  CRP 
concentration
 in the plasma significantly associates with the presence
 of macrophages and T 
lymphocytes  in  plaques  in  high-grade  carotid
  stenosis  patients.
306.CRP  is  also  shown  to 
accelerate aortic atherosclerosis development in apolipoprotein-E deficient mice, which points 
out that CRP is an active player in CVD process.  CRP also contributes to the formation of   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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foam cells in atherosclerotic
 lesions by causing the aggregation of LDL molecules that are
 then 
taken up by macrophages through a CD32-independent pathway.
306-307  
 
In a synchronous
 fashion, CRP has been shown to stimulate endothelin-1 and interleukin-6
 
release, upregulates adhesion molecules, and stimulates monocyte
 chemotactic protein-1 while 
facilitating macrophage LDL uptake
308.
 CRP
 potently downregulates endothelial nitric oxide 
synthase (eNOS)
 transcription and destabilizes eNOS mRNA in the vascular endothelium that 
decreases both
 basal and stimulated nitric oxide (NO) release
309 (Figure-1.7).  
 
 
 
Figure-1.7:  Human recombinant CRP at concentrations known to predict adverse cardiovascular events directly 
interacts with the endothelium to decrease the production of the multifactorial vasoactive peptide NO. This effect 
appears to occur in part via decreased eNOS mRNA stability. In a synchronous fashion, CRP promotes the EC 
release of the potent endothelium-derived vasoconstrictor, ET-1, and a key inflammatory cytokine, IL-6. These 
actions of CRP induce EC dysfunction and promote a proinflammatory and proatherosclerotic phenotype.  CRP 
also promotes EC apoptosis and inhibits angiogenesis via decreasing NO production.
309 
 
CRP has also been shown to facilitate endothelial cells (EC) apoptosis
, inhibits angiogenesis 
and upregulates nuclear
 factor- κB (NFκB; a key nuclear factor that facilitates the transcription
 
of numerous proatherosclerotic genes).
307-310 The direct proatherogenic
 effects of CRP extends 
beyond  the  endothelium  to  the  vascular
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angiotensin type-1 receptors and stimulates vascular smooth muscle migration,
 proliferation, 
neointimal formation, and reactive oxygen species (ROS)
 production.
309,311,312 This detrimental 
effect
 of CRP is also reported to extend to bone marrow derived endothelial progenitor cells 
(EPCs) that contribute to postnatal neovascularisation (Figure-1.8).
 
 
 
Figure-1.8:  Bone  marrow–derived  EPCs  contribute  to  postnatal  neovascularization.  CRP,  at  concentrations 
known to predict cardiovascular disease, inhibits EPC survival, differentiation, and function, thereby inhibiting 
an important mechanism of angiogenesis and compensatory response in chronic ischemia.
302 
 
1.10.3 Role of bone marrow derived endothelial progenitor cells 
Altered angiogenesis is a key component of the later development of vascular dysfunction and 
CVD, while the endothelium plays a major role in the development of the vasculature. The 
adherent endothelium undergoes a continuous renewal from tissue and circulating progenitor 
cells that originate in the bone marrow. In turn, circulating endothelial cells and microparticles 
are released from the adherent endothelium.
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angiogenesis in various experimental models,
318 possibly through decreased proliferation and 
increased apoptosis of endothelial cells and dysregulation of the angiogenic factor VEGF. 
Early  endothelial  dysfunction  may  well  pave  the  way  for  later  hypertension,  as  reduced 
vascular  density  and  increased  vascular  resistance  are  considered  to  be  among  the  early 
alterations that lead to hypertension
319. 
 
Ingram et al
317 previously showed that endothelial progenitor cells (EPCs) from the offspring 
of diabetic mothers display altered angiogenic functions. Such early endothelial dysfunction 
consists  of  reduced  colony  formation  and  self-renewal  capacity  and  capillary-like  tube 
formation  due  to  reduced  proliferation  and  accelerated  senescence.
317  High  glucose 
concentrations in vitro are responsible for similar effects. Concentrations of circulating soluble 
markers  of  endothelial  function,  such  as  intercellular  adhesion  molecule-1,  vascular  cell 
adhesion molecule-1 and E-selectin, have been found to be increased in offspring of type-1 
diabetic mothers compared with offspring from non-diabetic pregnancies
318. 
 
Differentiation of mesodermal cells to angioblasts and subsequent
 endothelial differentiation 
were believed to exclusively occur
 in embryonic development. This dogma was overturned in 
1997,
 when Asahara and colleagues
319 published that purified CD34
+ hematopoietic
 progenitor 
cells from adults can differentiate ex vivo to an
 endothelial phenotype. These cells were named 
"endothelial progenitor
 cells" (EPCs) and showed expression of various endothelial markers,
 
and incorporated into neovessels at sites of ischemia. Rafii‘s
 group
320  in 1998 also reported 
the existence of "circulating bone
 marrow-derived endothelial progenitor cells" (CEPCs) in the
 
adult. Again,  a subset of CD34
+ hematopoietic stem  cells  is
 shown to  differentiate to  the 
endothelial  lineage  and  incorporated  Dil-Ac-LDL,  Acetylated  Low  Density  Lipoprotein, 
labeled with 1,1\'-dioctadecyl – 3,3,3\',3\'-tetramethyl-indocarbocyanine perchlorate.
  Because 
CD34
+ is not exclusively expressed on hematopoietic stem
 cells but, albeit at a lower level, 
also on mature endothelial
 cells, further studies used the more immature hematopoietic
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cell  marker  CD133
320  and  demonstrate  that  purified  CD133
+  cells  can  differentiate  to 
endothelial cells in vitro.
321 
 
EPCs reflect the phenotype of embryonic angioblasts, which are migratory endothelial cells 
with the capacity to circulate, proliferate, and differentiate into mature endothelial cells, but 
which  have  neither  acquired  characteristic  markers  of  mature  endothelium  nor  formed 
lumina.
321-322  Although  there  is  abundant  evidence  of  the  existence  of  angioblasts  during 
embryonic development, the isolation and characterization of EPCs from adult circulation has 
been  hampered  by  the  absence  of  specific  endothelial  markers  and  functional  assays. 
However, it is suggested that certain hematopoietic cells are able to incorporate acetylated 
LDL  (AcLDL)  and  to  bind  lectins  such  as  ulex  europaeus,  which  are  usually  considered 
endothelial specific.
318-320 
 
Several  studies  have  attempted  to  identify  EPCs  by  performing  bone  marrow  (BM) 
transplantation  studies  in  which  recipient  and  donor  cells  could  be  distinguished  by 
endothelial-specific  markers.  One  study
321  has  suggested  that  BM-derived  VEGFR2
+ 
endothelial progenitor cells could be detected in the peripheral circulation and contribute to 
vasculogenesis. However, although 27% of freshly isolated CD34
+ cells were VEGFR2
+ as 
determined by flow cytometry, the authors of this study were not able to detect VEGFR2 
mRNA in the first 7 days of culture using RT-PCR, perhaps because the isolated cells were 
not, in fact, of endothelial origin. In subsequent studies, populations of cells enriched for EPCs 
were derived from murine peripheral blood cells or BM and labelled with DiI to track the 
mobilization and recruitment of these cells into ischemic limbs.
322-329 However, given that 
subsets  of  hematopoietic  cells  have  the  capacity  to  express  CD31,  Tie-2,  and  incorporate 
AcLDL, it is not clear whether the mobilized cells and the cells incorporated into the vessel 
wall were of primarily hematopoietic or endothelial origin.
330-331 
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Rafii  et  al  have  shown  that  allogeneic  sex-mismatched  BM  transplantation  results  in  the 
transfer of endothelial cells to recipient dogs.
332 Replacement of the aorta of the recipient dogs 
months after transplantation with impervious Dacron grafts resulted in graft endothelialization 
arising exclusively from the transplanted BM. In humans, evidence for EPCs originates from 
patients implanted with  a left ventricular assist  device (LVAD).  It has  been demonstrated 
colonization of the flow surface of the titanium housing of LVADs with CD34
+ endothelial-
like cells 6 months after the devices were removed
332. These studies suggest that transplanted 
EPCs  residing  in  the  bone  marrow  have  the  capacity  to  be  mobilized  to  the  peripheral 
circulation  and  incorporate  in  the  sites  of  active  angiogenesis.  However,  because 
transplantation  of  whole  bone  marrow  results  in  transfer  of  both  mature  bone  marrow 
endothelium and putative EPCs, none of these studies have conclusively demonstrated the 
existence  of  a  phenotypically  and  functionally  distinct  population  of  EPCs.  Given  the 
significant contribution of EPCs to vascular homeostasis, it may not be surprising that EPC 
has emerged as a contributing risk factor to developing adult CVD.  
 
1.11 Therapeutic Strategies to Reverse Early Cardiovascular Disease 
 
The early identification of factors that play a role in preclinical CVD and the understanding of 
the plausible mechanisms are important to implement strategies for reversing this situation, if 
possible, in early life   
 
1.11.1 Lifestyle modification 
Increased physical activity and fitness are established inverse risk factors for CVD. Exercise 
training is associated with both enhanced endothelium-dependent dilatation and increased NO 
production  in  young  men  of  average  fitness.
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correlated with endothelial function in males with known CVD.
334 The beneficial effect of 
exercise can be noted much earlier even by the first decade of life. However, the intensity and 
frequency of the exercise-training programme should be validated for a long-term clinical 
benefit. Other lifestyle modifications such as weight loss, reduction in obesity and smoking 
cessation have also been shown to have a beneficial effect on markers of inflammation and 
endothelial  activation.
335  We  recently  proposed  that  pathophysiology  of  several  conditions 
including  CVD  is  partly  attributable  to  a  failure  of  the  cell  energy  metabolism  and  that 
exercise training (ET) improves quality of life (QOL) and is beneficial in terms of reduction of 
symptoms, mortality and duration of hospitalization
336. However, the mechanisms underlying 
the beneficial effects of ET are far less understood and do not address the point that if problem 
arises in development, what stands the role of exercise in adults. Hence this requires further 
evaluation.  
 
1.11.2 Nutrient supplements—dietary modification 
Dietary  L-arginine supplementation has been shown to improve endothelial function in the 
brachial artery of young people with hypercholesterolemia.
337 Other nutrient supplements such 
as folic acid restore endothelial function in high-risk children for CVD.
338 Although folic acid 
supplementation is originally related to decreased levels of homocysteine, a novel risk factor 
for  atherosclerosis,  further  evidence  suggests  a  direct  effect  of  folate  on  the  vascular 
endothelium.
339  Diets low in fat and high in olive oil, vegetables and fruits equivalent to 
Mediterranean  diet  has  been  recommended  to  decrease  cardiovascular  risk.  Different 
components of this diet can also have beneficial effects on endothelial function. Studies have 
evidenced that lifestyle modification in individuals at increased cardiovascular risk can delay 
and possibly prevent the progression of atherosclerotic disease.
339-340  
 
With  regard  to  antioxidant  therapy  it  has  been  shown  that  vitamins  C  and  E  restores 
endothelial  function  in  hyperlipidemic  children  (EARLY  trial) 
341  and  has  synergistic 
antioxidant  actions  in  improving  endothelial  vasodilatory  response  and  decreased  serum   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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inflammatory and thrombotic/fibrinolysis markers.
341-342 Although large randomized clinical 
trials  failed  to  demonstrate  so  far  a  beneficial  effect  of  antioxidant  vitamins  for  disease 
prevention and treatment of  late CVD stages, the above mentioned positive results derived 
from observational studies provide some evidence for a potential role of antioxidants in the 
early phase of the disease.
343 
 
However, lifestyle modifications/ interventions alone may be partially effective in that those 
who are already affected by inappropriate intrauterine conditions or PARs and may be difficult 
to  manage  with  lifestyle  interventions  in  adulthood.  Our  proposed  model  suggests  that 
improving maternal and fetal health will allow humans to cope better with current postnatal 
nutritional conditions- conditions that we did not evolve to inhabit.  
 
1.11.3 Pharmacological interventions- Statins 
There is emerging evidence that hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitor (Statin) treatment improves lipoprotein profile towards more physiological levels and 
restores endothelial function.
344 Landmark clinical trials with pravastatin (WOSCOPS) and 
simvastatin (4S) demonstrate that these statins markedly decrease serum cholesterol levels and 
reduce the incidence of myocardial infarction and also cardiovascular mortality in primary and 
secondary  prevention  in  individuals.
345-346  Additionally,  several  other  trials  such  as 
AFCAPS/TEXCAPS and LIPID report that other statins also had similar beneficial effects.
347-
348 In these studies, Lovastatin reduced the risk for the first acute major coronary event in men 
and women with average total and low-density lipoprotein (LDL)-C levels and below-average 
high-density lipoprotein (HDL)-C levels. While it is crucial to achieve lipid goals, it is also 
important to realize that half of all acute MI occur in patients with normal lipid levels.
349 
Emerging work in the literature cues to the beneficial effects of statins in the prevention of 
myocardial infarction independent to their effect of reducing serum cholesterol levels.
349 
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Other pleotropic effects of statins other than lipid lowering are speculated.  A non randomized 
cohort of patients with CVD demonstrates that statins decrease plasma levels of CRP.
350 Other 
effects includes improvement of endothelial function, reduction of pro-inflammatory events 
such as a decrease in monocyte adhesion and infiltration, and increases plaque stability.
351-352 
A number of studies described other properties of statin drugs that possibly contributed to their 
pleiotropism and interaction with the ubiquitin–proteasome system.
353-355 Statins are shown to 
reduce  atherogenic  plaques  in  vitro
356,  scavenges  free  radicals  and  inhibits  lipid 
peroxidation.
357-358 Wiegman and co-workers demonstrated earlier that long-term pravastatin 
therapy  induced  a  significant  regression  of  carotid  atherosclerosis  in  children  with  family 
history.
359 In addition, statin therapy had promising short-term efficacy and reassuring safety 
in terms of changes in hepatic and muscle enzymes in children.
356 Although statin therapy is 
not  yet  the  recommended  therapeutic  approach  for  children  with  familial 
hypercholesterolemia, it might prove a reasonable treatment policy considering the limited 
window  for  cardiovascular  prevention  in  this  high-risk  group  of  children.  Inhibitors  of 
cholesterol absorption had also been tested in children with familial hypercholesterolemia with 
a significant reduction in the levels of LDL cholesterol.
344  
 
First  evidence  for  potential  pharmacological  modulation  of  systemic
  EPC  levels  by 
atheroprotective  drugs  came  from  studies  using
  statins.  Statins  are  shown  to
  increase  the 
number and the functional activity of EPCs in vitro,
 in mice, and in patients with stable CAD. 
359-361 The increase in EPC numbers was associated with increased bone
 marrow-derived cells 
after balloon injury and accelerated endothelial
 regeneration.
362-363 Although statins are shown 
to increase the
 number of stem cells within the bone marrow, the mechanism for
 enhancing 
EPC numbers and function may additionally include
 an increase in proliferation, mobilization, 
and prevention of
 EPC senescence and apoptosis.
361-364 The molecular signalling pathways
 for 
such  an  effect  have  not  been  identified  so  far.  However,  several  studies
  indicate  that  the 
activation of the PI3K/Akt pathway, which
 has first been shown to be activated in mature 
endothelial cells
 by statins,
365-366 may also play an important role in statin-induced
 increase in 
EPC levels.
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1.11.4 Therapeutic potential of endothelial progenitor cells 
It is now well established that endothelial dysfunction underlies all of the major CVD process. 
Pathologic conditions  such as  hyperlipidemia,
  hyperglycemia,  and hypertension impair the 
ability of the vascular
 endothelium to produce vasodilatory and anti-adhesion moieties.
366 This 
increases  the  production  of  vasoconstrictor,  pro-adhesion,
  and  pro-thrombotic  molecules, 
leading  to  elevated  vascular  tone,
  enhanced  cell  adhesion,  proliferation  of  media  smooth 
muscle
 cells, and propensity toward thrombosis.
366  
 
Studies have suggested
 that EPCs originating
 in the bone marrow play a significant role in 
endogenous  neovascularization
  of  ischemic  tissues
367  and  re-endothelization
  of  injured 
vessels.
368-371 In addition, EPC mobilization
 and proliferation is reported to contribute to the 
salutary
  effects  of  3-hydroxy-3-methylglutaryl–coenzyme  A  reductase
  inhibitors  and 
estrogen.
371-372  EPC  transplantation  has  been
  shown  to  induce  new  vessel  formation  in 
ischemic  myocardium
  and  hind  limb
373  and  to  accelerate  re-endothelialization
  of  injured 
vessels  and  prosthetic  vascular  grafts  in  humans
  and  in  various  animal  models.
374  This 
demonstrates  their  therapeutic
  potential  as  a  cell-based  strategy  for  rescue  and  repair  of
 
ischemic  tissues  and  injured  blood  vessels.  Furthermore,  EPCs
  are  amenable  to  genetic 
manipulation,  underscoring  their  usefulness
  as  vectors  for  local  delivery  of  therapeutic 
genes.
373  However,  despite  the  excitement  regarding  the  possible  clinical
  use  of  EPC, 
upcoming studies have shown that age and other risk
 factors for CVD reduce the availability 
of
  EPC  and  impairs  their  function  to  varying  degrees,
374  thus  limiting  their  therapeutic 
usefulness in these patient
 populations. Furthermore, the relative scarcity of EPCs and
 their 
finite proliferative potential limit the ability to expand
 these cells in sufficient numbers for 
some therapeutic applications.
375-376 
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1.12 Summary 
In summary, epidemiological observations and biomedical evidence discussed so far (sections 
1.1-1.5) have focussed on the possible role of early life influences in altering later disease risk 
i.e.  the  ‗‗developmental  origins  of  health  and  disease‘‘  (DOHaD)  paradigm.  These 
observations have led to the recognition of concepts towards our understanding of human 
disease biology in specific CVD and metabolic syndrome. It is suggested in these reports 
(sections 1.5.2, 1.5.3 & 1.6) that the DOHaD phenomenon can be considered as a subset of the 
broader processes of developmental plasticity by which organisms adapt to their environment 
during their life course. Mismatch between the anticipated and the actual mature environment 
exposes the organism to risk of adverse consequences—the greater the mismatch, the greater 
the risk. For humans, prediction is inaccurate for many individuals because of changes in the 
postnatal environment toward energy-dense nutrition and low energy expenditure, contributing 
to the epidemic of CVD and metabolic syndrome (section 1.7).  
 
 
There  has  been  increased  attention  on  the  possible  association  between  altered  maternal 
nutrition and cardiovascular or metabolic disease in the offspring. Namely, alterations in fetal 
nutrition (either under- or over-nutrition) may result during critical periods when offspring are 
most  vulnerable
  to  developmental  adaptations  that  permanently  change  the  structure, 
physiology and metabolism of the offspring, thereby predisposing individuals to metabolic and 
cardiovascular diseases in adult life. Today the most common maternal dietary imbalance in 
populations
  is  an  excessive  intake  of  dietary  fat.  There  is  growing  body  of  evidence  that 
significant health problems for women of reproductive age result from being
 overweight or 
obese  due  to  overeating.  Upcoming  studies  to  some  extend  have  shown  that  maternal 
overnutrition retards placental and
 fetal growth, and increases fetal and neonatal mortality in
 
animal  models.    As  described  in  the  earlier  paragraphs,  results  of  recent  epidemiological
 
studies indicate that almost 65% of the adult population in
 the U.S. is overweight [defined as a 
body mass index (BMI) >
 25 kg/m
2], while 31% of the adult population is obese (defined
 as 
BMI > 30 kg/m
2). Many overweight and obese women
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continue overeating during gestation. These women usually gain more weight during the first
 
pregnancy  and  accumulate  more  fat  during  subsequent  pregnancies.
  Maternal  obesity  or 
overnutrition before or during pregnancy
 may result in fetal growth restriction and increased 
risk of
 neonatal metabolic syndrome and cardiovascular risk factors (sections 1.8-1.9).  
 
Previously, studies have demonstrated
 abnormalities in plasma lipids, vascular fatty acids, and 
evidence
 for reduced endothelium-dependent relaxation in adult offspring
 of rodent models fed 
a lard-rich diet during pregnancy, suckling or lactation.
  However neither the design of these 
studies  carried  out  nor  the  fat  intake  mimic  the  typical  high-fat  Western  diet  and  human 
situation. Although the epidemiological associations are strong, a mechanistic understanding is 
essential in order to demonstrate that these associations are causal and in what way can be 
identified for the potential of intervention. Mechanistically and experimentally, there is an 
increasing body of knowledge showing that manipulation of the environment in the period 
extending from conception to infancy can be associated with permanent changes in physiology 
and/or structure. In turn, many of these changes are associated with permanent alterations in 
gene  expression  regulated  by  epigenetic  factors  such  as  DNA  methylation  and  histone 
methylation/acetylation.  Moreover,  to  date  no  one  has  determined  the  role  of  early 
pharmacological intervention in mothers and its effects on offspring in terms of cardiovascular 
control using the animal model. In this thesis, it is proposed that until more insights on the 
pathogenic mechanisms associated with high fat high cholesterol during pregnancy have been 
gained, an intense understanding into the influence on early CVD risk in offspring (in their 
adult life) from such high fat high cholesterol mothers is difficult; let alone the interventions 
and which critical window when is best suited (section 1.8). 
 
The proposed model will change perspectives on how to intervene in the ―life-style‖ disease 
epidemic. It shows that lifestyle interventions alone may be only partially effective in those 
who are most affected by inappropriate PAR and may be difficult to manage with life-style 
interventions in adulthood. The model suggests that improving maternal and fetal health will 
allow humans to cope better with current postnatal nutritional conditions—conditions that we   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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did  not  evolve  to  inhabit.  If  high  fat  environment  is  the  core  process  underlying  such 
programming in today‘s world, then priority should be given to understanding what changes 
occur, when they occur, the key mechanisms involved, and whether there are windows of 
opportunity during which the effects can be reversed (section 1.11). The whole discussion 
presented here and the proposed model are summarised in Figure 1.9. 
 
 
 
 
 
 
 
 
 
 
 
Figure-1.9: A model that demonstrates the effect DOHaD paradigm representing three spectrums. Spectrum-I 
demonstrates the undernutrition limb of the DOHaD, where considerable yet controversial amount of information 
is available. Spectrum- II characterizes the high fat (HF) overnutrition environment and its effect on short and 
long term adaptations of the offspring and then the adult in clinically contracting the disease (CVD and metabolic 
syndrome).  This  information  with  regard  to  biomedical  perspective  and  disease  risk  is  either  still  scarce  or 
missing. Spectrum- III represents the arm of interventions and which critical window is the best opportunity to 
combat this epidemic of  CVD and  metabolic  syndrome.  Again, the information is  missing in the published 
literature so far.   
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In populations of the world that are undergoing the nutritional and epidemiologic transition to 
Western style of diet, sedentary behaviour, obesity and chronic diseases, the ominous pattern 
that Baker et al identify- the lower birth weight followed by excess weight gain in childhood- 
is both common and liable to persist for the foreseeable future. It is therefore imperative that 
along  with  vigorous  efforts  to  optimise  childhood  growth,  researches  and  policymakers 
identify, quantify and  evaluate strategies to  modify prenatal and perinatal determinants  of 
adverse adult health outcomes. 
 
1.13  Hypotheses 
Based  on  the  discussions  and  spectrums  presented  in  section  1.12  and  Figure  1.9 
respectively, the main hypotheses of this thesis are;  
1.   Does  long-term  prenatal  and  postnatal  high  fat  nutritional  environment  induce 
metabolic and cardiovascular disease in offspring later in its adult life?  
2.  Does early pharmacological intervention in mothers consuming a high fat diet exert 
beneficial effects in preventing metabolic and cardiovascular disease in the adult life of 
the offspring? 
 
1.14 Aims  
 
1.14.1 General Aims 
The thesis consists of small animal (rodents) based laboratory investigations. The primary 
focus of this work is to investigate the long term effects maternal high fat overnutrition may 
exert in their adult offspring both in prenatal and postnantal environments. The thesis also 
seeks to explore the effects of high fat rich in cholesterol nutrition in dams. The underlying 
mechanisms  by  which  these  effects  play  a  role  on  biochemical  and  cardiovascular  patho-  M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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physiology including liver, kidneys, blood and bone marrow derived endothelial progenitor 
cells are studied. Paying particular attention to a possible critical window for lipid lowering 
pharmacological intervention in mothers, the thesis also aims to address the effect of short and 
long term maternal treatment on biochemical and vascular physiology of their offspring in 
preventing metabolic and cardiovascular disease in offspring later in adult life.  
 
1.14.2 Specific Aims 
1.  To investigate whether long-term maternal high-fat (HF) feeding during pregnancy and 
lactation predisposes offspring to hypertension, raised plasma lipids and fatty liver in 
mice. 
2.  To investigate whether there are additive effects of feeding the offspring a HF diet 
from weaning to adulthood.  
3.  To  study  whether  lipid  lowering  pharmacological  intervention  with  statin  in  late 
pregnancy in HF fed dams reduces cardiovascular and metabolic risk factors in their 
offspring. 
4.  To investigate whether there are any sex differences in the offspring from these statin-
treated HF-fed dams in their cardiovascular and metabolic responses to post-weaning 
HF feeding. 
5.  To study whether statin administration to female mice from the time they were weaned 
until weaning of their offspring reduces cardiovascular risk factors in these offspring, 
even if offspring are fed a high fat diet 
6.  To study the expression of EPC in bone marrow cultures from the female offspring.  
 
In addition this study will also assess, and investigate the biochemical variants involved, by 
various  biochemical  and  molecular  biological  techniques.  The  plan  of  investigations  and 
laboratory techniques are therefore discussed in Chapter-2.  
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Just as the highest tower needs a deep foundation, 
so too the highest thinking is based on going deep within. 
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CHAPTER 2 
General Methods 
 
 
2.1   Animal Model 
 
Animal models provide a direct approach to determining possible mechanisms involved in 
disease  processes.  They  are  advantageous  in  that  they  allow  the  study  of  the  interaction 
between physiological and genetic mechanisms during the animal‘s lifespan. Furthermore they 
also allow the study of intergenerational effects, for example, induced vascular defects have 
been shown to be transferred from the mother to the next generation in rats.
377 Rodent models 
are widely used, and many experiments examining the DOHaD phenomenon have used these 
models. Rodents are advantageous in that they have a short gestation period and a relatively 
large number of offspring in which to study any effects. Furthermore, the rodent genomes 
have been widely studied and the genome sequences for mice and rats have recently been 
completed. However comparisons to  humans must  be made carefully  as  we have a much 
longer gestation period and fewer offspring. What is more, the brains of mice and rats are not 
fully developed at birth but continue to develop during the first few postnatal weeks, unlike 
humans whose brains are more fully developed at birth. Hence any effort
 to compare these 
studies and to apply them clinically must take into
 account interspecies differences in the 
stages
 of brain development occurring before and after birth. For example, the rat
 is an altricial 
species, born with the thyroid- hypothalamic- pituitary axis not yet
 fully matured. The sheep, 
in contrast, is a precocial animal
 born with the development
 of the thyroid-pituitary axis nearly 
complete at birth
378.  
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The human at birth is somewhat intermediate between
 the rodent and sheep in that it has a 
relatively immature central
 nervous system but a more fully developed thyroid hormone axis.
 
The importance of such differences in developmental
 timescales is illustrated by the fact that 
the majority of experimental
 studies in the rodent have analyzed the effect of thyroid
 hormone 
deprivation in the early neonatal period which corresponds
 to the late intrauterine phase of 
development  in  sheep  and  humans.
  Thus,  whereas  there  is  evidence  of  a  role  for  thyroid 
hormone in brain
 maturation during the intrauterine period in human
379-381 and sheep,
382-383 this 
is not yet clearly established
 in the rodent. Thyroid hormone appears to regulate processes
 
associated  with  terminal  brain  differentiation  such  as  dendritic
  and  axonal  growth, 
synaptogenesis, neuronal migration, and myelination. It is for these reasons that sheep models 
are also of great use for studying DOHaD. Sheep have a longer gestation period (5 months), 
more similar to humans and also give birth to one or two offspring. 
 
However, this thesis is concerned with the process of rodent development and how it can be 
affected  by  maternal  and  environmental  conditions.  The  processes  and  mechanisms  under 
investigation in this work are manifested at the level of the ‗organism‘, either before or after in 
utero  development.  Ethical  constraints  on  experimentation  in  humans  and  the  absence  of 
suitable alternatives (e.g. computer models) for studying the DOHaD phenomenon, mean that 
rodent models are vital in the study of developmental physiology and investigation of the 
mammalian developmental process.  Specific to  this  thesis  objectives,  I  shall  be collecting 
various  samples  at  different  stages  of  development  and  taking  an  integrated  approach  by 
combining in vivo systems physiology with cell/tissue culture and conventional biochemical 
analyses in order to maximise the amount of information obtained from an individual animal. 
 
 
I chose rodents as the appropriate animal model for this research program because; 
 
  The overwhelming bulk of our knowledge to date on reproductive and developmental 
biology  in  mammals  is  based  on  the  rodent.  Their  developmental  profile  is  well 
established and the periods in which different organs develop are known   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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  Rodents  offer  the  best  ―functionally‖  characterised  mammalian  model  system.  In 
particular the rodent maternal diet model has been firmly established for analysis of 
mechanisms involved in fetal programming at the laboratory where I have carried out 
the research work. 
  The size of these animals makes them ideal for physiological manipulations. 
  They have a high reproductive capacity. They produce many fetuses/ offspring per 
dam thus reducing the need for a large cohort of mothers per experimental group. 
  They have comparatively short generation time and lifespan. 
  And they are easy to care for and to handle and are small and inexpensive 
 
 
I used C57BL/6J mice, purchased from Charles River Labs UK, for my experiments in this 
thesis.  C57BL/6  is  the  most widely used inbred strain.  It  is  commonly  used as  a  general 
purpose strain and as  a background strain for the  generation of congenics carrying  either 
spontaneous or induced mutations. Although this strain is refractory to many tumours, it has a 
permissive background for maximal expression of many mutations. C57BL/6J mice are used 
in a wide variety of research areas including cardiovascular biology, developmental biology, 
diabetes  and  obesity,  genetics,  immunology,  neurobiology,  and  sensorineural  research. 
C57BL/6 mice breed well and are long-lived. Other characteristics include;
384-385 
 
1)  A high susceptibility to diet-induced obesity, type-2 diabetes, and atherosclerosis. 
2)  A high incidence of microphthalmia and other associated eye abnormalities. 
3)  Resistance to audiogenic seizures 
4)  Low bone density 
5)  Hereditary hydrocephalus (early reports indicate 1 - 4 %) 
6)  Hair loss associated with overgrooming 
7)  Preference for alcohol and morphine 
8)  Late-onset hearing loss 
9)  Increased incidence of hydrocephalus and malocclusion.  
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The first characteristic on this list is critical to this thesis. C57BL/6J mice when fed a HF diet 
develop obesity, hyperglycemia, and hyperinsulinemia. For example, feeding these mice an 
atherogenic  diet  (1.25%  cholesterol,  0.5%  cholic  acid  and  15%  fat)  for  14  weeks  led  to 
development of atherosclerotic lesions in the aorta ranging from 4500 to 8000 µm
2 in cross-
sections.
384-387  
 
 2.2   The High Fat High Cholesterol Diet Model 
 
All animal procedures carried out in this study are in accordance with the regulations of the 
British  Home  Office  Animals  (Scientific  Procedures)  Act,  1986.  The  protocols  of  the 
experiments are described below;  
 
2.2.1   Animal husbandry and experimental diet 
 
 
Virgin female C57BL/6N mice (supplied by Charles River Labs UK) at 4 weeks of age and 
weighing  approximately  8  to  10  gm  were  fed  ad  libitum,  before  mating  and  through  to 
pregnancy and lactation, either a control diet of standard laboratory chow (C) or a high fat-
high  cholesterol  (HF)  experimental  diet  supplemented  18%  wt/wt  with  animal  lard  with 
additional vitamins, protein, choline and minerals to correct for the dilution (Rat and Mouse 
Diet no.3, Special Diet Services, Witham, Essex, UK)
388 as shown in Table-2.1. 
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Table-2.1: Composition of diets 
 
 
Maternal weight and food intake were measured twice a week.  The females were time mated 
with in-house males and the day of vaginal plug detection was defined as day 0 of pregnancy. 
After confirmation of pregnancy, dams were housed individually in standard mouse cages 
containing wood shavings as bedding and were given experimental diet each day throughout 
pregnancy, with free access to water. This amount of the diet consumed had been shown to be 
approximately 10 grams above pregnant dam‘s average daily food intake and could therefore 
be considered ad libitum. Prior to any new food being placed in the cages, all uneaten food 
was removed and weighed. All mice were kept in the same room with constant temperature 
maintained at 25
0C and a 12:12-h light-dark cycle.  
 
 
The dams were allowed to deliver naturally at term (approximately 21 days). After birth, pups 
were weighed and litter size recorded. Two days postpartum (to avoid rejection) pups were 
sexed and to standardise litters, culled to eight by cervical dislocation, leaving four male and 
four female offspring where possible. The offspring were weaned from their mothers at 21 
days  of  age  and  separated  into  male  and  female  cages  when  each  mouse  was  given  an 
Components (wt/wt)  Standard Laboratory 
Chow Diet (C) 
High-Fat High 
Cholesterol Diet (HF) 
Protein  21.2  20 
Fat   5.3  45 
Carbohydrate  49.2  35 
Fibre  4.65  24.3 
Ash  6.0  0 
Moisture, Minerals & 
Vitamins  10.1  8.2   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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individual identification number. After weaning offspring of HF and C dams were fed either 
HF or C diets themselves, as shown in Figure-2.1.  
 
 
The adult offspring born to HF dams are referred as HF/HF and HF/C according to the post 
weaning diet. Similarly  adult offspring born to  C dams  are  referred to  as  C/HF and C/C 
according to post-weaning fed diet. Food intake and animal weights were recorded from 1 
week of age (to avoid maternal rejection of the pups) until animals were fully grown.  At the 
time  of  the  sampling,  animals  were  euthanized  by  isofluorane  inhalation  and  cervical 
dislocation. This was at an average age of 36 days depending on the studies, as described later 
in  the thesis.  Blood  was  collected by cardiac puncture and liver tissue was  dissected and 
transferred to 10% neutral buffered formaldehyde and stored for further histological analyses. 
Other maternal and offspring samples including heart, lung, kidneys, adrenals, pancreas and 
adipose tissues were dissected, weighed, snap frozen in liquid nitrogen and stored at -80
0C for 
further analysis. 
 
 
2.2.2   Assessment of offspring blood pressure by tail cuff method 
 
Blood pressure (BP) was measured by tail-cuff plethysmography using an IITC blood pressure 
monitor (model BP 2000 Blood Pressure
 Analysis System, Visitech Systems; Apex, NC). This 
was based on a method of Krege et al.
389 and the manufacturer's instructions. For 5–7
 days, 
mice  were  acclimatized  to  restraint  and  tail-cuff  inflation.
  The  restraint  platform  was 
maintained at 33–34°C.
 In order to achieve vasodilatation of the tail artery, mice were allowed 
to acclimatise in their cages in a room maintained at 28˚C for two hours and then settled into a 
Perspex tube, (Figure 2.2a). To minimise the stress incurred, the tube was covered by a paper 
towel and then a suitably sized cuff was fitted over the tail. The cuff was inflated to 200 
mmHg and deflated over a period of 10 seconds. Systolic blood pressure was then calculated 
(Figure 2.2b).  
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Figure-2.1:  Flow diagram of the experimental protocol (please note that for practical reasons the experiments 
are staggered). Symbols in the parenthesis indicate breeding animals drawn from the stock colony as explained in 
the text. 
 
A            B 
           
Figure- 2.2:  (a) 28 day old mice inside Perspex tube with tail cuff around tail. (b) Perspex tube is covered in 
paper towel to make mice feel more secure and calm during blood pressure measurement. 
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For each session, the mouse was placed in a plastic restraint
 tube with its tail passing through 
the optical sensor and compression
 cuff and taped to the platform. A tail-cuff
 occluder was 
placed proximal on the mouse's tail. Pressure was then released at a rate of 6 mmHg per 
second and systolic blood pressure determined during deflation by use of IITC acquisition 
software (Figure 2.2c). On inflation, the occluder
 stopped blood flow through the tail, and on 
deflation the return
 of blood flow was detected by the sensor.  
 
 
An initial series
 of inflation-deflation cycles was used to set amplifier and
 instrument levels. 
Blood pressure measurement was repeated five times for each animal with a total recording 
time per mouse of approximately 15 minutes. To control for the reproducibility of the method, 
measurements  were  taken  until  3  similar  readings  were  obtained  for  each  animal.  The 
experimenter  was  blinded  to  the  groups  to  reduced  intra-observer  error.  Day  to  day 
measurements produced a coefficient of variation equivalent to 7.5 %. The same subgroup of 
mice was measured at each age point.  
 
In my preliminary experiments, I passed the tail through a cuff (13 mm long, with a 9-mm 
diameter)
 and immobilized it by adhesive tape in a V-shaped block between
 a light source 
above and a photoresistor below the tail. Evaluated
 photoelectrically, blood flow in the tails 
produced oscillating
 waveforms that were digitally sampled 200 times per second per
 channel. 
The waveforms,  displayed in  real  time on a monitor,
 were computer analyzed before and 
during  a  programmable  routine
  of  cuff  inflation  and  deflation.  Programmable  functions 
available
 by drop-down menu included: 
 
1. The number of waveforms analyzed
 to identify the amplitude and heart rate before each 
cuff inflation,
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2. Number of preliminary unrecorded measurements 
3. Number of recorded measurements per session.  
 
C 
 
Figure 2.2c: Consecutive reading of representative flow waveforms shown during blood pressure determination. 
The system first determines full waveform amplitude (A, top) and then seeks waveforms having amplitudes less 
than 20% of A (numbered in the bottom waveform). Note that the waveform present at the second arrow is 
indistinguishable from baseline noise; therefore, the cuff pressure at this point (when five consecutive waveforms 
are less than 20% of A) accurately represents blood pressure 
 
The software assigned
 BP values from a further set of programmable parameters. Tail-cuff
 BP 
was  defined  as  the  cuff  inflation  pressure  at  which  the  waveform
  amplitude  fell  below  a 
programmable percentage, p, of its original
 amplitude for a specified number, n, of waveform 
Waveform 
Amplitude 
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cycles.  Adjustment
  of  these  parameters  allowed  me  to  determine  systolic  blood  pressures 
without  interference
  from  background  noise.  In  Figure  2.2  C,  I  show  a  representative 
waveform
 and decay and illustrate here a BP determination when p is 20% and
 n is 5—the 
values chosen for my preliminary study. If the
 system was unable (before a cuff pressure of 
>200  mm  Hg  is
  reached)  to  identify  a  waveform  decay  (usually  because  of  excessive
 
movement of the mouse), the computer recorded "systolic time-out"
 for the measurement. Care 
was taken to make sure that systolic time-out did not happen routinely.  Owing to the stressful 
nature of the restraint tube, the tube was covered to minimize the stress and time was allowed 
for the rats to acclimatise before any measurements were made.  
 
 
2.2.3   Open-field activity testing protocol 
The  open  field  test  is  now  one  of  the  most  popular  procedures  in  animal  psychology.
389 
Voluntary locomotor activity was assessed in the offspring at predetermined times during the 
peripubertal period and in adulthood. This was done using a behavioural testing apparatus 
consisting  of  transecting  photon  beams.  Behaviour  was  measured  in  terms  of  distance 
travelled, stereotypic movement, ambulatory time and time spent resting. Different versions 
are available, differing in shape of the environment (circular, square or rectangular), lighting 
(lighting from above with a bulb above the open field or lighting from underneath with a bulb 
placed under a transparent floor, sometimes using red light and presence of objects within the 
arena  such  as  platforms,  columns,  tunnels.
390  The  procedure  generally  involves  forced 
confrontation of a rodent with the situation. The animal is placed in the centre or close to the 
walls of the apparatus and the following behavioural items are recorded for a period ranging 
from 2 to 20 min (usually 5 min): horizontal locomotion (number of crossings of the lines 
marked on the floor), frequency of rearing or leaning (sometimes termed vertical activity) and 
grooming (protracted washing of the coat). In such a situation, rodents spontaneously prefer 
the periphery of the apparatus to activity in the central parts of the open field. Indeed, mice 
and rats walk close to the walls, behaviour called thigmotaxis. Increase of time spent in the 
central part as well as of the ratio central/total locomotion or decrease of the latency to enter   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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the central part is an indication of anxiolysis. Some authors use a procedure in which the 
animals are allowed free access to the open field, from a familiar cage.
391 
 
Behaviour  in  the  open  field  measurement  technique  allowed  me  to  measure  the  different 
variables such as distance, time taken to cover specific distance and other episodes of activity. 
The  computerised  software  gave  these  activities  a  mathematical  number  at  predetermined 
times. I must thus emphasize there is a possibility of misinterpretation of data related to effects 
of some treatments on the sensory characteristics of the animals. Behaviour of mice in the 
open field depends mainly on the tactile sensory factors.  
 
 
I  used  the  standard  protocol.
392  I  placed  the  mice  individually  into  brightly  lit  automated 
activity cages equipped with rows of infrared photocells interfaced with computer (San Diego 
Instruments, San Diego, CA) as described previously.
392-393 I used a 100 X 100-cm arena with 
45-cm- high walls constructed of four pieces of grey Trovicel plastic. I defined a minimum 
displacement  of  2.5  cm  to  constitute  a  change  in  location,  a  minimum  angle  of  30
0  to 
constitute a turn, and a 3-cm-wide wall zone. After a 1-min adaptation period, open field 
activity was recorded for 3-min. Within a measurement day, I assigned randomly the order of 
the mice. At the start of each trial, a mouse was grasped by the tail and placed in the centre of 
the arena. The arena floor was wiped with a moist sponge (1mM acetic acid) between trials 
and allowed to dry before the next trial, as is standard protocol in open-field testing. Recorded 
beam  breaks  were  used  to  calculate  active  times,  path  lengths,  rearing  times  and  rearing 
events. An example is presented here to show the behavioural open- field measurements in 
two mice on two different diets over 3 minutes. The measurements are single runs (Table 2.2). 
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Table-2.2: 
Variables  C/C mice  HF/HF mice 
Distance (mm)  662.45  440.37 
Time stereotypic  0.54  0.42 
Stereotypic counts  732  522 
Average Velocity  29.25  27.85 
Jump Counts  9  4 
Ambulatory counts  442  235 
Episodes  35  19 
Time Resting  1:36  2:01 
 
 
2.3 Blood Measurements 
 
 
2.3.1   Lipid profile 
I drew blood samples by direct heart puncture after terminally anaesthetizing the animal with 
isoflourane.  I  followed  the  previously  reported  study 
394  for  measuring  serum  cholesterol, 
LDL-cholesterol and HDL-cholesterol with commercially available kits (Vitros Products, NY, 
USA) using enzymatic methods and measured by reflectance spectrophotometry.  
 
a)  HDL cholesterol analysis 
 
I  used  the  VITROS  Magnetic  HDL-Cholesterol  Reagent  and  VITROS  CHOL  Slides  that 
quantitatively  measure  HDL  cholesterol  (HDLC)  concentrations  in  serum  and  plasma.  I 
prepared  the  samples  for  analysis  of  HDL  cholesterol  with  VITROS  Magnetic  HDL- 
Cholesterol Reagent before measuring by the VITROS CHOL Slide.    M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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The principle of this assay is that the reagent separates HDL by precipitating LDL and VLDL 
using dextran sulfate (MW 50,000) and magnesium chloride.
395 The reagent also contains iron 
particles that are coated with polymer. Once the drop of pretreated sample is deposited on the 
slide, iron particles in the reagent then enhance the capture of the non-HDL lipoproteins when 
a  magnetic  field  is  applied  on  the  slide.  HDL  cholesterol  undergoes  reactions  to  produce 
hydrogen peroxide. Hydrogen peroxide reacts with a leuco dye to produce a blue dye complex. 
After a fixed incubation period of 5 minutes at 37
0C, the amount of colorimetric light reflected 
from the dye at a detection wavelength level of 670πm, gives the amount of HDL cholesterol 
present in the sample.  
 
In summary, the reaction sequence at a sample drop of 10µL is described as follows;  
 
 
I then turned my attention to the untreated sample, diluted with an equal volume of VITROS 
7% BSA Diluent and pipetted 500 µL of serum into the sample tubes. The reagent was swirled 
and 100µL of it was added. I immediately vortexed the mixture for 5 to 10 seconds, placed the 
sample tube in the test tube rack and incubated for minimum of one minute. Following the 
incubation, the sample tube was left for three minutes to check the tube for a clear supernatant 
as shown in Figures 2.3a & b.    M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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(a)                                                                             (b) 
Figure2.3a &b: Sample Tube at first stop and sample tube on magnet. (derived from VITROS Products 
operating manual). 
 
The lower limit of the reportable (dynamic) range is 3.0 mg/dL (0.08 mmol/L). The plot in 
Figure 2.3c shows a comparison of this method analyzed on the VITROS system with CDC 
Dextran Sulfate/ Enzymatic reference method,
396 using pretreated serum specimens.  
 
Figure 2.3c: The plot shows a comparison of the VITROS Magnetic HDL- Cholesterol Method analysed on the 
VITROS  system  with  CDC  Dextran  sulphate/  enzymatic  reference  method.  Cholesterol  in  duplicate  dextran   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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sulfate-Mg2 supemates of 48 subjects, as assayed by the Lipid Research Clinic assay with Liebermann-Burchard 
reagent (x) and the enzymic assay (y) as described. The dotted line  indicates the line of perfect agreement, y = x. 
The solid line illustrates the relationship between the two cholesterol assays by linear regression: slope 0.958, y-
intercept 9.2 mg/L, and r = 0.988. [Ref=395] 
  
b)  Cholesterol measurements 
The measurement of cholesterol is based on an enzymatic method.
397 I deposited a drop of 
sample  on  the  VITROS  CHOL  Slide  (dry,  multilayered,  analytical  element  coated  on  a 
polyester support). 
 The Triton X-100 (TX100) surfactant on the slide aided in dissociating the 
cholesterol which was then acted on by cholesterol ester hydrolase. Free cholesterol was then 
oxidized in the presence of cholesterol oxidase to form cholestenone and hydrogen peroxide. 
Finally I added the leuco dye that oxidized hydrogen peroxide in the presence of peroxidase to 
generate  coloured  dye  (Figure  2.3d).  The  density  of  dye  formed  is  proportional  to  the 
cholesterol  concentration  present  in  the  sample  and  is  measured  by  reflectance 
spectrophotometery at a wavelength of 540πm at 37
0C. The sample drop volume is usually 
5.5µL.  
(d)  
Figure 2.3d: Slide diagram used for measuring cholesterol. As shown the  slide components are upper slide 
mount, spreading, buffer and support along with lower slide mount (Derived from VITROS Products operating  
manual). 
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Figure 2.3e: The plot shows the results of a comparison of serum specimen analysed on the VITROS system (y) 
with those analysed using the Abell-Kendell reference method (x). (derived from VITROS Products operating 
manual). The dotted line indicates the line of perfect agreement, y = x. The solid line illustrates the relationship 
between the two cholesterol assays by linear regression: slope 0.958, y-intercept 9.2 mg/L, and r = 0.988. 
 
 The lower limit of the reportable dynamic range is 50mg/dL (1.29 mmol/L; 0.50g/L). The plot 
in Figure 2.3e shows the results of a comparison of serum specimens analyzed on the VITROS 
system with those analyzed using the Abell-Kendell reference method
398. 
   
c)  Triglyceride measurement 
The analysis for triglycerides is based on an enzymatic method as described by Spayd et al
399. 
I  deposited  a  drop  of  sample  on  the  VITROS  TRIG  Slide  (dry,  multilayered,  analytical 
element coated on a polyester support). 
 The Triton X-100 (TX100) surfactant on the slide 
aided in dissociating the triglycerides from lipoprotein complexes present in the sample. The 
triglyceride  molecules  were  then  hydrolyzed  by  lipase  to  yield  glycerol  and  fatty  acids. 
Glycerol diffused to the reagent layer, where it was phosphorylated by glycerol kinase in the 
presence of adenosine triphosphate (ATP). In the presence of L-α-glycerol-phosphate oxidase, 
L-α-glycerophosphate  was  then  oxidized  to  dihydroxyacetone  phosphate  and  hydrogen 
peroxide. The final reaction involved the oxidation of a leuco dye by hydrogen peroxide,   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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catalyzed by peroxidase. The density of the dye formed is proportional to the triglyceride 
concentration present in the sample and is measured by reflectance spectrophotmetery at a 
wavelength of 540πm at 37
0C (Figure-2.3f). 
 
The volume of the sample drop is usually 5.5µL and the reaction sequence is: 
 
 
 Figure 2.3f: Slide diagram used for measuring Triglycerides. As shown the slide components are upper slide 
mount, spreading, Reagent and support along with lower slide mount. (derived from VITROS Products operating 
manual).   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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2.3.2             C-reactive protein 
 
I measured the CRP using a quantitative sensitive double-antibody sandwich immunoassay 
enzymatic ELISA using rabbit antihuman CRP and peroxidase conjugated rabbit anti-mouse 
CRP. In this assay, monoclonal anti-CRP antibody conjugated to horsedish peroxidase (HRP) 
serves as a signal generator. The assay is linear up to 5mg/l and logarithmic thereafter
400. I 
pre-coated the microtiter plate provided in the kit with the monoclonal antibody specific for 
CRP. I added samples to the appropriate microtiter plate wells and incubated them according 
to the manufacturer‘s instructions. If present CRP would bind and become immobilised by the 
antibody pre-coated on the wells. I thoroughly washed the microtiter plate wells to remove 
unbound  CRP  and  other  components  of  sample.  In  order  to  quantify  the  amount  of  CRP 
present  in  the  sample,  I  added  a  standardised  preparation  of  horsedish  peroxidise  (HRP)-
conjugated antibody specific for CRP to each well to sandwich the CRP immobilised during 
the second incubation. I again thoroughly washed the wells to remove all unbound HRP-
conjugated antibodies and added TMB (3,3‘5,5‘ tetramethyl-benzidine) substrate solution to 
each well with a short incubation period. Only those wells that contain CRP and enzyme 
conjugated  antibody  exhibit  a  change  in  colour.  The  enzyme–substrate  reaction  was 
terminated by the addition of a sulphuric acid solution and the colour change was measured 
with spectrophotometery at a wavelength of 450nm + 2ƞm. In order to determine the correct 
concentration of CRP in the samples, the assayed standard kit was used to produce standards.   
 
2.4   Tissue Histology 
 
I performed the microscopic examination on the livers of all animals to investigate the effects 
of the experimental diets used in my work. I dissected the livers, fixed for 24h in 10% neutral 
buffered formalin, processed and embedded in paraffin. From fixed liver tissues embedded in 
paraffin 5-10 micron sections were cut and mounted on glass slides.  After deparaffinization, 
sections were stained with hematoxylin and eosin. Microscopic examination was performed on   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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stained liver sections from representative animals in each group. This is in accordance with 
Ehrlich’s  protocol
401 already  established in  our laboratory.  For  further details  of Ehrlich‘s 
Method and preparation of solutions please refer to appendix-i. 
 
 
2.5      Endothelial Progenitor Cells  
        2.5.1 Culture and staining 
The  use  of  endothelial  progenitor
  cells  (EPCs)  for  angiogenic  therapies  or  as 
biomarkers to assess
 cardiovascular disease risk and progression relies on their identification. 
However,
 there is neither a uniform definition of these cells nor a method without limitations. 
At  present,  bone  marrow  (BM)  is  the  most  common  source  of  cells
  used  for  clinical 
therapeutic strategy
402.  
 
To date, experimental approaches to produce EPCs mainly involve culture of mononuclear 
cells  (MNCs)  on  fibronectin  in  the  presence  of  growth  factors  in  order  to  bring  about 
differentiation of MNCs into EPCs or mature endothelial cells. The majority of the cultured 
MNC population remains committed to being leukocyte or lymphocyte lineage and only a 
very small percentage can be identified as EPCs
325, 402-403. Here I adopted and refined a more 
efficient technique for culturing EPCs from autologous BM. For reagents and materials used 
to culture and stain BM, please refer to appendix-ii.    
 
I collected the bone marrow from mice femurs into tubes containing buffered saline (HANKS).  
I  carefully layered 6ml  of diluted sample  over  3ml lymphoprep in  a 15ml centrifuge tube, 
centrifuged at 800 x g for 20 minutes at room temperature (approximately 20
0C). While the 
samples were spun, I coated the wells (Lab-Tek ™ II Chamber slide) with the D-MEM/F-12, 
Dulbecco‘s modified Eagle medium (400 microlitres (μL). The plates were left in an incubator   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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until required for cells (incubation time 30 min for 1hr). I also added a small vial containing the 
same medium (~ 5mls) in the incubator.  
 
Once the centrifugation was over, I carefully took out mononuclear cells in the interphase and 
transferred it to another 15ml centrifuge tube. I then mixed the cells (interphase) with 10ml 
saline buffer and centrifuged at 200 g for 5min at room temperature (25*C) with brakes. This 
step was repeated twice more.  The supernatant was removed and the cells suspended in the 
preincubated plates. This time, I placed the plates in the incubator for another hour. After an 
hour, I gently aspirated 200µl out of each well, added 200-300 µl of fresh medium to each well, 
and placed the slide back to the incubator for further 48-96 hrs. After > 48 hrs, I examined the 
slide for live cells. 
 
2.5.2 Counting of the cells: 
The cells were counted with a haemocytometer, after mixing 10µl of cell solution with 0.4% 
tryptan blue of stock solution under the microscope.  I used the following formula for counting:  
 
Count of cells X 20,000= number of cells/ ml. 
 
2.5.3 Detection of EPCs with double staining 
To 500 µl of incubated wells, I added 20-25 ul of acetylated low density lipoprotein labelled 
with 1,1‘-deoctadecyl-3,3,3‘,3‘-tetramethyllindo-carbocyanine perchlorate (Dil-Ac-LDL) stain 
to culture medium from the stock solution of 10µg/L and gently mixed it once or twice. I then 
incubated this time for 4hrs at 37
0C. After 4hrs, the chamber slides were observed under the 
microscope with green filter for red staining (RITC). Following this step, I removed the media 
from the wells, washed them with PBS X3 gently, fixed cells in 500µl/well of formaldehyde 
(3.7%) in PBS on ice for 30 min. I incubated them with UEA (10 µl of UEA in 990ul of PBS 
(stock 1mg/ml) and added 200µl/ well for 1hr at 37
0C in incubator.  This time the incubation   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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was without CO2 and in the dark. Washings were performed for 3 times each 5 minutes in the 
dark.  The  slides  were  mounted  on  citiflour  and  examined  under  UV  purple  by  inverting 
coverslip on a drop of 90% glycerol and 10% PBS onto a microscope slide. 
 
2.5.4 Phase contrast and fluorescence imaging  
Phase
  contrast  and  fluorescence  images  were  collected  using  a  Zeiss  Axiovert
  2  inverted 
microscope  with  a  5x  CP-ACHROMAT/0.12  NA  objective.
  Images  were  acquired  using  a 
SPOT RT colour camera (Diagnostic
 Instruments, Sterling Heights, MI) with the manufacturer's 
software.
 Composite images were assembled in Adobe Photoshop version 8.0.
  
 
 
2.6   Statistical Analysis  
 
All of the data are expressed as means +/- SEMs. In the female offspring, effect estimates are 
from  a  mixed  model  analysis  that  considers  all  of  the  time  points  through  the  study, 
controlling for the set of dam-pup relationships.  
All data was tested for normality using a Kolmogorov-Smirnov test. Subsequently statistical 
significance of differences between biochemical and biophysical parameters was determined 
by using 1-way ANOVA followed by the Tukey-Kramer comparisons test. A P < 0.05 was 
considered to be statistically significant. All of the statistical analysis was calculated  with 
SPSS 14.0 (SPSS Inc). The initial ANOVA model incorporated
 sex as an independent variable 
and, where this showed significance,
 sexes were analyzed separately.  Risk estimates for HF 
diet when compared  with  C diet towards developing CVD and metabolic syndrome  were 
obtained with the use of logistic regression analyses.  
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2.6.1       Power calculations 
The statistical power of a null hypothesis
 (Ho) significance test is the probability that the test 
will
  reject  Ho  when  a  research  hypothesis  (Ha)  is  true
404-406.  Knowledge
  of  effect  size  is 
particularly important for statistical power
 analysis. Power calculations are performed when 
setting up an experiment to determine the sample size required in order to test for a significant 
difference of given magnitude. Thus they are performed to maximise the chance of finding a 
significant result if indeed it exists. The power calculation is based around two variables, the 
power (1-, typically 80-90%) and the standardised difference (
/, where  is the standard 
deviation of the mean and  the difference between the control and study group considered a 
priori to be meaningful). These numbers are then applied to the nomogram (Figure 2.4) to 
determine  the  n  number  required  to  demonstrate  a  given  change  at  suitable  power  and 
significance  ().  However,  as  the  nomogram  shows,  calculating  the  power  requires 
approximating both the expected magnitude of change and the standard deviation around the 
mean. This can be dealt with either by calculating the power from a preliminary study or the 
analysis of the first numbers through the study, or alternatively the power may be calculated 
based on the results of a similar study. 
 
Figure 2.4: Nomogram for calculating sample size or power. From  Altman, Practical Statistics for Medical 
Research. Chapman and Hall (Ref 403)   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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There are many kinds of effect size measures
 available (e.g., Pearson's r, Cohen's d, Hedges's 
g), but most
 of these fall into one of two major types, namely the r family
 and the d family
404. 
The r family shows the strength
 of relationship between two variables while the d family 
shows
 the size of difference between two variables. As a benchmark
 for research planning and 
evaluation, Cohen in 1988
406 proposed
 ‗conventional‘ values for small, medium, and large
 
effects: r =.10, .30, and.50 and d =.20, .50, and .80, respectively
 (in the way that p values 
of.05, .01, and .001 are conventional
 points, although these conventional values of effect size 
have
 been criticized; e.g., by Rosenthal et al., 2000
407.
 Bonferroni
 corrections are employed to 
reduce Type I errors (i.e., rejecting
 Ho when Ho is true) when multiple tests or comparisons are 
conducted.
  Two  kinds  of  Bonferroni  procedures  are  commonly  used.  One  is
  the  standard 
Bonferroni procedure, where a modified significant
 criterion (/k where k is the number of 
statistical  tests  conducted
  on  given  data)  is  used.  The  other  is  the  sequential  Bonferroni
 
procedure, which was introduced by Holm
408 in 1979. A serious problem associated with the 
standard Bonferroni
 procedure is a substantial reduction in the statistical power
 of rejecting an 
incorrect Ho in each test. The sequential Bonferroni procedure
 also incurs reduction in power, 
but to a lesser extent (which
 is the reason I used the sequential procedure)  
 
The number of mice used in this study was based on my previous preliminary work to assess 
the power of the study. I conducted the blood pressure measurements in mice with different 
treatment groups i.e. control (fed on normal laboratory Chow; C); High Fat (HF) and High fat 
with treatment (Statin; HF+S). The initial results obtained from this work showed systolic 
blood pressure on average of C =110 ± 0.16, HF= 140 ± 0.04, and HF + statin= 120 + 0.06; 
p<0.05.  A  statistical  simulation  of  probable  effects  brought  about  by  different  treatments 
suggested a minimum  n size of 8 mice per  group was  required to  detect  90% power for 
detecting differences in blood pressure at the 5% level of statistical significance). However, no 
power calculations were performed on work presented on EPC studies in the offspring. Due to 
the novelty of the EPC work in the thesis, it is felt that no previous studies are appropriate to   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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base a power calculation on, and as a result anything gained from such a calculation would be 
meaningless. 
 
2.6.2    Maternal and offspring data 
 
All values are expressed as mean ± SEM.  Differences between the means of each group were 
calculated  using  one-way  ANOVA  with  Bonferroni  post  hoc  test  to  correct  for  type-1 
statistical error.  
 
2.6.3     Systolic blood pressure 
 
All values are given as systolic blood pressure (mmHg) and are expressed as mean ± SEM. 
Means were then taken for each group and differences analysed using one-way ANOVA with 
Bonferroni post hoc test to correct for type-1 statistical error.  
 
 
2.6.4     Offspring weight gain 
 
All  values  are  given  as  weight  in  grams  and  are  expressed  as  mean  ±  SEM.  Differences 
between the groups were analysed for each age using mixed analysis, which takes into account 
the variation both within and between each litter thus minimising any litter effects. Differences 
between the growth curves of the mean weights of the groups were analysed using time and 
group as the two factors. 
 
2.6.5    Post-mortem organ weights 
 
All values are given as either weight in grams or organ to body weight ratio and are expressed 
as mean ± SEM. Differences between the groups were analysed for each organ, both as a 
weight and as a ratio to body weight using a mixed analysis, taking age, weight and diet as 
variable parameters.   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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2.6.6     Immunohistochemistry 
 
Values are given as percentage of area stained for each protein and expressed as mean ± SEM 
for each group. Differences between the means of each group were calculated using one-way 
ANOVA.  
 
The following sections described in chapters 3 to chapter-6 will now describe the results of the 
experimental work carried out in this thesis.   
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My mother is my root; my foundation. She planted the seed in me that I base my life on.  
She always advises me 
 “A bend in the road is not the end of the road….Unless I fail to make the turn” 
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CHAPTER 3 
Effects on Offspring of Long-term Maternal High Fat Feeding 
from Weaning through Pregnancy and Lactation  
 
 
3.1  Introduction 
Coincident with the rise in obesity internationally, the number of women who enter pregnancy 
obese has reached an all-time high. Based on the prevalence of obesity among women of 
reproductive age, it appears that at least one third of all pregnant women in the United States 
are obese. Data from the Centres for Disease Control and Prevention collected in 2000 showed 
that 50% of African American women, 40% of Hispanic women and 30% of white women 
were  obese.
409-410  Many  studies  of  thin,  undernourished  women  have  shown  that  maternal 
nutrition at conception influences the metabolic response to pregnancy and fetal growth and its 
development.
411-412 Hence a transition
 from an environment where food is poor/ adequate to 
one where diet is high in fat and carbohydrates, especially during pregnancy, is associated with 
higher  prevalence  of  the  metabolic  syndrome,  typified  by  type-2  diabetes,  hypertension, 
hypercholesterolemia and obesity in their offspring.
15,207,413-416 Such a ‗nutritional transition‘ to 
a Western diet may have deleterious consequences  on the health of future  generations  by 
affecting early development and influencing susceptibility to disease in later life.  
 
Today,  there  is  considerable  evidence  that  undernourished  women  gain  less  weight,  have 
smaller increases in basal metabolism, and give birth to smaller babies.
89,91,94-100,193,195,210 But 
the  number  of  studies  of  pregnancy  outcomes  among  women  who  enter  pregnancy  with 
excessive amounts of fat stores is more limited. As the prevalence of obesity increases, it is 
becoming  evident  that  these  women  are  susceptible  to  an  increased  risk  of  metabolic 
complications and poor pregnancy outcomes.
211,416-418 Fetal anomalies as well as deviations in   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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fetal growth rates  are  more  common among obese compared with  normal-weight  women, 
suggesting that maternal adiposity affects development during both the embryonic period as 
well as later in gestation. The intrauterine effects on fetal growth and development may also 
affect  postnatal  development  of  the  child,  particularly  if  fetal  growth  rates  are  abnormal. 
Large-for-gestational age infants are at increased risk for childhood obesity, which can lead to 
insulin resistance, diabetes, and hypertension later in life.
419 Small-for-gestational age infants 
born to obese women are susceptible to CVD and diabetes later in life, particularly if their 
postnatal catch-up growth produces truncal obesity but the child remains short. 
 
Two  factors  can  influence  fetal  growth  and  development—genetics  and  the  maternal 
environment.
420 Although genetics influences intrauterine growth rates and development of 
fetal anomalies, it is unlikely that the increased prevalence of fetal complications among obese 
mothers is due to genetics alone. It is more likely that the environment of obese mothers 
interacts with genetic factors to induce changes in fetal growth and development. The fetus 
―perceives‖ the maternal environment through signals transmitted by the placenta, such as 
nutrient transfer, blood  hormone or oxygen levels. The fetus uses this information in two 
ways: (a) to make immediate survival choices and (b) to make longer-term adjustments to 
maximize its advantage postnatally.
421 For example, if blood oxygen levels drop, fetal growth 
rates slow to conserve oxygen. On the other hand, if the fetus experiences a chronically high 
blood glucose level, it might anticipate being born into a carbohydrate-rich environment and 
prepare for that situation by synthesizing and secreting more insulin. 
 
Environmental  signals  to  the  fetus  from  obese  mothers  that  influence  fetal  development 
include adjustments in the placental transfer of nutrients (e.g., glucose, fatty acids,  amino 
acids),  hormones  (e.g.,  insulin,  leptin,  adiponectin),  and,  possibly,  inflammatory  markers. 
When these metabolic parameters reach abnormal  levels,  metabolic complications  such as 
gestational  diabetes,  pregnancy-induced  hypertension,  and  preeclampsia  are  diagnosed. 
Although it is well known that diet influences the development of diabetes and hypertension in   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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nonpregnant  adults,  the  role  diet  plays  among  obese  pregnant  women  and  their  offspring 
physiology has received little attention.  
 
On the other hand, non-alcoholic fatty liver disease (NAFLD), a common cause of chronic 
liver disease occurs  commonly with  metabolic syndrome (central  obesity, type-2 diabetes, 
dyslipidemia  and  CVD.  NAFLD  is  the  subject  of  substantial  research  interest,  since  its 
incidence in adults and children is rising rapidly along with obesity and type-2 diabetes.
422-425  
NAFLD  is  linked  to  excessive  triglyceride  (TG)  accumulation  and  encompasses  a  broad 
spectrum  of  liver  disease  ranging  from  simple  fatty  liver  (steatosis),  to  non-alcoholic 
steatohepatitis  (NASH)  with  fibrosis  that  may  progress  to  liver  cirrhosis  and  portal 
hypertension.
426-427  Recent  estimates  of prevalence in  the USA are 20%-30%  for hepatic 
steatosis, 3.5%-5% for NASH, and up to 80% of people with type-2 diabetes may have some 
form of NAFLD.
427-428   
 
It is unlikely that such a high prevalence of NAFLD can be explained by obesity alone, since 
not  all  obese  individuals  develop  NAFLD,  and  not  all  individuals  with  simple  steatosis 
progress to NASH.  In fact, the pathogenic mechanisms involved in the disease progression 
from  simple  steatosis  to  NASH  are  still  unrevealed.  One  candidate  factor  for  disease 
progression is maternal obesity, since one third of women of child bearing age in the US are 
currently  obese.
429  Maternal  obesity  at  conception  has  been  shown  to  alter  gestational 
metabolism  and  affects  placental,  embryonic  and  fetal  growth  and  development.
430  I 
hypothesize that maternal HF feeding can influence the development of hepatic steatosis in 
adulthood mice.   
 
Developmental induction of cardiovascular and metabolic risk factors has been observed in 
rodent models in which the pregnant dam is exposed to nutrient restriction and the offspring 
fed  normal  chow  diet.
15,232  However,  there  are  fewer  studies  that  examined   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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adaptive/maladaptive
 mechanisms during fetal development when pregnant dams are exposed 
to overnutrition. Several studies, including ours, have shown in rats that a maternal diet rich in 
fat during pregnancy results in features of the metabolic syndrome such as obesity, sedentary 
behaviour and vascular dysfunction in the offspring. 
212-213,246-248 However, these studies were 
confined to short-term modifications in the maternal diet during pregnancy and/or lactation 
periods alone. Altering the maternal diet during critical periods of gestation
216,249 or throughout 
gestation and/or the suckling period
217,250 results in a varying degree of phenotypic outcomes 
associated with the metabolic syndrome, suggesting the importance of the timing and duration 
of the nutritional insult.  
 
In humans, consumption of HF diet just during pregnancy or suckling is not common, but 
there is increasing concern about the effects of obesogenic diets in children on the health of 
their future offspring.  Hence, the aim of this study is to; 
1.   Investigate in our animal model, the consequences for their offspring of feeding dams 
a HF diet from the time that they were weaned, through their pregnancy and lactation 
until their pups are weaned.   
2.  Determine whether there are additive effects of feeding these offspring themselves a 
HF diet from weaning to adulthood.  
 
 
3.2   Methods 
 
Methodology has been discussed earlier in detail in Chapter-2. Here I summarise the salient 
points for this specific research work. 
1.  Four  week  old  virgin  Female  C57BL/6  mice  were  randomly  allocated  to  either  a 
control diet of standard laboratory chow (C) or a HF experimental diet.  At 10 weeks 
old the females were time-mated with C57BL/6 males and after confirmation of mating 
were individually housed    M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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2.  After  birth,  pups  were  weighed  and  litter  size  was  reduced  to  8  pups  and,  when 
possible, to equal numbers of males and females. Following weaning (21 days post 
partum) offspring from the HF and C dams were fed either HF or C diets. I referred to 
the offspring born to HF dams as HF-HF and HF-C according to their post-weaning 
diet. Similarly offspring born to C dams were referred to as C-HF and C-C according 
to post-weaning diet. The experimental protocol is explained in Figure-3.1.  
3.  Food intake and body weights were monitored weekly until they reached adulthood. 36 
weeks old adult offspring were killed by cervical dislocation and the samples collected 
(blood, fat depots, and livers) 
4.  Cumulative fat depot weights for each animal were compared to total body weights 
and body fat as a percentage of total body weight was calculated.  
 
 
Figure-3.1:  Flow diagram of the experimental protocol. Symbols in the parenthesis indicate breeding animals 
drawn from the stock colony as explained in the text. 
 
5.  BP was measured at 13, 18, 23, 27, 30 and 36 weeks post weaning.  
6.  C-reactive protein (CRP) and total cholesterol were measured in the serum.   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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7.  Fixed  liver  sections  were  stained  with  hematoxylin  and  eosin  (H&E)  for  visual 
assessment of steatosis and cellular infiltrate. Alternate sections were stained with Oil-
Red-O to visualise lipid accumulation.  
8.  The Kleiner scoring system
431 was used to assess the severity of non-alcoholic fatty 
liver disease (NAFLD). The NASH Clinical Reseasch network Committee
431 agreed 
that  only  H&  E  and  Masson‘  trichrome  stains  would  be  sufficient  to  perform  the 
evolution. An activity score (AF) was generated by adding the individual score for 
necroinflammatory features;  Steatosis (<5% = 0, 5-33% = 1, 33-66% = 2, >66% = 3); 
Ballooning (none = 0, few = 1, prominent = 2); and Lobular inflammation (none = 0, 
<2 foci = 1, 2-4 foci = 2, >4 foci = 3).  A score of <3 correlates with mild NAFLD, a 
score of 3-4 correlates with moderate NAFLD and a score of 5 or more correlates with 
NASH. The average (mode) score for each histological characteristic in each group was 
used.  
9.  The results were statistically analysed and value of P<0.05 was set as significant. 
 
3.3 Results 
 
3.3.1    Maternal parameters 
The body weights of the HF dams were significantly greater at day 7 and day 16 of
 gestation 
and also at birth and at weaning (HF study group vs. controls at each stage, p<0.05). Although 
average daily food
 intake was significantly reduced in the HF dams during
 pregnancy [average 
daily food intake (g) days 0-20, 13.6 ±
 0.99 for HF vs. 18.9 ± 0.94 for C dams P < 0.005], the 
higher gross energy value of the HF diet meant that gross energy intake of the HF dams were 
similar to the C dams [average daily gross energy intake (kJ) 38.9 ±
 4.85 for HF vs. 41.7 ± 
8.42, for
 C dams; P =0.436].
  
 
 
During lactation, gross energy intake in the HF dams was
 significantly higher compared with 
C dams [average daily gross
 energy intake (kJ) 47.3 ± 8.9 for HF vs.
 28.8 ± 3.5 for C dams, P
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< 0.0001] despite a significant reduction
 in their average daily food intake [average daily
 
intake (g) during suckling, days 22-42, 15.2 ± 1.26
 for HF vs. 19.9 ± 0.69, for C dams P < 
0.005]. Overall HF mice were significantly heavier, hypertensive and hypercholesterolemic 
than C during pregnancy and at weaning of their offspring as shown below (Table-3.1) 
 
Table-3.1: Statistical analyses of biochemical and biophysical parameters in dams. 
Variables  HF                          C  ANOVA 
P Value     
Pre-
pregnancy 
Pregnancy  Weaning  Pre-
pregnancy 
Pregnancy  Weaning 
Weight (gm)  54.3±2.0  67.4+2.4  57.4+3.4  31.2+2.8 
 
41.2+1.8  30.7+1.3  <0.001 
systolic blood 
pressure 
(mmHg) 
135.2± 2.6  139.4 + 1.8  136.2+1.4  110.5 + 1.7  112.7 + 2.0  108.7+2.
4 
<0.001 
 
LDL cholesterol 
(mmol/L) 
2.1+0.2  4.1+0.4  3.5+0.1  0.8+0.02  1.1+0.04  0.2+0.03  <0.001 
 
cholesterol 
(mmol/L) 
4.08+0.4  6.3±0.5  6.1+0.2  1.99+0.2  2.3 +0.2  2.3+0.1  <0.001 
 
 
Values mean ± SEM (n = 8 for all groups). Statistical test is the ANOVA result for all groups. Statistical 
result displayed in each cell is for the dietary group comparison with the others group using the Tukey-
Kramer test.  The significance of P<0.001, is for all the columns between HF vs. C groups at pre-pregnancy, 
pregnancy and weaning.  
 
3.3.2  Offspring 
3.3.2.1 Food intake   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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I first examined the effects of maternal HF diet during pregnancy on daily energy intake in the 
offspring. As shown in Figure- 3.2, I observed a gender specific effect in offspring from HF 
mothers  on  their  food  intake.  As  shown  in  Figure-3.2  (a),  at  weaning  no  difference  was 
observed  in  male  offspring  either  fed  HF  or  C  diets.  At  15  weeks  of  age,  there  was  no 
difference in food intake but by 18 weeks till 27 week, HF/HF male offspring were prone to  
significantly increased food intake than C/C (p<0.001). In case of female offspring from HF 
mothers either fed on C or HF diets (Figure 3.2 (b), at weaning no difference was observed in 
the food intake as like males. However, with age feeding a HF diet resulted in the reduction of 
total energy intake as compared to C/C female from 15  weeks (p<0.001). 
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Figure-3.2: Maternal high fat diet during pregnancy has a gender specific effect on daily energy intake in the 
offspring 
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3.3.2.2 Body weight and adiposity  
In female offspring the HF-C offspring were lighter than the HF-HF and C-HF animals but 
heavier compared with the C-C animals (Figure 3.3a). Corresponding increases in total body 
fat were observed in these groups compared with the C-C females (Fig 3.3c). HF-HF and C-
HF male offspring were heavier at 36 weeks post weaning than HF-C and C-C males (Fig. 
3.3b). These changes were also reflected in their total body fat (as % body weight), where the 
HF-HF and  C-HF males  had greater fat  depots compared with  the C-C and HF-C groups 
(Figure  3.3d).  However,  the  combined  effect  of  the  maternal  and  postweaning  diets  (i.e. 
HF/HF) in both sexes had a greater effect (p<0.001) on fat accumulation. 
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Figure- 3.3: Comparison of body weight (a, b) and total body fat (c, d) in male (left panels) and female (right 
panels) offspring from control fed mothers that were then fed a chow diet (C-C) or a high fat diet (C-HF) and 
from high fat fed mothers that were then fed a high fat diet (HF-HF) or a chow diet (HF-C). Values are means ± 
SEM (n =8-10/group). Bars with different letters are significantly different (p<0.05) from each other (by the 
Tukey-Kramer comparisons test).  
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3.3.2.3  Blood pressure  
Systolic  blood  pressure  was  elevated  in  the  HF-HF,  HF-C  and  C-HF  male  and  female 
offspring at 36 weeks post weaning compared to C-C offspring (Figures 3.4a &b). The HF-C 
males had the highest blood pressure and this was significantly greater than the HF-HF and C-
HF  groups.  In the females,  the HF-HF  and HF-C groups had significantly elevated blood 
pressure levels compared with the C-HF offspring. 
 
Figure 3.4: Comparison of systolic blood pressure (a, b), in male (left panels) and female (right panels) offspring 
from control fed mothers that were then fed a chow diet (C-C) or a high fat diet (C-HF) and from high fat fed 
mothers that were then fed a high fat diet (HF-HF)  or a chow diet (HF-C). Values are means ± SEM (n =8-
10/group). Bars with different letters are significantly different (p<0.05) from each other (by Duncan‘s Multiple 
Range Test). Bars with different letters are significantly different (p<0.05) from each other (by the Tukey-Kramer 
comparisons test).  
 
 
3.3.2.4   C-reactive protein and cholesterol levels  
In females, total cholesterol and CRP level was elevated in the HF-HF and C-HF animals 
compared to the C-C offspring (Figures 3.5a & c, respectively). Total cholesterol in the HF-C 
group was also elevated but was not significantly different from C-C or from the C-HF and 
HF-HF groups. Total cholesterol was elevated in the HF-HF, HF-C and C-HF males at 36   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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weeks post weaning compared with the C-C males (Figures 3.5b). Interestingly, no difference 
was observed in CRP levels among these four treatment groups (Figure 3.5d).  
 
 
 
Figure 3.5: Comparison of total cholesterol (a, b) and C-reactive protein (CRP) levels (c, d) in male (left panels) 
and female (right panels) offspring from control fed mothers that were then fed a chow diet (C-C) or a high fat 
diet (C-HF) and from high fat fed mothers that were then fed a high fat diet (HF-HF)  or a chow diet (HF-C). 
Values are means ± SEM (n =8-10/group). Bars with different letters are significantly different (p<0.05) from 
each other (by Duncan‘s Multiple Range Test). Bars with different letters are significantly different (p<0.05) from 
each other (by the Tukey-Kramer comparisons test).  
 
3.3.2.5   Development of fatty liver in adult offspring 
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I  assessed  liver  morphology  in  36  week  old  female  offspring  (Figure  3.6).  No  lipid 
accumulation and a normal hepatic architecture were observed in livers from C/C group. In 
livers from HF/C some lipid vacuoles were observed. C/HF offspring livers showed mild to 
moderate steatosis. However, histological examination of the liver from HF/HF demonstrated 
several  lipid  vacuoles  of  various  sizes  within  hepatocytes,  mononuclear  cell  infiltration, 
indicating an evidence of severe inflammation.  
 
 
 
 
Figure 3.6: Liver histology in female offspring from control fed mothers that were then fed a chow diet (C-C) or 
a high fat diet (C-HF) and from high fat fed mothers that were then fed a high fat diet (HF-HF) or a chow diet 
(HF-C). C-C offspring had normal liver structure. However, lipid vacuoles of various sizes could be observed 
within hepatocytes of the C-HF, HF-HF and HF-C offspring. Staining with hematoxylin and eosin; magnification 
x20; bar scale = 40 m. 
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The severity of the NAFLD in the offspring livers assessed using the Kleiner scoring system, 
demonstrated that C/C offspring received no scores, the HF/C and C/HF offspring achieved a 
score of 4, indicative in human histopathology Kleiner scoring as NAFLD (Table  3.2). In 
contrast,  the  HF/HF  liver  generated  a  necro-inflammatory  score  of  7,  compatible  with  a 
diagnosis  of NASH. These findings  demonstrate that exposure to  a post-weaning HF diet 
causes hepatic steatosis and that this effect is markedly exaggerated when the offspring have 
also been exposed to a HF diet in the developmental environment leading to development of 
NASH in the offspring.  
 
Table-3.2:  Assessment  of  NAFLD  severity  in  offspring‘s  liver  using  the  Kleiner  scoring 
system.  
Groups  Steatosis  Ballooning  Lobular  
Inflammation 
Activity 
Score 
Indication 
C/C  0  0  0  0  Normal 
C/HF  2  1  1  4  NAFL 
HF/C  2  1  1  4  NAFL 
HF/HF  3  2  2  7  NASH 
 
For each group (n=5) the mean score for each characteristic is given. 
 
3.4  Discussion 
 
Nutritional status during critical periods of early life
 has important influences on development. 
Modification
 of the quality and/or quantity of maternal nutrition during pregnancy has been 
shown to have consequences on the later health of the offspring, changing their responses to 
environmental challenges and thus their predisposition to disease.
432-433 In the present
 study, 
the consequences to the offspring of a long-term maternal HF dietary regimen, starting from 
when the prospective mothers were themselves weaned until weaning of their offspring is 
studied. This contrasts with earlier animal experiments, which focussed on the consequences
   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
 
117 
 
 
for the offspring of maternal HF feeding during only gestation and/or lactation periods. 
218,254, 
434 The long-term HF feeding results in changes in the dam‘s physiology, including increased 
body weight  and raised circulating total  and  LDL  cholesterol  levels  compared with  C-fed 
group, similar to what we have observed in our previous work.
435 These changes in the HF 
dams  may  provide  ‗cues‘  used  by  the  developing  offspring  in  altering  phenotype  in 
anticipation of their postnatal environment. The long-term dietary regimen used in the present 
study  may  better  represent  the  situation  in  human  populations,  following  socioeconomic 
transitions where consumption of HF food occurs very early in life and continues in women 
through  pregnancy  and  lactation.  The  present  study  demonstrates  that  offspring  of  such 
mothers are predisposed to becoming fat, hypercholesterolemic and hypertensive in adulthood, 
thus perpetuating the cycle of chronic disease. 
 
 
Our laboratory previously reported that prenatal and early postnatal exposure to a maternal diet 
rich in animal fat led to the development of characteristics similar to the human metabolic 
syndrome in adult rats, even when they were reared on a balanced diet.
246-248 The present study 
clearly shows that long-term consumption of a HF diet by the female dams predisposes their 
offspring to obesity, hypercholesterolemia, hypertension and fatty liver in adult life, at least 
when they are also fed a HF diet. Greater adiposity is also seen in females, even when they are 
fed a C diet post-weaning, suggesting that predisposition to obesity has been induced during 
development. This is not however seen in the HF-C male offspring.  
 
 
In males the elevation of SBP is less pronounced in the HF-HF group than in HF-C or C-HF 
groups.  This  supports  the  partially  beneficial  cardiovascular  effect  of  reducing  the  dietary 
mismatch in the HF-HF offspring reported in our earlier study.
247 In that study the dams were 
only fed the HF diet during pregnancy and weaning and endothelial dysfunction rather than 
elevated SBP was observed to be attenuated when compared with C fed offspring. These data 
are broadly in support of the predictive adaptive response concept
247. However, as outlined in 
the  original  exposition  of  the  concept 
90  such  an  effect  only  operates  within  a  range  of   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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postnatal environments, beyond which the risk of pathophysiology is increased. The postnatal 
HF used in the present study is likely to take the offspring into such a range, one which from 
an  evolutionary  point  of  view  is  novel,  possibly  explaining  the  pathophysiological  effects 
observed in them.  
 
 
I also observed a substantial number of lipid vacuoles within hepatocytes of the HF-HF, HF-C 
and C-HF but not the C-C offspring. Previous studies in rats have demonstrated that offspring 
of fat-fed dams show profound metabolic defects such as increased liver weight and liver 
triglyceride content.
218,  254 It has been reported in humans that there is a strong association 
between hypercholesterolemia, NAFLD and increased risk of CVD
436 but it is unclear whether 
certain diets are more likely to produce these effects than others. NAFLD and atherosclerosis 
are both produced in apo-E lipoprotein deficient mice, suggesting pathophysiological effects 
on both the liver and aorta of cholesterol-enriched diets.
437-438 The accumulation of lipids in 
hepatocytes  suggests  possible  interference  with  mitochondrial  and  microsomal  function 
leading to disruption in lipoprotein transport and fatty acid accumulation vs. metabolism.
248 
The accumulation of lipids in hepatocytes in the HF-C offspring suggests that susceptibility to 
development of fatty liver can be induced during early development.  
 
 
This study demonstrates that offspring of dams fed a HF diet, which were also fed a HF diet 
post-weaning (HF/HF), are predisposed to develop steatosis, a phenotype similar to humans; 
progressive liver condition that may result in cirrhosis and end stage liver failure.  This was 
also  true  for  offspring  from  C  mothers  that  were  only  fed  a  HF  diet  post-weaning  and 
exhibited steatosis with evidence of inflammation. Therefore exposure to a HF diet during 
development and post-weaning is worse than HF exposure post-weaning alone.  
 
My  further  observations  from  these  animals  show  that  a  maternal  HF  diet  can  lead  to 
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environment, evidence that changes occurring during development are persistent, and affect 
disease out-come in later life. Importantly, analysis of the HF/HF offspring‘s livers, revealed a 
progressive form of steatosis, which was (again) severe than their C/HF counterparts.  This 
collectively demonstrates that HF exposure in early development exacerbates the effect of a 
HF diet in later life, leading to progressive fatty liver disease and highlighting the critical 
nature of maternal nutrition.    
 
Reports have suggested that a stimulus in addition to baseline steatosis is required for NAFLD 
disease  progression  to  occur.
439-440  Based  on  the  findings  from  this  present  study,  it  is 
investigated whether a HF maternal diet may constitute this stimulus and lead to increased 
susceptibility to NASH development in adult offspring.  At this point I am unable to define a 
mechanism that leads to this developmental priming as this was not the focus of my aims here. 
However it is plausible to speculate that this suboptimal nutrition during the developmental 
period  may  alter  the  epigenetic  profile  of  key  metabolic  genes,  subsequently  leading  to 
persistent  modulations  in  gene  transcription,  thus  increasing  the  risk.  But  chronic 
inflammation is central to lipid homeostasis and is maternally inherited; therefore providing a 
good  candidate  vector  for  the  inheritance  of  developmentally  primed  contributor  to 
atherosclerosis and CVD.
279  An important marker of inflammation
 is an elevation in CRP,
 an 
acute-phase reactant secreted by hepatocytes in response
 to pro-inflammatory cytokines such 
as  interleukin  (IL)-6.
440-441 In
 large  epidemiological  studies,  CRP has  been shown to  be a 
strong,
 independent predictor of CVD risk in both men and women.
442-443 The mechanism by 
which  inflammation  increases  CVD  risk  is  not  known,  but  during  periods  of  acute 
inflammation
 lipid metabolism is altered, giving a a proatherogenic profile.
444 
 
Emerging reports are suggesting that alterations in mitochondrial form and function could 
constitute a central element for this pathophysiology
438,445-446 and is likely to lead to increased 
generation of ROS.
447-448 This has previously been shown to initiate lipid peroxidation and 
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needed  during  the  postabsorptive  state,  to  minimize  protein  catabolism,  and  to  preserve 
glucose  and  amino  acids  for  the  fetus.  The  breakdown  of  fat  stores  in  adipose  tissue  is 
enhanced, increasing plasma free fatty acid (FFA) and glycerol levels
448-450 (Figure-3.7). In 
case  of  maternal  hyperlipidemia,  triglyceride  production  by  the  liver  increases  thus 
representing the enhanced levels of lipolytic products in circulation. Although triglycerides do 
not cross the placenta, they represent a ―floating energy deposit‖ that is easily accessible by 
the actions of lipoprotein lipase and other lipases releasing ketogenic byproducts that cross the 
placenta  and  provide  a  source  of  ROS  for  the  fetus,  thus  increasing  the  element  of 
inflammation
450. These elevated expression profiles then persist into early adulthood
449-450.  
Therefore, offspring that have received a HF diet in development and are also exposed to a HF 
diet in  adulthood (HF/HF offspring) shuttle their cytosolic fatty  acids  towards lipogenesis 
resulting  in  severe  steatosis  and  a  metabolic  syndrome  like  phenotype.  Conversely,  this 
hypothesis also explains why the offspring exposed to a HF diet in the adult life do not exhibit 
such  a  severe  phenotype;  since  their  mitochondrial  function  may  be  maintained  and  their 
lipogenesis pathways are not developmentally primed. 
 
Moreover, HF-HF and C-HF female offspring in this study demonstrate elevated CRP levels. 
Interestingly, such increasein CRP levels are not observed in the male offspring. This suggests 
that the effect of HF exposure on CRP levels is sex specific. The increase in CRP levels found 
only in female offspring on HF diet may be a consequence of increased sensitivity to the HF 
diet brought about by circulating female sex hormones
442-443 or due to the fact that the HF diet 
itself may result in high CRP in females. This observation is supported by human studies 
where CRP levels tend to be higher in women than in men.
441-442, 444,451 
 
This  study  shows  for  the  first  time  that  the  maternal  HF  feeding  developmentally  and 
biochemically  ―primes‖  metabolic  pathways  associated  with  NAFLD  disease  onset  and 
progression.    Specifically,  in  the  case  of  the  HF/HF  offspring  exposed  to  HF  in  both   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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developmental  and  adult  environments,  these  ―primed‖  pathways  are  induced  to  a  greater 
effect resulting in a florid NAFLD phenotype.  
 
In  conclusion, our data  provides evidence that  exposure to  a maternal  HF diet primes  an 
increased susceptibility to hepatic steatosis and inflammation in adult offspring. Specifically, 
if previously ―primed‖ offspring (due to increased maternal fat intake) are subsequently fed a 
HF diet, this results in severe disease similar to progressive human metabolic syndrome and 
NAFLD. These data emphasise the importance of the consumption of a balanced diet during 
pregnancy and lactation and the consequences for incidence of chronic disease if an unhealthy 
diet is consumed across generations.   
 
Here,  I  reasoned  that  it  is  crucial  to  understand  the  mechanisms  contributing  to  disease 
progression from exposure to a HF diet in the developmental period. This is important in 
developing  strategies  to  prevent  the  maternal  influences  on  the  offspring‘s  susceptibility 
towards the metabolic syndrome and NAFLD later in its life. To explore such possibilities will 
be the focus of the chapter-4. 
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Figure  3.7:  Schematic  representation  of  the  effect  of  pregnancy  on  carbohydrate,  lipid,  and  amino  acids 
metabolism. Arrows with (+) markings are those pathways enhanced during late pregnancy; arrows with (-) 
markings are those reduced. In general, these metabolic shifts are more enhanced in obese than in normal-weight 
women. Part A shows the response in a postabsorptive state; part B depicts a postprandial state. FFA, free fatty 
acids; VLDL, very-low-density lipoproteins; LPL, lipoprotein lipase. From Herrera with permission 
449 
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My father always mentored me. I remembered him advising me once  
“Son! Never lose three things in life; 1. Hope 2. Words 3. Honesty” 
I have never lost this advice in my life. 
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CHAPTER-4 
Effects on Offspring of Statin Treatment in Hypercholesterolemic 
Mice from Pregnancy to Lactation 
 
 
4.1  Introduction 
Five key messages emerge from the results described earlier in Chapter-3: 1) Long-term 
HF feeding results in changes in the dam‘s physiology, including increased body weight 
and raised circulating total  and  LDL  cholesterol levels  compared with  C-fed group 2) 
Long-term consumption of a HF diet by the dams predisposes their offspring to obesity, 
hypercholesterolemia, hypertension and fatty liver in adult life, when these offspring are 
also fed a HF diet. 3) There is greater propensity towards adiposity in offspring from HF 
dams, even when they were fed a C diet post-weaning thus suggesting that predisposition 
to obesity had been induced during development; 4) Feeding a HF diet during pregnancy 
and/or lactation induces gender-specific BP and CRP effects in the offspring and 5) A 
maternal HF diet can lead to development of NAFLD in offspring later in life, even if a 
control diet has been adopted in the adult environment. Taken together, these findings 
extend  our  knowledge  of  the  pathophysiology  of  maternal  HF  diet  and  its  effects  on 
offspring. This provides further evidence that changes occurring during development are 
persistent, and effect disease outcome in later life.  
 
 
In  recent  years  there  has  been  increasing  focus  on  optimizing  women‘s  nutrition  and 
lifestyle in the periconceptional
 period, as this is a key time for fetal development.
452 For 
example,
  clinical  trials  have  shown  that  folic  acid  supplementation  during
  the 
periconceptional period reduces the risk of neural tube
 defects.
453 Therefore promoting
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good  health  and  nutrition  before  pregnancy  may  be  at  least  as
  important  as  during 
pregnancy. Recently the National Institute for Health and Clinical Excellence
 (NICE) has 
reinforced this focus on the periconceptional period. Its
 guidance on nutrition of mothers 
and  children
454  not  only  advises
  improving  the  nutrition  of  pregnant  women  but  also 
includes
  recommendations  for  those  who  may  become  pregnant.  Indeed  a
  review 
commissioned by  NICE focused exclusively on interventions  to
  improve the health of 
women during the periconceptional period
455 and the health of their babies. Arguably the 
best known international recommendation so far for women who plan
 a pregnancy is to 
take 400 µg of folic acid a day in supplements
 to prevent neural tube defects
456-463. Until 
recently women planning
 a pregnancy in the United Kingdom  are encouraged to limit 
alcohol
 consumption, to eat a healthy balanced diet, take exercise, and avoid smoking.
464-
467 Despite the information available for women planning a pregnancy,
 data are limited on 
how closely the recommendations are followed.
 Recently, Southampton Women‘s Survey 
and others
468-474 reported that only a small proportion of women planning a pregnancy
 
follow the recommendations for nutrition and lifestyle. This proportion is even less for the 
population as a whole as many pregnancies are unplanned.  
 
 
So improved nutrition and lifestyles are becoming as important for women of
 childbearing 
age  as  women  planning  a  pregnancy;  we  now  face  a  bigger  challenge  than  just  the 
noncompliance of pregnant women adhering to healthy lifestyle. Today in a culture where 
food is more abundant and high in fat and carbohydrates, there exists a higher prevalence 
of metabolic syndrome especially before and during pregnancy and this may impact the 
health of future generations.  A pattern of fat distribution, development of type-2 diabetes 
and obesity in young women are becoming more prevalent not only in developed countries 
(e.g. USA, UK) but also in developing countries (e.g. Mexico, India). 
474-476 Reports have 
suggested that higher waist circumference
477 and higher waist to hip ratio
478-479 are both 
associated with type-2 diabetes and CVD. This suggests that impaired fetal growth could 
lead to increased
 metabolic syndrome in a given population. This is especially true in the 
case of females where events in their fetal lives could lead to persisting
 changes in the 
body's structure and metabolic
 function.    M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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In humans, the influence of a HF diet is unlikely to commence during pregnancy. Early 
interventions may be effective, either in the form of low fat diets (as shown in studies 
where the introduction of a low saturated fat diet in infancy and maintaining it during the 
first decade of life is associated with a reduction in serum cholesterol concentration and 
enhanced  endothelial  function  in  children.
254,481  Lipid-lowering  interventions  such  as 
HMG-Co-A  reductase  inhibition  using  statins  are  widely  used  to  control 
hypercholesterolemia; is proven to reduce risk of CVD. 
482-487 Because maintaining the 
population on low fat diet all the time is neither possible no ethical, statins may be a good 
choice as an early intervention.  
 
 
The existing data thus raise the important question of whether lipid-lowering interventions 
during  pregnancy  in  mothers  already  consuming  a  HF  diet  could  provide  long-lasting
 
benefits to their offspring. Palinski et al
254demonstrated a reduction of atherosclerosis in 
offspring of rabbits treated with cholestyramine or vitamin E, as well as those receiving 
combined treatments. Prevailing practice advocates that interruption of total cholesterol 
synthesis  during  first  trimester  is  potentially  hazardous  to  the  growing  embryo.  The 
cholesterol-lowering statin drugs are therefore clinically contraindicated in pregnancy, and 
initial animal studies have shown that they are potentially teratogenic.
488-489 Although a 
recent  study  reported  no  evidence  of  an  increase  in  congenital  anomalies  in  humans 
compared  within  the  general  population  after  maternal  exposure  to  simvastatin  or 
lovastatin,
490 these statins are still highly lipophilic and can result in embryo-placental 
concentrations similar to those in maternal plasma. Pravastatin, on the other hand, is the 
most hydrophilic statin and has not been reported to induce abnormal pregnancy outcomes, 
even in animals.
490-491  
 
 
We now know that pravastatin is an HMG-CoA reductase inhibitor that lowers plasma 
cholesterol  levels  by  inhibiting  de  novo  cholesterol  synthesis,  increasing  the  receptor-  M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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mediated catabolism of low density lipoprotein (LDL).
492 Pravastatin produces consistent 
dose-dependent  reductions  in  both  total  and  low  density  lipoprotein  (LDL)-cholesterol 
levels in patients with primary hypercholesterolaemia.
492 Reductions in LDL-cholesterol 
levels reported are 18% (10 mg/day), 23% (20 mg/day) and 31% (40 mg/day) after 12 
weeks  (discussed  in  reference  493).  Favourable  changes  in  other  parameters  such  as 
decrease in total triglyceride and consistent increase in high density lipoprotein (HDL) are 
generally not dose dependent
494-495. Combination therapy with other antihyperlipidaemic 
agents such as cholestyramine further enhances the efficacy of pravastatin in patients with 
severe dyslipidaemia.
492-493 Available data suggest that pravastatin is effective in CVD and 
in patients with hypercholesterolaemia secondary to diabetes mellitus or renal disease.
492  
 
 
The effect of pravastatin on cardiovascular events related to elevated plasma cholesterol 
levels  is  under investigation in  several  large scale disease regression  and primary and 
secondary  prevention  trials.  Regression  studies  such  as  PLAC  I,  PLAC  II,  and 
REGRESS
495-497 showed that pravastatin slows progression of atherosclerosis and lowers 
the  incidence  of  coronary  events  in  patients  with  mild  to  moderately  severe 
hypercholesterolaemia  and  known  coronary  heart  disease.  Large  scale  primary 
(WOSCOPS  and  PROSPER)  and  secondary  prevention  studies  (as  summarised  by 
Rajpathak  et  al,
498)  moreover  demonstrate  that  pravastatin  has  beneficial  effects  on 
coronary morbidity and mortality. In WOSCOPS, all-cause mortality was reduced by 22%, 
Pravastatin was generally well tolerated by most patients.
498 As with other HMG-CoA 
reductase inhibitors, myopathy occurs rarely (< 0.1% of patients treated with pravastatin): 
approximately  1  to  2%  of  patients  may  present  with  raised  serum  levels  of  hepatic 
transaminases. Thus, with its favourable effects on cardiovascular morbidity/mortality and 
total  mortality,  pravastatin  is  considered  a  first-line  agent  in  patients  with  elevated 
cholesterol levels, multiple risk factors or coronary heart disease who are at high risk of 
cardiovascular morbidity. 
498-500 
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Pravastatin is also the most rigorously tested drug in the ―first generation‖ of statins due to 
its pleiotropic properties. Despite, the identification of CVD and metabolic syndrome risk 
factors  (e.g.  hypertension,  hyperlipidemia,  smoking,  and  diabetes)  by  the  Framingham 
Heart Study,these traditional factors showed a very low specificity.
501-503 Therefore, the 
American Heart Association (AHA) suggested that inflammatory soluble mediators such 
as acute phase reactant CRP, (shown to play a central role in all phases of atherosclerosis), 
might be useful indicator of cardiovascular risk
504-508. Basic research and clinical studies 
have  shown  that  pravsatatin  not  only  lowers  LDL  cholesterol  levels  but  also  inhibits 
atherosclerotic  inflammatory  processes.  As  I  mentioned  earlier  that  pravastatin  is  a 
hydrophilic compound (different from fluvastatin or simvastatin that are lipophilic), and 
does  not  get  metabolized  by  the  cytochrome  P450  complex.
509  Probably  due  to  this 
property,  treatment  with  pravastatin  induces  different  effects  even  in  vascular  cells. 
Wiesbauer and coworkers showed that among six different statins, only pravastatin did not 
decrease PAI-I production in human endothelial and smooth muscle cells.
510 Furthermore, 
pravastatin increased E-selectin and vascular cell adhesion molecule (VCAM)-1-induced 
expression on vascular endothelial cells stimulated with TNF-α or LPS.
511 This suggests 
that  pravastatin  could  be  considered  a  very  promising  pleiotropic  agent  against 
inflammatory processes as well. Figure 4.1 summaries this as follows. 
 
 
Due to its beneficial lipid lowering effects, reducing CVD risks and pleiotropic effects 
inducing  molecular  intracellular  mechanisms  in  both  vascular  and  immune  cells  statin 
(pravastatin) therapy should be considered as a promising approach to give cardiovascular 
protection in future generations. Therefore the aim of this chapter is to test the hypothesis 
that statin therapy (pravasatain) during pregnancy and lactation in hypercholesterolemic 
mothers  prevents  adverse  phenotype  in  their  offspring.  Once  again  C57BL/6 
hypercholesterolemic mouse model was used, giving the HF diet from the time the dams 
were weaned, then throughout pregnancy and lactation 
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Figure-4.1:  Activatory‖  and  ―inhibitory‖  intracellular  signaling  pathways  regulate  pravastatin-induced 
pleiotropic  activities.  Pravastatin  diminishes  proinflammatory  effects  and  promote  anti-inflammatory 
activities through the direct inhibition/activation of chemokine-, cytokine-, and acute phase reactant-induced 
intracellular signaling pathways in several cell types (such as leukocytes, vascular cells, adipocytes, and 
hepatocytes). In particular, the inhibition of ERK 1/2, rho, JAK/STAT3, or mevalonate pathways is crucial to 
reduce inflammation. On the other hand, statins directly activate AMPK and PI3K/Akt/NFkB pathways, 
thus, increasing cell survival, endothelial, and neuronal protection. (Adapted from references
509-510) 
 
 
.  
4.2     Methods 
The protocol for conducting the experiments is shown in Figure-4.2.     M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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Figure-4.2:  Flow diagram of the experimental protocol.  
 
The main point of this experimental protocol was the administration in their drinking water of 
a water-soluble Pravastatin (Sigma UK; 5mg/kg/day), to half of the pregnant females on HF 
diet from the second half of the pregnancy and throughout lactation. Later in this chapter I 
explain the results of my preliminary experiments for pravastatin dose optimisation. This let 
me decide the appropriate standardized dosages of Pravastatin to be given to HF pregnant 
dams in this protocol.   
 
 
The  pregnant  dams  were  allowed  to  give  birth,  pups  were  weighed  and  litter  size  was 
standardised to 8 pups with equal numbers of males and females if possible. From weaning (3 
weeks post partum) offspring from the C dams were fed the same C diet as their mothers. The 
offspring of HF and HF-S dams were fed ad libitum the HF diet to generate the HF/HF and 
HF-S/HF  groups.  Body  weights  of  the  offspring  (from  1  week  of  age  to  avoid  maternal 
rejection of the pups) and food intake (from weaning) were monitored this time until 27 weeks 
of age. Systolic blood pressure, biochemical markers (total, LDL and HDL cholesterol) and   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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physical activity was measured at 13, 18, 23 and 27 weeks. All the data were expressed as 
mean +/- SEM. A p<0.05 was considered to be statistically significant. 
 
4.2.1  Metabolism  and  optimization  of  pravastatin  in  C57BL/6  Mice-  Preliminary 
experiments 
 
Before I discuss my preliminary experiments, I would like to mention the mechanism of action 
and functional properties of pravastatin as below; 
 
a) Mechanism 
As I mentioned earlier, pravastatin catalyses the conversion of HMG-CoA to mevalonate, the 
rate-limiting step in de novo cholesterol synthesis. Competitive inhibition of this enzyme by 
the statins decreases hepatocyte cholesterol synthesis (Figure-4.3).  
 
Figure-4.3: The mammalian mevalonate pathway; PP, pyrophosphate. Adopted from Corsisni et al
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The  associated  reduction  in  intracellular  cholesterol  concentration  induces  LDL-receptor 
expression on the hepatocyte cell surface, which results in increased extraction of LDL-C from 
the  blood  and  decreased  circulating  LDL-C  concentrations.
512-513  Pravastatin  also  has 
beneficial effects on other lipid parameters, including increases in high-density lipoprotein 
cholesterol (HDL-C) concentration and decreases in triglyceride concentration.
514 Secondary 
mechanisms  by  which  pravastain  may  reduce  levels  of  atherogenic  lipoproteins  include 
inhibition of hepatic synthesis of apolipoprotein B100 and a reduction in the synthesis and 
secretion of triglyceride-rich lipoproteins.
514-515 In addition, pravastatin may exert beneficial 
cardiovascular  effects  independent  of  their  lipid-modifying  properties.
516  These  pleiotropic 
properties may be explained by inhibition of synthesis of nonsteroidal isoprenoid compounds, 
which are also produced from mevalonic acid (Figure-4.3),
517 and include improvement of 
endothelial cell function, modification of inflammatory responses, and reduction of smooth 
muscle cell proliferation and cholesterol accumulation.
516,518 
 
b) Chemistry and functional properties 
Pravastatin is a fungal-derived inhibitor of HMG-CoA reductase, and is not a fully synthetic 
compound as like other statins.
494 The chemical structures of the different statins are shown 
for comparison in Figure-4.4.    M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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Figure-4.4: Chemical structures of the statins
512 
 
These structures can be broadly divided into three parts
519: an analogue of the target enzyme 
substrate, HMG-CoA; a complex hydrophobic ring structure that is covalently linked to the 
substrate  analogue  and  is  involved  in  binding  of  the  statin  to  the  reductase  enzyme;  side 
groups on the rings that define the solubility properties of the drugs and therefore many of 
their  pharmacokinetic  properties.  Atorvastatin,  fluvastatin,  lovastatin  and  simvastatin  are 
relatively lipophilic compounds, while pravastatin and rosuvastatin are more hydrophilic as a 
result of a polar hydroxyl group and methane sulphonamide group, respectively. For a detailed 
comparison of pharmacokinetic properties of the statins, please refer to Appendix-iii   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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Pravastatin, unlike other statins does not bind fully to plasma proteins and as a result systemic 
exposure to unbound, pharmacologically active drug is relatively high.
520 Thus widespread 
tissue  distribution  is  prevented  by  the  hydrophilic  nature  of  the  drug.
521  Pravastaitn  is 
relatively hepatoselective with  respect to  inhibition  of HMG-CoA reductase,  an important 
property given that the majority of endogenous cholesterol production occurs in the liver. The 
mechanisms contributing to this hepatoselective effect are governed by the solubility profile of 
the statin. For lipophilic statins, passive diffusion through the hepatocyte cell membrane is 
primarily responsible for efficient first-pass uptake, while for hydrophilic statins extensive 
carrier-mediated  uptake  is  the  major  mechanism.
521-522  This  contributes  to  the  fact  that 
hydrophilic  statins  exhibit  greater  hepatoselectivity.  Indeed,  the  lack  of  influence  of 
pravastatin on smooth muscle cell proliferation is likely to be due to low penetration of the 
cells by the drug.
523  
 
c. Safety of pravastatin for use in experiments 
Current utilization studies that ascertain the most commonly used drugs in pregnancy have 
suggested  the  teratogenic  potential  of  statins  mainly  in  the  first  trimester.
524-525  Thus  the 
selection and timing of administration of statin to the female dams in my experiments was a 
major challenge. Consideration of the differences between the statins (as described above) 
helped me to  provide a rational  basis  for the safe  and effective use of pravastatin in  my 
experiments. On the basis of the current knowledge about pravastatin (salient features; that 
include  hydrophilic  nature,  higher  and  rapid  peak  plasma  concentration  within  4hrs,  easy 
systemic bioavailability, more liver protection, low penetration into smooth muscle cells and 
increased effectiveness in lowering cholesterol and LDL without too much affecting HDL 
levels), I used this statin in the second half of the pregnancy through to lactation.  
   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
 
135 
 
 
d. Determination of pravastatin levels in samples using liquid chromatography 
20 Female C57 mice (Charles River Labs UK) maintained on a HF experimental diet were 
randomly assigned to either pure water available ad libitum or water with soluble  pravastatin 
added (100µg/ ml made up solution; Sigma UK) This group is called HF-S. This study is the 
first to use hydrophilic statins in the drinking water rather than given via intraperitoneal (i.p.) 
injection. This is to avoid unnecessary stress to the animals, especially during pregnancy that 
could affect the findings of the study. As there was no prior study available in terms of dosing 
regimen in  drinking water, the calculation for the dosing regimen  was based  on previous 
studies where a single 0.5 gm/kg dose administered to C57BL/6 mice caused an elevation in 
both plasma cholesterol and triglycerides 2 h post-dosing and a subsequent return of both 
lipids to normal plasma concentrations after approximately 120 h.
526 On the basis of this, it 
was  calculated  that  an  average  25  gm  mouse  would  require  5mg/kg/day  of  pravastation 
dissolved solution for effective results.  Water with or without pravastatin was available to 
mice the whole day, as it was established that these agents did not need to be specifically 
dosed  prior  to  sleep  when  HMGR  (3-hydroxy-3-methylglutaryl  Coenzyme  A  reductase) 
attained its maximum biological activity for maximum effects.
526 
 
From Sigma- Aldrich UK, Pravastatin sodium salt that came in the form of white powder with 
the  solubility  of  H20>10mg/mL  was  purchased.  The  linear  formula  of  this  product  is 
C23H35O7NA
527-528.  This  powder  was  dissolved  in  an  appropriate  volume  of  demonized 
sterilized water and working solution of statin and all standard solutions were stored in a 
−10 °C freezer to minimize the interconversion of statins. Samples were collected, separated 
for plasma and serum and stored at -20C before been transferred to Wickham Laboratories in 
Hampshire  UK  (www.wickhamlabs.co.uk)  for  liquid  chromatography.  Though  I  did  not 
directly  carry  out  the  analysis,  the  principles  of  the  mass  spectrometry  and  liquid 
chromatography are mentioned in Appendix-iv. 
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Time  scheduled  chromatography  performed  on  the  standard  solution  of  statin  containing 
10ƞg/ml pravastatin identified, in at least 50% of
 the samples, the presence of analytes over a 
period of 7 days (Figure 4.5).   
 
Figure-4.5: Time scheduled chromatogram of a standard solution of statin. 
Extracted  ion  chromatograms  were  constructed  from  the  FT-MS
  data,  and  peak  area  was 
determined with LCQuan software (Thermo
 Electron). Ion chromatograms were reconstructed 
for the peptide
 charge state identified by SEQUEST. Differences in statin levels over time 
were  determined  by
  analyzing  peak  areas  using  a  repeated-measures  2-way  ANOVA  as 
within-subject  factors based on natural  log-transformed
  values
528. The following Table-4.1 
demonstrates the results in control sera and plasma as well in treated animals. Table 4.1a 
shows non-detectable peaks however, Table 4.1b demonstrates the peak levels within sera and 
plasma.    M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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Moreover the bottom Table-4.1 (c) demonstrates concentrations (ƞg/ml) in adult at 1 and 8 
days of statin treatment and in weaned and adolescent mice at 15 days treatment (n=5/sample 
group) 
 
Table-4.1 (d) demonstrates the concentration of pravastatin (ug/ml) in the aqueous phase over 
a storage period of 90 days by chromatographic examination in 100µg/ml of stock solution. 
a 
b 
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4.3   Results 
 
4.3.1 Statin treatment in hypercholesterolemic dams ameliorates  their blood pressure 
and alters total cholesterol, LDL cholesterol and HDL cholesterol Profiles 
 
Prior to becoming pregnant, 14-week old HF females (fed the HF diet for 10 weeks) showed 
significantly  raised  total  cholesterol  (4.08±0.4  vs.  1.99±0.2mmol/l,  p<0.001)  and  LDL 
cholesterol (2.1±0.2 v. 0.8±0.02mmol/l, p<0.001) relative to their C counterparts. HF dams 
were heavier than C during mid pregnancy (body weight 67.4±2.4 v. 41.2±1.8g, p<0.001) and 
at the time of weaning their offspring (57.4±3.4 v. 30.7±1.3g, p<0.001). At weaning of their 
offspring, HF dams were more hypertensive with raised total cholesterol and LDL cholesterol 
compared with C dams (Table 4.2). Statin treatment in HF dams reduced systolic BP, total 
cholesterol  and  LDL  cholesterol  levels  at  weaning  of  their  offspring.  Additionally, 
administering statin to HF dams increased HDL cholesterol concentrations compared to the 
untreated HF mothers. 
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Table-4.2: Statistical analyses of biochemical and biophysical parameters in dams at 
weaning,  with  comparisons  among  the  groups.  Values  mean  ±  SEM  (n  =  8  for  all 
groups). Statistical test on the right hand column is the ANOVA result for all groups. 
Statistical result displayed in each cell is for the dietary group comparison with the other 
groups such as HF vs. HF-S; HF vs. C and C vs. HF-S using the Tukey-Kramer test. 
**P<0.01, *** P <0.001.  
 
Variables  Dietary Groups  ANOVA 
P Value   
HF 
HF  C 
vs HF-S  vs C  vs HF-S 
total cholesterol 
(mmol/l) 
6.02±0.20  3.45±0.24***  2.29±0.12***  *** 
 
<0.001 
systolic blood 
pressure 
(mmHg) 
136.2±1.4  123.6±1.1***  108.7±2.4***  ***  <0.001 
 
LDL 
cholesterol 
(mmol/L) 
3.50±0.09  1.13±0.09***  0.21±0.03***  *** 
 
<0.001 
 
HDL 
cholesterol 
(mmol/L) 
1.12±0.17  2.60±0.05***  1.78±0.10**  *** 
 
<0.001 
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4.3.2 Statin treatment in hypercholesterolemic dams has beneficial effects on offspring 
blood pressure, total cholesterol profiles and locomotor activity 
 
HF/HF offspring were of similar weight as the C/C offspring one week postpartum (Figure 
4.6a and Table 4.2). However they became heavier at weaning (3 weeks of age) and at 13 to 
27 weeks of age compared to the C/C offspring. The HF-S/HF offspring showed a smaller 
increase in body weight gain compared with the HF/HF offspring. Systolic blood pressure 
(SBP) was lower at 13 to 27 weeks in HF-S/HF compared to HF/HF offspring (Figure 4.6b 
and Table 4.3).  
 
 
As expected, SBP for the C/C group was lower at all time points examined. We also found 
that SBP in the HF-fed offspring at 27 weeks of age was much more elevated compared with 
their HF-fed mothers (151.6±3.6 v 136.2±1.4mmHg, respectively, P<0.01). Offspring from 
HF-S mothers were significantly more active at 13 to 27 weeks of age than HF/HF offspring, 
although not as much as the C/C animals (Figure 4.6c and Table 4.3). Total serum and LDL 
cholesterol concentrations for offspring on HF or C diets followed a similar pattern to dams on 
HF  or  C,  respectively  and  previous  exposure  of  their  dams  to  pravastatin  resulted  in 
significantly lower total or LDL cholesterol levels, similar to its effect in the dams themselves 
(Figure 4.6d and 4.6e respectively, and Table 4.3). The elevated levels of total cholesterol 
observed in HF/HF offspring at 27 weeks were similar to levels found in the HF dams. It is 
interesting to note that total serum and LDL cholesterol concentrations in HF-S/HF offspring 
become progressively closer together over time to levels found in the HF/HF group. The HDL 
cholesterol concentrations for offspring on HF or C diets also showed a similar pattern to 
dams on HF or C resepectively and previous exposure of their dams to pravastatin resulted in 
significantly  higher  HDL  cholesterol  concentration,  similar  to  its  effect  in  the  dams 
themselves (Figure 4.6f and Table 4.3).  
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Figure-4.6: Statin treatment in hypercholesterolemic mothers during late pregnancy and lactation has beneficial 
effects on the cholesterol profile, blood pressure and locomotor behaviour in their offspring. (a) Body weight 
gain, (b) systolic blood pressure (c) locomotor activity, (d) serum cholesterol, (e) serum LDL and (f) serum HDL 
in offspring from mothers on standard chow (C), high fat-high cholesterol (HF) diet or HF diet and treated with 
statin during pregnancy and lactation (HF-S). Weaned offspring were then fed either HF or C diets to adulthood, 
thus generating the dam/offspring dietary groups: HF/HF, HF-S/HF and C/C (n = 8 per group). See Table 2 for 
result of statistical analysis. 
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Table-4.3: Statistical analyses of biochemical and biophysical parameters in offspring. 
 
Variables 
 
Age 
(weeks) 
 
Dietary Groups 
 
ANOVA 
P Value   
HF/HF 
HF-/HF  C/C 
vs. HF-S/HF  vs. C/C  vs. HF-S/HF 
body 
weight (g) 
1 
3 
13 
18 
23 
27 
3.2±0.1 
10.8±0.2 
15.4±0.2 
18.3±0.4 
19.5±0.5 
22.2±0.4 
2.9±0.2ns 
9.3±0.2*** 
12.1±0.2*** 
13.9±0.6*** 
14.9±0.4*** 
17.7±0.7*** 
3.3±0.2ns 
7.5±0.2*** 
10.2±0.4*** 
11.0±0.5*** 
12.5±0.4*** 
14.4±0.5*** 
ns 
*** 
*** 
*** 
*** 
*** 
ns 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
systolic blood 
pressure 
(mmHg) 
13 
18 
23 
27 
141.9±1.7 
146.7±2.3 
148.6±2.6 
151.6±3.6 
122.2±1.4*** 
125.7±1.9*** 
129.5±2.2*** 
132.9±1.9*** 
98.4±1.1*** 
99.9±0.6*** 
105.2±1.3*** 
104.7±1.0*** 
*** 
*** 
*** 
*** 
<0.001 
<0.001 
<0.001 
<0.001 
total 
cholesterol 
(mmol/l) 
13 
18 
23 
27 
6.0±0.2 
5.3±0.3 
6.0±0.4 
5.5±0.2 
3.0±0.3*** 
5.2±0.3ns 
5.9±0.2ns 
5.6±0.2ns 
1.8±0.4*** 
2.3±0.3*** 
2.3±0.3*** 
1.9±0.3*** 
** 
*** 
*** 
*** 
<0.001 
<0.001 
<0.001 
<0.001 
HDL 
cholesterol 
(mmol/l) 
13 
18 
1.1±0.2 
1.1±0.2 
1.3±0.2ns 
1.2±0.2ns 
1.3±0.2 ns 
1.3±0.2ns 
ns  
ns 
ns  
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23 
27 
1.2±0.2 
1.1±0.2 
1.4±0.2ns 
1.3±0.2ns 
1.5±0.2ns 
1.4±0.3ns 
ns 
ns 
ns 
ns 
LDL 
cholesterol 
(mmol/l) 
13 
18 
23 
27 
1.2±0.2 
1.3±0.1 
1.3±0.2 
1.5±0.2 
1.0±0.1ns 
1.3±0.4ns 
1.3±0.2ns 
1.4±0.2ns 
0.4±0.0*** 
1.0±0.1ns 
0.5±0.0** 
0.9±0.0* 
** 
ns 
** 
* 
<0.001 
ns 
<0.01 
<0.05 
locomotor 
activity  
(cm/3min) 
13 
18 
23 
27 
302.8±5.1 
287.8±6.5 
285.0±13.3 
281.4±15.4 
440.5±7.7*** 
398.5±17.4*** 
393.9±14.8*** 
373.9±18.4*** 
554.3±7.2*** 
519.6±14.7*** 
512.7±11.8*** 
510.3±6.7*** 
*** 
*** 
*** 
*** 
<0.001 
<0.001 
<0.001 
<0.001 
 
Values mean ± SEM (n = 8 for all groups). Statistical test on the right hand column is the ANOVA result for 
all groups. Statistical result displayed in each cell is for the dietary group comparison with the other groups 
using the Tukey-Kramer test. * P<0.05, **P<0.01, *** P <0.001, ns = not significant.  
 
4.4 Discussion 
 
The present study demonstrates that treating pregnant animals that are hypercholesterolemic 
and hypertensive with pravastatin not only improves their health but can also have long-lasting 
beneficial effects on their offspring in terms of blood pressure and activity, and induces a 
transient reduction of cholesterol in their offspring even if they consume a similar high fat 
diet. Further, the present  findings  provide the first  indication that cholesterol-lowering, or 
other effects of statins, benefits postnatal blood pressure. 
 
Several studies, including ours, have shown that a maternal diet rich in fat and cholesterol 
during  pregnancy  can  induce  obesity,  vascular  dysfunction,  impaired  skeletal  muscle   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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development,  sedentary  behaviour  and  gender-specific  hypertension  in  the 
offspring.
213,217,246,247,250,253,254  However  these  studies  have  been  confined  to  short  term 
modifications in the maternal diet such as during pregnancy and/or lactation periods only. In 
the present study, future mothers were given a HF diet very early in life to produce an effect 
on offspring health. Thus the experimental approach is more relevant to the human condition.   
 
 
Altering the maternal diet during critical periods of gestation 
216,249 or throughout gestation 
and/or  the  suckling  period
247,250  results  in  a  varying  degree  of  phenotypic  outcomes, 
suggesting  the  importance  of  the  timing  and  duration  of  the  nutritional  insult.  This  is 
emphasized by one of the novel findings using this animal model, namely that SBP in the 
HF/HF  offspring  was  much  greater  than  their  HF-fed  mothers  despite  having  similar 
cholesterol  levels  (Table-4.4).  Such  effects  are  fundamental  to  the  concept  of  the 
developmental origins of disease
15 and also indicate that intervention in early life may be 
particularly important in reducing later risk of disease in the face of lifestyle factors such as a 
HF diet.  
 
 
Table-4.4: HF Dams vs. HF/HF offspring at 27 wk   
 
Variables  HF 
(dams) 
HF/HF 
(Female offspring) 
t-test 
cholesterol conc. (mmol/l)  6.02±0.2  5.5±0.2  p=ns 
Systolic blood pressure 
(mmHg) 
136.2±1.36  151.625±3.59  p<0.01 
 
The significance of maternal hypercholesterolemia in DOHaD remains to be investigated. We 
believe that the presence of severe developmental
 physiological defects in offspring (reported 
here and in Chapter-3; e.g. HF/HF) and with inborn errors of high cholesterol synthesis
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result from the distinct processes
 involved in cholesterol transfer across the placenta. It has
 
been long assumed that most, if not all, cholesterol required
 for fetal growth is synthesized de 
novo by the fetus itself,
 thus making it autonomous from maternal or placental cholesterol
 
supply. However, several lines of evidence have cast doubt on
 this notion.
528-531 For example, 
fetuses that lack the ability to synthesize
 cholesterol, such as those with the Smith–Lemli–
Opitz
  syndrome,  are  nevertheless  born  with  low  levels  of  tissue
  and  plasma  cholesterol, 
indicating  that  they  have  acquired  maternal
  cholesterol  in  utero.
532  Similarly,  studies 
demonstrate
 a strong correlation between the size and number of atherosclerotic
 lesions in 
human  fetal  arteries  and  maternal  cholesterol  levels.
278,292  Moreover,  maternal 
hypercholesterolemia  also  modifies  early
  predictors  of  CVD  in  the  offspring,  thus
 
corroborating  the  concept  of  DOHaD  in  humans.
533  Considering  that  progression  of 
atherosclerosis
 in adults takes time, these striking results support the assumption
 of a strong 
maternal impact on the comparatively short period
 of fetal development.
  
 
These results have sparked strong interest in delineating the
 mechanism of maternal-to-fetal 
cholesterol transfer, because
 identifying possible mechanisms might offer an insight into the 
statin intervention adopted in this study. Maternal cholesterol entering the fetal
 circulation 
traverses the syncytiotrophoblast layer and
 the endothelium of the fetoplacental circulation. In 
vitro studies
 on human syncytiotrophoblast membranes and on human primary
 trophoblasts
534-
536  demonstrated  the  presence  and  functional
  role  of  LDL)  receptor  and  HDL  receptor 
scavenger  receptors  in  cholesterol  uptake  and  subsequent  transport  across
  the 
syncytiotrophoblast layer. Recent work has further suggested that endothelial cells (ECs) of 
the  fetoplacental  vasculature  display  a  high  and  tightly  regulated  capacity  for  cholesterol 
release.
537  In  brief,  the  sequential  steps  in  transplacental  transfer  of  lipoprotein-derived 
cholesterol at the end of gestation are demonstrated in Figure-4.7  
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Figure-4.7:  Overall  maternal–fetal  transfer  likely  encompasses  an  "uptake/influx"  component  for  maternal 
lipoproteins  and/or  their  cholesterol  into  the  syncytiotrophoblast  (STB),  transport  of  lipoprotein-derived 
cholesterol (C) to the basal side of the STB, subsequent release into the villous core for passage through the 
extracellular matrix (ECM), uptake into ECs, and, finally, an efflux component by which cholesterol is released 
from ECs into the fetal circulation. To date, only the uptake and degradation of LDL and HDL in cultured 
trophoblasts have been described. 
 However, other lipoproteins and their respective receptors have not been 
analyzed, and the subsequent intraplacental transport steps are still uncharacterized. (Adapted with permission
535) 
 
It  is  plausible  that  statin  may  indirectly  affect  growth  and  development  of  the  fetus  by 
influencing  maternal-fetal  cholesterol  transfer  across  the  placenta,  and  prevent  changes  in 
liver, kidney and vascular function in the fetus. This may also up-regulate EC activity by 
enhancing  eNOS,  increase  NO  bioavailability  and  decrease  oxidative  stress.
537  Statin  can 
therefore blunt the deleterious effects of placental insufficiency by preventing the alteration of 
these pathways associated with such inadequate utero-placental function. 
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It is also possible that effects of statin on offspring might be related to excretion of statin 
during lactation and this is supported by recent studies.
492,493,538 In this respect, characteristics 
of statins vary. Atorvastatin, simvastatin, lovastatin, fluvastatin, cerivastatin and pitavastatin 
are lipophilic in nature and are metabolized by cytochrome P(450). They are more likely to be 
excreted in substantial amount in the milk. However, this is not the case with pravastatin that 
is relatively hydrophilic and not significantly metabolized by cytochrome P(450) enzymes. 
Hence its concentrations in milk should usually be negligible.
539-540 Though the HMG-CoA 
reductase inhibitors are not generally recommended for nursing mothers, a previous study 
conducted in humans that pravastatin excretion in milk is negligible.
541 There may therefore be 
an  argument  for  testing  statin  treatment  in  early  postnatal  life  in  hypercholesterolemic 
mothers, initially in animal models.   
 
We also observed that offspring from hypercholesterolemic dams were less active, providing 
another aspect of the model that mimics the early origins of the ‗couch-potato‘ syndrome in 
humans
542.  Although  this  has  been  previously  observed  when  dams  were  undernourished 
during pregnancy
543-544 the present study is the first to show that a maternal HF diet during 
pregnancy can also result in sedentary behaviour in the offspring. Moreover statin treatment of 
the dams ameliorates this effect. The mechanisms underlying these effects are not known. 
Although  inadequate  cholesterol  provision  to  the  developing  fetus  is  deleterious  to 
development of the central nervous system
545 the effects of a hypercholesterolemic condition 
during pregnancy have not been reported.  
 
We recognise that prolonged exposure to the HF diet not only led to hypercholesterolemia and 
hypertension prior to and during pregnancy, but can also result in the development of obesity. 
This would almost certainly be associated with insulin resistance, increased inflammation and 
concomitant immune responses, which also affect developmental origins of cardiovascular 
disease.
532,538 It is therefore not possible at this time to attribute unequivocally the changes in 
offspring blood pressure and activity level to maternal hypercholesterolemia. It also remains to 
be  determined  whether  the  protective  effects  of  statin  treatment  are  due  to  cholesterol-  M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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lowering during pregnancy or to a lesser degrees of obesity, hypertension, or insulin resistance 
in mothers, i.e. whether statins prevent pathogenic effects by improving maternal health or 
whether they interfere with in utero mechanisms.  It is more likely that the protective effect is 
due to cholesterol lowering.  We however cannot discount the possibility that there may be 
other pleiotropic effects of the drug (e.g. on endothelial cells).  
 
Although it has been suggested that maternal hypercholesterolemia enhances atherosclerosis in 
offspring,  and  is  inhibited  by  antioxidant  or  lipid-lowering  intervention  during 
pregnancy,
253,278, 287,546 it is difficult to establish that this is also true for the effect of statin on 
postnatal BP or activity levels.  To resolve these questions, it would be necessary to compare 
the effect of statin to that of other hypocholesterolemic drugs, and to utilize an experimental 
design that minimizes differences in body weight and other parameters prior to pregnancy. 
This would be beyond the scope of the present work but should be considered a limitation of 
this work. It is also possible that the programming effect of statin occurs during early postnatal 
period since we continued giving it in the dam‘s drinking water during the lactation period. 
Studies have shown excretion of statin into the milk in rat dams that were treated postpartum 
with the statin atorvastatin.
224 Statin could at this point reverse the programming effect of the 
maternal hypercholesterolemia similar to the effect of leptin administration in early postnatal 
life to offspring from undernourished mothers in preventing obesity, vascular dysfunction, 
sedentary behaviour and gender-specific hypertension in the offspring.
287,547 More recently, it 
is debated about the pleiotropic actions of statin that includes  increased NO bioavailability 
and reduced  inflammation
 and oxidative damage.
548 In this context, in a model of endothelial 
dysfunction, independent of dyslipidemia [rats fed a control
 (18% casein) or protein-restricted 
(9% casein) diet throughout
 pregnancy], statin treatment on
 vascular function was assessed. At 
weaning, a subset of the protein-restricted group
 was given atorvastatin (10 mg/kg per day) in 
the drinking water.
 The authors demonstrated that atorvastatin restored endothelial function 
and CRP to control levels in the females (P<0.05) but its effects were gender specific and 
dependent on the vascular
 bed.
549 
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Statins  in  general  are  still  regarded  as  contraindicated  during  pregnancy,  mainly  due  to 
previous reports of their teratogenic effects. Despite widespread use of statins however, and in 
many instances their inadvertent use during pregnancy, there is little evidence of their adverse 
effects in humans. A reconsideration of the use of statin in high risk situations therefore seems 
to be indicated, but this will remain controversial. 
 
To summarise, the findings indicate that 1) Statin administration to HF pregnant dams during 
second half of pregnancy is safe and does not indicate any adverse effects on dams or their 
offspring; 2) Statin administration to HF pregnant dams not only improves their cardiovascular 
and metabolic health but it also gives some post-weaning protection to their offspring even 
when they are fed a HF diet 3) This might allow time for other intervention strategies to be put 
in place before the effects of a poor post-weaning diet set in, and 4) The improvement in 
offspring phenotype following statin treatment of their dams seen in our study further signifies 
the  importance  of  mother's
  health  during  pregnancy  as  a  major  contributing
  factor  to  the 
rapidly developing cardiovascular epidemic.
287,546  
    
The  significance  of  this  new  evidence  from  the  current  work  suggests  that  maternal 
hypercholesterolemia has  a detrimental  effect  on the next  generation.  This  is  in  line with 
interest by US National Cholesterol Education Program (NCEP) for drug therapy in children 
aged >10years of age whose LDL cholesterol remains elevated after dietary therapy, though 
this has not been tested fully.
548 Based on this background, it would now be interesting to 
examine  whether  early  postnatal  statin  treatment  to  offspring  from  hypercholesterolemic 
mothers would show the same protective effects  against a post weaning HF diet, both  in 
themselves and in their offspring. This will be the focus of the next chapter. 
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For me when GOD solves my problems, I have faith in HIS abilities; 
 when God doesn’t solve my problems, I believe HE has faith in my abilities 
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CHAPTER-5 
Effects of Long-term Statin Treatment in Hypercholesterolemic 
Pregnant Mice on their Offspring Fed a High Fat Diet. 
 
 
5.1  Introduction 
As discussed earlier (Chapter-1), current literature supports the concept that maternal under-
nutrition of calories, proteins and a number of micronutrients has a profound effect on the 
fetus and increases its risk of metabolic and CVD disease.
550-555 But what is more important 
today  is  the  notion  of  HF  overnutrition-mediated  teratogenesis,  predominantly  based  on 
animal  studies,  such  as  described  by  Freinkel  and  colleagues.
556  This  explains  the  wide-
ranging fetal effects of maternal hyperglycemia and related metabolic abnormalities. Pettit and 
colleagues  made  very  interesting  observations  in  Pima  Indians.  Using  prospective  serial 
databases from a Pima Indian community, they assessed the contribution of genetics and the 
intrauterine environment to the risk of obesity and metabolic syndrome in the offspring.
557-558 
These authors demonstrated that children of diabetic mothers had a higher risk of being obese. 
Subsequently, they showed that risk of diabetes in the child was many times higher if the 
mother had diabetes during pregnancy (intrauterine exposure) compared with the risk in the 
children  whose  mothers  developed  diabetes  after  pregnancy  (genetic  risk).  These  results 
suggest that intrauterine overnutrition is more important in intergenerational propagation of 
metabolic  syndrome  and  eventually  CVD  compared  with  genetic  factors.  Therefore, 
overnutrition in young girls is beginning to become a major factor in the escalating epidemic 
of diabetes, obesity and hypercholesterolemia. Up to 70% of young diabetes could be ascribed 
to maternal diabetes and children of diabetic mothers have a higher risk of glucose intolerance 
at a young age.
559-560  
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Previous studies have provided compelling evidence for close
 associations among obesity, 
essential hypertension, and metabolic
 disorders [discussed in Ref 559]. It is reported that these 
disorders  could  lead  to  end-stage  renal  disease  (ESRD)
561-562  associated  with  increased 
glomerular  filtration  rate,  renal  blood  flow,  glomerulomegaly  and  in  extreme  cases  focal 
segmental  glomerulosclerosis.
562  Though
  two  main  risk  factors  (hypertension  and 
hyperglycemia)  for  ESRD  are  closely  linked  to  excess
  body  weight,  this  association  in 
particular with metabolic syndrome still remains robust in some but not in all studies.
563-566 Yet 
several lines of evidence now indirectly suggest that dyslipidemia may be an
 important factor 
in the development and progression of ESRD.
 Observational data and a recent meta-analysis 
point  out  that  elevated
  triglycerides  and  low  HDL  are  independent  risk  factors  for  the
 
development or acceleration of ESRD and early atherosclerosis lesions and that the use of 
statin
 may slow their progression.
567-574 
 
In view of the current environment of increasing fat utilization, decreasing energy expenditure, 
adiposity  and  increasing  body  weights  in  young  adults,  we  can  assume  that  CVD  (e.g. 
atherosclerosis) begins in early childhood,
575 Also, it is reported that elevated serum levels of 
total and LDL-C are
 associated with fatty streaks and fibrous plaques in aorta in adolescents
 
and young adults
575-576 and reducing dietary saturated fat and cholesterol reduces blood
 total 
cholesterol  and  LDL-C.
577  So  diets  reduced  in  total  fat,  saturated  fat,  and  cholesterol
  are 
recommended  for  healthy  children  2 years  of  age  and  older,
  with  greater  reductions 
recommended  for  children  with  elevated
  blood  cholesterol  and  with  a  family  history  of 
premature coronary heart
 disease.
575-578  
 
Questions have been raised about the safety of such interventions, including possible growth 
retardation,  nutritional
  inadequacy,  and  adverse  psychosocial  effects,
579-580  and  about  the 
effects on blood lipids and cholesterol in children.
581 In 1987, the Dietary Intervention Study 
in Children (DISC), a
 multicentre, controlled, randomized trial, addressed
 these efficacy and 
safety questions in children aged 8-10 years with LDL-C levels greater than or equal to the   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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80th and less than the 98th percentiles for age and sex. The participants were randomized into 
an intervention group (n = 334) and a non-treatment group (n = 329). The trial reported that at 
3 years, dietary total fat, saturated fat, and cholesterol levels decreased significantly in the 
intervention  group  (P  <  .001).  Levels  of  LDL-C  decreased  in  the  intervention  and  non-
intervention  groups  by  0.40  mmol/L  (15.4  mg/dL)  and  0.31  mmol/L  (11.9  mg/dL), 
respectively. When variables adjusted for baseline level and sex, the mean difference between 
the groups was -0.08 mmol/L (-3.23 mg/dL) (95% confidence interval [CI], -0.15 to -0.01 
mmol/L [-5.6 to -0.5 mg/dL]) (P = 0.02).
582-583 Accordingly, early initiation of statin treatment 
in children
 might be advantageous to them, but
 unfortunately studies of such treatment have so 
far only addressed
 short-term tolerability and safety.
584-588  These important findings reasons 
that once diagnosed, adult hypercholesterolemic patients are
 prescribed lifelong treatment with 
statin  and  that  postponing  statin
  treatment  until  adulthood  could  allow  development  of 
significant
 arterial lesions in young hypercholesterolemic patients.
  
 
The findings of preceding chapters in this thesis that a maternal diet rich in fat, either during 
pregnancy alone or long-term, induces obesity, vascular dysfunction, sedentary behaviour and 
gender-specific  hypertension  in  the  offspring.
435,574  The  situation  is  analogous  to  the 
description  by  Freinkel  et  al
556  in  a  diabetic  pregnancy.  The  results  of  the  last  chapter 
(Chapter-4) demonstrate that treating pregnant animals that were hypercholesterolemic and 
hypertensive  with  pravastatin  during  the  second  half  of  pregnancy  and  lactation  shows
 
evidence of improved dam‘s health and effects on total cholesterol, LDL and HDL cholesterol 
in offspring and lasting beneficial effects on blood pressure and activity if their offspring 
consumed a similar high fat diet.
435 I also showed that maternal treatment with pravastatin is 
well tolerated and has no deleterious effects on their offspring.
435  
 
Now  when  the  safety  and  effects  of  statin,  given  to  dams  consuming  a  high-fat,  high-
cholesterol diet in the second half of pregnancy and lactation, have been demonstrated in 
reducing cardiovascular risk factors in offspring (chapter-4), it is now hypothesized that statin   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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in mice from the time they are weaned until weaning of their offspring could modify their 
lipid/ lipoprotein profile to such an extent that effect could be sustained
 into adulthood of the 
offspring consuming HF diet.  
 
Based  on  hypothesis,  in  this  chapter  I  designed  experiments  1)  to  evaluate  the  long-term 
administration of pravastatin in young mice fed a HF from the time they are weaned; 2) the 
overall safety and tolerability of long-term pravastatin treatment pre-pregnancy, pregnancy 
and  lactation;  3)  to  assess  the  influence  of  such  a  regimen  on  CVD  risk  factors  in  their 
offspring, even if both dams and offspring are fed a HF diet and 4) finally whether there are 
any gender-linked differences in offspring of these dams in their cardiovascular responses. 
 
5.2   Methods 
The protocol for conducting experiments is explained in Figure-5.1 
 
Figure-5.1:  Flow diagram of the experimental protocol.    M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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The  main  point  of  this  experimental  protocol  was  the  administration  of  a  water-soluble 
Pravastatin  (Sigma  UK;  5mg/kg/day),  to  females  on  HF  diet  from  weaning  through  to 
pregnancy and lactation.  
 
After birth, pups were weighed and litter size was reduced to 8 pups and, when possible, to 
equal numbers of males and females. From weaning (21 days post partum) offspring from the 
HF, C and HF+ S dams were fed HF, C and HF diets respectively.  We refer to the offspring 
born to HF dams as HF-HF, born to C dams as C-C and born to HF+S and on HF diet as 
HF+S-HF  according  to  their  post-weaning  diet  (Figure-5.1).  Body  weights,  SBP  and 
biochemical markers (LDL-C and CRP) of the offspring were measured at 24 weeks. All the 
data were expressed as mean +/- SEM. A p<0.05 was considered to be statistically significant. 
 
5.2.1 Histological analyses of kidneys 
Kidneys were removed at 24 weeks and immediately placed in ice-cold phosphate-buffered 
saline
 (PBS). A coronal cross-section containing the hilus was removed
 from the right kidney, 
fixed  in  neutral  buffered  formalin,  and
  embedded  in  paraffin.  Sections  (5-µm  thick)  of 
formalin-fixed,
 paraffin-embedded tissue were mounted on glass slides and stained
 with the 
hematoxylin and eosin, for general histological
 assessment. Frozen sections were used for Oil 
Red O staining to determine renal accumulation of neutral fats. All
 tissues were evaluated 
without my knowledge of the
 group from which they originated.
  
 
5.2.2 Other Blood and Urine Chemistries 
Plasma  glucose  was  measured  using  the  glucose  CII  kit  (Wako  Chemicals  USA,  Inc., 
Richmond,  VA).  Plasma  insulin  was  determined  using  a  mouse  insulin  enzyme-linked 
immunosorbent  assay  kit  (LINCO  Research,  Inc.,  St.  Charles,  MO).  Urine  albumin   M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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concentration was determined by using a competitive enzyme-linked immunosorbent assay via 
the  Albuwell  M  kit  (Exocell,  Philadelphia,  PA).  Urine  creatinine  concentration  was 
determined by the Creatinine Companion kit (Exocell).  
 
5.3   Results 
 
5.3.1 Long-term statins administration to dams fed HF diet improves their body weights, 
systolic blood pressure and alters total cholesterol profile 
 
The food and water intake was similar in female mice of all three groups throughout the study. 
However, body weight gain in C dams was lower than in HF dams at the weaning of their 
offspring.  Predictably,  the  cholesterol-enriched  HF  diet  increased  cholesterol  levels  in  HF 
dams. At mating, the total serum cholesterol levels were twofold higher in the HF group than 
the C group. At weaning, the cholesterol values in HF dams reached their highest levels, to 
three fold higher than in C dams. This was also reflected in the tail cuff SBP in the HF group 
when compared with C group. Long-term statin treatment in HF dams reduced SBP, total 
cholesterol and LDL cholesterol levels at weaning of their offspring (Table-5.1) 
 
 
5.3.2 Long-term pravastatin treatment to dams fed a HF diet reduces body weight & 
improves systolic blood pressure in offspring on a post-weaning HF diet  
 
In female offspring, a significant increase in weights was observed in HF diet fed offspring 
from mothers on similar diet (HF/HF) when compared to offspring fed laboratory chow from 
mothers  on  laboratory  chow  (C/C)  (P<0.01).  Similarly,  HF/HF  male  offspring  were  M.M. Elahi (2011)- Maternal High Fat & DOHaD   
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Table-5.1: Body weight, total serum cholesterol, and tail cuff blood pressure evaluated in control (C), High Fat (HF) and High Fat + Statin 
from weaning (HF+S) female mice. Body weight gain was taken as difference between body weight at mating and body weight at weaning of 
their offspring (n=8/group) 
 
 
1= at mating;  2= at weaning of their offspring. Statistical result displayed in each column is for the dietary group comparison with the 
other group using the Turkey-Kramer test.*P<0.01 and ‖P<0.001 for HF+S or C against HF. ÂP<0.001 for C against HF+S. The 
number of animals is 8 for all of the groups and the results are expressed as mean + SEM 
Groups   Body 
weight (g) 
Cholesterol  mmol/L  Systolic Blood Pressure 
 (mm Hg) 
Plasma Glucose  
(mg/dL) 
Plasma Insulin 
(ng/ mL) 
1                        2   1                      2  1                            2  1                               2 
C  34.2 +3.0*‖  2.95 + 0.2*‖  2.76 + 0.3*‖  110.5 +2.3*‖  114.3 +2.4*‖  128.7+ 12.3*‖  130.7+ 14.3*‖  0.51 + 0.06*‖  0.49 + 0.04*‖ 
HF  52.3 + 3.0  5.59 + 0.3  6.31 + 0.2  140.2 + 3.2  137.6 + 3.1  234.5+ 16.7  233.5+ 17.8  4.84 + 0.30  5.34 + 0.45 
HF+S  45.2 + 3.0Â  3.56 + 0.2Â  3.51 + 0.3Â  128.4 + 2.3Â  122.3 + 3.0Â  130.6+ 14.3Â  132.5+ 15.4Â  0.50 + 0.10Â  0.53 + 0.08Â  
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significantly heavier as compared to C/C (P<0.001). However, long-term pravastatin treatment 
to dams fed a HF diet reduced body weight in offspring on a post-weaning HF diet (HF+S/HF; 
P<0.001; Figure-5.2 a & b).  
 
 
In female offspring, SBP was significantly lower at 24 weeks in HF+S/HF compared with 
HF/HF  offspring  (p<0.001).  However,  the  differences  were  not  so  pronounced  in  male 
offspring although still significant (p<0.05). As expected, SBP for the C/C group was lower at 
the time point (24 weeks) examined (Figure-5.2 c& d).  
 
 
 
5.3.3 Long-term pravastatin treatment to dams fed a HF diet reduces total cholesterol & 
effects CRP in offspring on a post-weaning HF diet  
 
Total  serum  cholesterol  concentrations  for  offspring  on  HF  or  C  diets  followed  a  similar 
pattern to dams on HF or C, respectively and long-term exposure of their dams to pravastatin 
resulted  in  significantly  lower  total  cholesterol  levels,  similar  to  its  effect  in  the  dams 
themselves (P<0.001, Figure 5.3a and 5.3b respectively). Of particular note is that a similar 
effect was observed in males (P<0.001). In females, HF/HF exposure significantly increased 
CRP in contrast to C/C group. The effect was the same though the magnitude of difference 
was less in male offspring. Pravastatin administration in early life to dams fed a HF diet 
significantly abolished CRP mediated inflammation in their offspring on a post-weaning HF 
diet (P<0.001; Figure 5.3c and 5.3d respectively).  
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Figure-5.2:    Long-term  statin  treatment  in  hypercholesterolemic  mothers  has  beneficial  effects  on  the  body 
weights and blood pressure in their offspring. (a) Body weight gain males, (b) body weight gain in female (c) 
systolic blood pressure in male (d) systolic blood pressure in female offspring from mothers on standard chow 
(C), high fat-high cholesterol (HF) diet or HF diet and treated with statin during pregnancy and lactation (HF-S). 
Weaned offspring were then fed either HF or C diets to adulthood, thus generating the dam/offspring dietary 
groups: HF/HF, HF-S/HF and C/C (n = 8 per group).   
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Figure-5.3:    Long-term  statin  treatment  in  hypercholesterolemic  mothers  has  beneficial  effects  on  total 
cholesterol and CRP in their offspring. (a) Total cholesterol levels in males, (b) Total cholesterol levels in female 
(c) CRP levels in male (d) CRP levels in female offspring from mothers on standard chow (C), high fat-high 
cholesterol (HF) diet or HF diet and treated with statin during pregnancy and lactation (HF-S). Weaned offspring 
were then fed either HF or C diets to adulthood, thus generating the dam/offspring dietary groups: HF/HF, HF-
S/HF and C/C (n = 8 per group).  
 
 
 
 
A  B  
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5.3.4 Long-term pravastatin treatment to dams fed a HF diet reduces plasma glucose and 
insulin in offspring on a post-weaning HF diet  
 
Plasma glucose and insulin levels were significantly higher in HF/HF than in those with C/C 
(p < 0.001). However, these diet-induced changes were not observed in HF+S/HF.  In fact, 
HF+S/HF exhibited no diet-induced hyperglycemia and hyperinsulinemia. The diet-induced 
changes in plasma free fatty acid levels were not statistically significant in either of the group 
(Table-5.2) 
 
Table 5.2:  Comparison of variables in three groups.  
  C/C  HF/HF  HF+S/HF 
Plasma glucose (mg/dl)  131.5+ 14.3  215.6 + 15.6  139.6 + 13.3 
Plasma Insulin (ng/ml)  0.42 + 0.07  5.48 + 0.40  .48 + 0.09 
Plasma free fatty acid (mM)  0.69 + 0.06  0.88 + 0.08  0.71 + 0.1 
 
Results are expressed as mean + SE. Each group includes 8 animals.  
 
 
5.3.5 Long-term pravastatin treatment to dams fed a HF diet reduces renal triglycerides 
and total cholesterol and lipid accumulation in offspring on a post-weaning HF diet  
 
Kidney weights were similar between the HF/HF and C/C offspring. HF/HF showed lower 
values than C/C group when kidney weights were expressed relative to body weight (P<0.01). 
However, when kidney weights were expressed relative to body weight, HF+S/ HF showed 
higher values than HF/HF offspring (P<0.01).  To study whether HF caused an increase in 
renal lipid accumulation I performed oil red O staining in kidney sections, which demonstrated 
the accumulation of lipids in the glomerular and tubulointerstitial cells of HF/HF. There were  
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significant increases in renal triglycerides and cholesterol content in HF/HF, which cholesterol 
with the increased oil red o staining (Figure 5.4a). However, HF+S/HF mice had no increases 
in renal triglycerides and cholesterol contents (Figure 5.4b). No attempt was made to quantify 
the cell types using a definitive method. 
 
 
5.4  Discussion 
 
The purpose of this chapter was to investigate the role of long-term statin administration in a 
HF-induced metabolic syndrome mouse model. I examined 1) whether statin treatment was 
efficacious earlier in the life course; 2) whether lipid lowering in HF fed dams prevented future 
CVD/ metabolic syndrome in their offspring in which the response to lifestyle could often be 
inadequate; 3) whether cholesterol lowering in dams or other effects of statins benefit postnatal 
kidney specific changes.  
  
Once  again  characteristics  of  metabolic  syndrome  such  as  obesity,  hypercholesterolemia, 
hypertension and hyperinsulinemia in HF dams as well as in HF/HF offspring are observed 
and thus confirmed that maternal nutrition with a HF diet induces developmental disturbances 
in  their  offspring.    The  results  also  demonstrate  that  treating  dams  fed  a  HF  diet  with 
pravastatin after weaning not only improved their health but also showed long-term beneficial 
effects on offspring BP, cholesterol profile, body weight and CRP levels even if their offspring 
consumed  a  similar  HF  diet.  This  effect  is  seen  in  males  and  females  although  more 
pronounced  in  females.  The  latter  is  an  interesting  finding  that  I  did  not  observe  in  my 
previous study where statin therapy was initiated in the 2
nd half of pregnancy (Chapter-4). 
Furthermore, the present findings provide the first indication that renal lipid accumulation 
could mediate the kidney disorder associated with HF feeding in dams, however, cholesterol 
lowering in these mice on HF diet after their weaning prevents such lipid accumulation in 
HF+S/HF offspring.  
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(a) 
 
 
(b) 
 
 
Figure  5.4:  Representative  photomicrographs  of  Oil  Red  O  stained  renal  sections  from  (a)  HF/HF  and  (b) 
HF+S/HF mice. The sections were counterstained with hematoxylin and eosin. Lipid droplets appeared as red 
spots that revealed the accumulation of neutral lipids in the glomerular and tubulointerstitial cells and showed an 
increase in HF/HF compared with HF+S/HF (n=8)  
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It is very clear now that the early life environment has a significant role in the aetiology of 
later CVD disease.
589-590 Treating future mothers on HF diet with pravastatin very early in life 
(post weaning) to study the effect on their offspring health is more representative experimental 
approach  of  the  human  situation.  Though,  giving  pregnant  HF  dams  pravastatin  induces 
healthy changes in them and their offspring when put on similar HF diet, the approach in 
Chapter-4  was  confined  to  short-term  administration  of  pravastatin  to  pregnant  HF  dams, 
during pregnancy and lactation only. This may explain why the effects of such treatment were 
only transient in their offspring for 10-12 weeks post weaning. Such short term effects are not 
observed the present work.  
   
Only a few studies have been conducted to date evaluated statin
 therapy in a young age group 
(children  and  adolescents).  Stein  was  the  first  to
  show  a  40%  reduction  of  LDL-C  in 
hypercholesterolemic and obese children treated with
 statin. But this study was not controlled
 
and involved only a small group of boys
591. Ducobu and colleagues in a small
 (n=32) and 
uncontrolled  study  with  simvastatin  reported  a  37%
  LDL-C  reduction  and  excellent 
tolerability.
592 Later, three other
 statin studies in children or adolescents were reported.
 In the 
first  study,
593  72  hypercholesterolemic  children  (66%  girls),  aged  10  to
  16  years,  were 
randomized to placebo or pravastatin (5, 10,
 or 20 mg/ day). After 12 weeks, LDL-C levels 
were reduced by 23%,
 24%, and 33% in the groups receiving pravastatin at 5, 10, and
 20 mg/ 
day,  respectively.  The  second  study
594  was  an  uncontrolled  study  in
  which  boys  were 
randomized to lovastatin at 10, 20, 30, or 40
 mg/day for 12 weeks. LDL-C levels were reduced 
by 21% to 36%.
 In the last study
595, 132 boys, aged 10 and 17 years were randomized
 to either 
lovastatin or placebo. Lovastatin was started at
 10 mg/dL, and the dosage was doubled every 8 
weeks  to  a  maximum
  of  40  mg/d.  Mean  LDL-C  levels  decreased  significantly  relative
  to 
placebo  in  all  treatment  groups.
  In  these  studies,  short-term  safety  and  tolerability  were
 
observed to be excellent with no serious adverse events (in terms of myopathy, drug-related 
events  or  clinically
  meaningful  elevations  in  hepatic  transaminases  (ALT  and  AST)
  and 
creatine phosphokinase). These results are
 comparable to those observed in the present work 
namely  that  cholesterol  and  SBP  in  HF+S  remained  within  normal  limits  at  all  times  (at  
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mating and weaning; Table 5.1) relative to their HF fed counterparts. This is a very novel 
finding. I believe that such effects are fundamental to the DOHaD concept and indicate that 
intervention in early life may be particularly important in reducing later risk of disease in the 
face of lifestyle factors such as a HF Western cafeteria diet. 
 
Another original finding is, that in HF/HF mice, there is increased Oil Red O staining in the 
kidney  sections  and  higher  renal  content  of  cholesterol.  Thus  confirming  that  HF  diet  in 
mothers  cause  histological,  biochemical  and  functional  changes  in  the  kidneys  of  their 
offspring fed a similar diet (i.e. HF/HF). These changes include accumulation of neutral lipids 
in glomerular and tubulointerstitial cells (Figure-5.4a). These changes are also associated with 
marked  hyperinsulinemia,  hypertension  and  hypercholesterolemia.  This  is  not  the  case  in 
HF+S/HF  kidney  sections  (Figure  5.4b)  where  quite  normal  histological  morphology  is 
demonstrated. It is observed that long-term statin administration in HF dams ameliorates these 
effects in their offspring even when fed HF diet postnatally.   
 
Although I did not design these studies to elucidate the specific mechanisms
 by which a HF 
diet caused structural changes in the kidney, there
 are several hemodynamic and hormonal 
alterations in obese dams
 fed a HF diet that might contribute to the renal changes in their 
offspring.
  For  example,  I  observed  that  a  HF  diet  caused  increased
  SBP,  glomerular 
hyperfiltration, and increased
 renal fat deposits and that these hemodynamic alterations were
 
sustained for up to 24 wk in HF/HF. The combination of increased
 arterial pressure and renal 
vasodilation likely caused marked glomerular
 hypertension, that stretched the mesangium and 
initiates a
 complex cascade of biochemical and histologic changes.
596 Similarly, using
 isolated 
glomeruli, Cortes et al.
597 reported that an acute increase in glomerular pressure could stretch 
the mesangium
 and stimulate collagen production.  
  
 
      166 
 
In  addition  to  the  hemodynamic  alterations,  there  are  also  hormonal
  changes  that  could 
contribute  to  renal  remodeling  in  obesity.
  One  possibility  includes  hyperinsulinemia
  that 
occurred in this model. Evidence that
 elevated insulin levels could contribute to glomerular
 
structural changes is derived primarily from in vitro studies
 of mesangial cell cultures.
598-599 
Moreover, the effects of insulin
 on angiotensin II seemed
 to be additive
598. However, these 
effects had been observed
 in vitro using very high concentrations of angiotensin II (usually 10
-
6 M or higher) and insulin. In vivo studies with animals and humans
 suggest that blockade of 
angiotensin II reduces renal
 function associated with severe renal disease, but angiotensin II 
blockade also
 decreases arterial and glomerular hydrostatic pressures. However, it is yet not 
clear whether angiotensin II blockade prevents or ameliorates
 changes in renal structure and 
function mainly occurring early
 in obesity, even before severe renal injury. Hence, the role
 of 
increased angiotensin II levels and hyperinsulinemia in mediating
 the renal changes associated 
with a HF diet and obesity yet remains to be elucidated.
  
 
These observations may partly explain the structural changes
 observed in glomeruli after a HF 
diet. Yet the contribution
 of long-term statin treatment in HF dams and its effect on glomerular 
hyperfiltration to the production of biochemical
 and structural changes in the renal cortex of 
their offspring (HF+S/HF) still remains
 unclear.
 There is increasing evidence that demonstrates 
the role of lipid metabolism in renal disease. It has been reported that inhibition of cholesterol 
synthesis by statins and of triglyceride synthesis by peroxisome proliferator activated receptor-
α agonists (fibrates) protects against diabetic and non-diabetic renal disease.
600-601 A recent 
meta-analysis of several small scale interventional studies in diabetic and non-diabetic human 
subjects with glomerulosclerosis and proteinuria indicates that long term treatment with statin 
and/or fibrates significantly prevents the decline in glomerular filtration rate.
602  
 
The importance and direct effects of lipids per se in causing kidney cell injury is mediated by 
pro-inflammatory cytokines that includes interleukins, TNF-α and CRP.
603 The findings of this 
study demonstrate an increase in total cholesterol and result in CRP upregulation towards  
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glomerular injury. This association has also been demonstrated in cell culture studies.
604-605 
Studies in renal mesangial and tubular cells grown in culture have shown that incubation, of 
these  cells  with  LDL  or  vLDL,  results  in  up-regulation  of  the  growth  factors,  including 
transforming  growth  factor-β  and  platelet  derived  growth  factor;  ECM  proteins;  adhesion 
molecules, including monocyte chemoattractant protein-1, intercellular adhesion molecule 1, 
and vascular cell adhesion molecule-1.
604-606 My previous findings in chapter-3 suggested that 
hepatocytes  lipid  accumulation  associated  with  increased  lipid  synthesis  is  involved  in 
NAFLD seen in the HF animal model. Whether a similar alteration in renal lipid metabolism 
and  accumulation  of  lipids  mediates  the  kidney  disease  associated  with  obesity-initiated 
metabolic syndrome, is yet to be established. 
 
In summary, the present evidence links pathological effects in offspring with impaired fetal 
environment  modulated  by  maternal  HF  diet.  These  changes  are  more  pronounced  in  the 
female  offspring  unlike  the  non-gender  effects  observed  in  chapter-4.  HF/HF  exposure 
increases inflammation (CRP) and results in renal fat deposits, early components of functional 
changes and structural changes in the kidney (ESRD). Pravastatin administration in early life 
to  dams  fed  a  HF  diet  protected  their  offspring  from  risk  of  later  cardiovascular 
pathophysiology even if they consumed a HF diet. Furthermore, pravastatin administration to 
dams before and during pregnancy produced no deleterious effects on their offspring. Because 
the phenotypic changes observed in the HF+S-HF offspring appears to be permanent in nature, 
the question of an extension of the clinical use of statin arises, yet caution.  
 
Therefore,  after  defining  these  important  links,  it  is  speculated  that  these  changes  may 
possibly relate to the effects on endothelial dysfunction in a manner dependent or independent 
of cholesterol  levels,  inflammation or even hepatic and renal  lipid  accumulation. Because 
endothelial dysfunction is a pathological precursor for early hypertension and CVD, it would 
be interesting to study the ability of HF and pravastatin in modulating vascular responses in  
 
      168 
 
offspring.  One  way  of  investigating  this  is  to  study  the  impact  of  maternal  HF  diet  on 
endothelial progenitor cells (EPCs) in offspring.  This will be the focus of the next chapter. 
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Life has taught me a succession of lessons  
which I think must be lived to be understood 
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CHAPTER-6 
Effects of Maternal High Fat Diet and Statin Treatment on Bone 
Marrow Derived Mononuclear Cells in  
Offspring fed a Similar Diet. 
 
 
6.1  Introduction 
The  results  presented  so  far  in  the  thesis  lead  to  the  next  question  of  whether  HF  diet 
consumption  in  pregnancy  plays  any  role  in  vascular  response.  This  is  characterised  by 
endothelial dysfunction in their offspring; thus increasing the risk of early CVD in their adult 
life. 
 
Endothelial dysfunction is a common phenomenon in CVD, occurs in the metabolic syndrome 
and is known to be a primary event in the aetiology of atherosclerosis.
607-608 Experimental and 
clinical  evidence  suggest  that  diabetes  and
  hyperlipidemia  are  related  to  endothelial  cell 
dysfunction,
  peripheral  blood  and  bone  marrow  stem  cell  dysfunction,  and
  excessive 
vasoconstriction.
360,609-614  In  addition,  the  extent
  of  diabetes-  and  hyperlipidemia-related 
impaired  potency  of  bone  marrow  mononuclear  cells  can  affect  effective  vascular 
angiogenesis.
247,615 Endothelial dysfunction is also a common phenotype in a number of rodent 
models  of  DOHaD  that  include  both  maternal  HF  and  total  maternal  nutrient  restriction 
models. 
616-618 
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Recent work has raised the possibility that bone marrow derived endothelial progenitor cells 
(EPCs; mononuclear in phenotype) may help restore normal vascular function after injury or 
in disease.
619-620 Despite much that is known about EPCs (see Chapter-1), there are some 
important points that warrant discussing before focusing on the specific study question in this 
chapter. 
 
It is reported that functional integrity of the endothelial morphology is essential to protect 
against  the  initiation  of  atherogenesis.
76,280,621  Marked  changes  in  endothelial  morphology 
include a loss of orientation of endothelial cells in the direction of the blood flow, decreased 
overlap between adjacent endothelial cells, and an accelerated turnover of endothelial cells in 
response to hyperlipidemia, hypertension and inflammatory stress.
622 It has been proposed that 
this kind of disruption of vascular homeostasis predisposes the vessel wall to vasoconstriction, 
leukocyte  adherence,  platelet  adhesion,  thrombosis,  vascular  inflammation,  and  eventually 
atherosclerotic lesion formation. 
76,621-622  
 
Recent  studies  suggest  that  in  response  to  these  marked  morphological  changes  in  the 
surrounding  mature  endothelial  cells,  EPCs  play  a  critical  role  in  maintaining  endothelial 
function  in  mature  blood  vessels  by  contributing  to  re-endothelialization  and 
neovascularisation.
623-624 It is therefore conceivable that the mobilization and differentiation of 
EPCs are important in this process of adult neovascularization
623,625-628 and any impairment of 
this  vasculogenic  element  of  endothelial  regeneration  may  account  for  the  progression  of 
endothelial dysfunction and CVD.
628 Accumulating evidence also suggests that the number 
and  migratory  activity  of  circulating
  EPCs  inversely  correlate  with  circulating  CRP 
349,361,442,629-630 one of the risk factors
 for CVD that interacts strongly with LDL cholesterol
 631-
632. 
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Reports have proposed that CRP has a direct effect of inhibiting angiogenesis, promoting
 
atherosclerotic  processes  and  EC  activation.
308,309,633-637  In  a  synchronous
  fashion  CRP
 
downregulates eNOS
 and destabilizes eNOS mRNA transcription; decreases both
 basal and 
stimulated  NO  release;
308  upregulates  NFκ-B  (a  key  nuclear  factor  that  facilitates  the 
transcription
 of numerous proatherosclerotic genes);
638 mediate adhesion molecules and LDL 
uptake.
633-634  
 
These  interrelations  among  LDL  cholesterol,  CRP  and  EPCs,  suggest  that  CRP-related 
alteration in progenitor cell number and function in offspring may be induced by maternal HF 
consumption. Also it would be interesting to study, through net reduction effect on maternal 
dyslipedemic load, whether statin therapy in dams exerts any advantageous effect on EPC 
circulation in their offspring fed a similar HF diet. These hypotheses are supported by several 
experimental models  and  in  vivo ischemic disease patients‘ studies.
359,360,364,639-640 In these 
studies,
359,360,364,639-640  the  precise  mechanisms  remain  unclear,  yet  it  is  shown  that  statin 
improves  endothelial    function  by  activating  protein  kinase  Akt,
640  mobilizing  EPCs,
360 
reducing senescence, and increasing proliferation of EPC. 
363  
 
A major area of DOHaD research also concerns the fate of progenitor cells within the early 
embryogenesis. This involves modifications in vascular endothelial cell function and changes 
such  as  reduced  numbers  of  nephrons,  pancreatic  beta  cells  or  cardiomyocytes,  enhanced 
development of the islets of Langerhans in fetuses of diabetic mothers and hypertrophy of the 
endocrine pancreas, induced in early life. These experimental data in laboratory animals are 
confirmed  by  epidemiological  studies  on  infants  of  mothers  suffering  from  diabetes  or 
malnutrition  during  pregnancy.  This  provides  a  novel  paradigm  that  disturbances  in  the 
maternal metabolism alter the nutrient supply from mother to fetus and induce structural and 
functional  adaptations  during  fetal  development  which  persist  throughout  life.
15,65,86-94,110-
111,129,134-137,152,157-158,170,176,178-182,193-197   
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In this  chapter,  I propose to  examine the question  of how maternal  HF diet consumption 
affects EPCs of their offspring also fed a HF diet. Therefore, the aims of the study are;.  
Study-1:  
1.  To determine the effects of feeding a HF diet to dams during pregnancy and lactation 
on cardiovascular function, EPC expression and serum CRP levels in their offspring 
2.  To  examine  the  effect  of  statin  treatment  of  HF-fed  dams  during  pregnancy  and 
lactation  on  these  cardiovascular  variables  (EPC  expression  and  CRP)  in  their 
offspring 
Study-II:  
To study the effects of statin administration to HF-fed female mice (from the time they were 
weaned  until  weaning  of  their  offspring)  on  expression  of  bone  marrow  derived  EPC  in 
offspring. 
 
6.2 Methods 
 
The method for isolating, culturing and staining of bone marrow derived mononuclear cells 
i.e. EPCs has already been described in chapter-2.  
 
The experimental protocol for Study-I is described in Figure-6.1. As shown in protocol, water-
soluble Pravastatin (Sigma UK; 5mg/kg/day) was given in their drinking water to half of the 
pregnant females on HF diet during the second half of pregnancy and throughout lactation. The 
female offspring of C, HF and HF-S dams were fed ad libitum with the C and HF diets after 
weaning to generate the C/C, C/HF, HF/HF, HF/C; HF-S/HF and HF-S/C groups respectively.  
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Body weights of the offspring (from 1 week of age to avoid maternal rejection of the pups) and 
food intake (from weaning) were monitored until 24 weeks of age. SBP, biochemical markers 
(total, LDL and HDL cholesterol) and CRP were measured at 24 weeks.  
 
 
Figure 6.1: Experimental protocol for Study-I 
Study-II: 
This  is  an  extension  of  work  on  the  bone  marrow  derived  EPC  samples  from  the  study 
described in Chapter-5. The EPCs were cultured and stained only in female offspring. The 
protocol  for  conducting  experiments  is  already  explained  in  Figure-5.1  and  described  as 
follows  
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Figure-5.1:  Flow diagram of the experimental protocol.  
 
For both the studies, the data were expressed as mean +/- SEM and p<0.05 was considered to 
be statistically significant. 
 
6.3 Results 
 
6.3.1 Study-I 
6.3.1.1 Prenatal and postnatal HF diet consumption increase the risk of cardiovascular 
disorders in offspring 
 
Female C/HF and HF/C and HF/HF offspring were heavier (Figure 6.2a), hypertensive (Figure 
6.2b), with increased serum levels of LDL-cholesterol (Figure 6.2c) and CRP (Figure 6.2d) 
than C/C offspring at 24 weeks. However, the results demonstrated that total cholesterol levels   
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were significantly increased in HF/C and HF/HF not in C/HF female offspring than C/C at 24 
weeks (Figure 6.2e). Short-term statin therapy (second half of pregnancy and lactation) in 
dams did not affect SBP (Figure 6.2b) but reduced the effect of prenatal and postnatal HF diet 
on bodyweight and LDL-cholesterol. Interestingly, pravastatin therapy reduced the levels of 
CRP to negligible in HF+S/C and HF+S/HF offspring.  
 
 
6.3.1.2 Prenatal and Postnatal HF diet consumption  attenuates bone marrow derived 
circulating endothelial progenitor cells in offspring 
 
 
HF  diet  (prenatal  or  postnatal)  had  significantly  reduced  percentage  of  positively  stained 
mononuclear cell and decreased number of double stained colonies with inhibited expression 
of  acetylated  low-density  lipoprotein  (Figure  6.3).  Pravastatin  treatment  to  these 
hypercholesterolemic dams significantly improved and increased the number of EPC observed 
in  the  culture.    Representative  photomicrographs  of  EPC  colonies  stained  for  endothelial 
markers Dil-Ac-LDL (red) and lectin (green) are shown in Figure 6.4) 
 
 
 
6.3.1.3 Correlation of hypercholesterolaemia to EPC number 
 
 
 
The number of EPCs was inversely correlated with total cholesterol (Figure 4A) and LDL-
cholesterol (Figure 4B) levels, whereas no correlation between the number of EPCs and HDL-
cholesterol levels (r=0.237, P>0.05) was observed. By multivariate analysis, total cholesterol 
(standard coefficient=−0.530, P<0.001) and LDL cholesterol (standard coefficient=−0.417, 
P<0.01) levels remained independent predictors of lower EPC numbers. 
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Figure-6.2: Statin treatment in hypercholesterolemic mothers during late pregnancy and lactation has beneficial 
effects on the cholesterol profile, blood pressure and CRP in their offspring. (a) Body weight gain, (b) systolic 
blood pressure (c) serum LDL-cholesterol, (d) serum CRP, (e) serum total cholesterol in offspring from mothers 
on standard chow (C), high fat-high cholesterol (HF) diet or HF diet and treated with statin during pregnancy and 
lactation (HF+S). Different letters indicate p<0.001 except between bars with different letters and asterisks (*) 
where p<0.05, showing the level of significance.  
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Figure  6.3:  Pravastatin  treatment  in  hypercholesterolemic  mothers  during  late  pregnancy  and  lactation  has 
beneficial effects on (a) the positively stained mononuclear cells (MNCs) and (b) the number of double stained 
colonies in offspring from mothers high fat-high cholesterol (HF) diet.  Different letters indicate p<0.001 except 
between bars with different letters and asterisks (*) where p<0.05, showing the level of significance. 
 
Figure- 6.4: Expression of endothelial markers on EPCs. Representative photomicrographs of EPC  colonies 
stained for endothelial markers Dil-Ac-LDL (red) and lectin (green). EPC colonies demonstrate reduced staining 
in HF/HF vs C/C. Statin treatment to HF-fed dams abolished these effects in their offspring.  
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Figure-6.5 Correlation between the number of EPCs from HF/HF offspring with hypercholesterolaemia and total 
cholesterol (A) and LDL-cholesterol (B) levels 
 
6.3.2 Study-II: 
 
Long-term pravastatin treatment to dams fed a HF diet improves EPCs number and 
colonies in offspring on a post-weaning HF diet  
 
Once  again,  HF/HF  exposure  significantly  inhibits  EPC  numbers  and  colonies,  therefore 
affecting key components of angiogenesis and endothelial repair in these offspring. Long term  
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pravastatin treatment in early life to dams fed a HF diet protects their offspring in a post-
weaning HF nutritional environment from such effects of EPC (Figure 6.5).  
 
 
 
 
 
 
 
Figure  -6.6:    Long-term  statin  treatment  in  hypercholesterolemic  mothers  increased  circulating  endothelial 
progenitor cells (a) number of stained EPC colonies (b) percentage of mononuclear cells that are FITC labelled. 
Weaned offspring were then fed either HF or C diets to adulthood, thus generating the dam/offspring dietary 
groups: HF/HF, HF-S/HF and C/C (n = 8 per group).  
 
6.4 Discussion 
The  present  study  investigates  whether  long-term  maternal  HF  diet  has  an  impact  on  the 
expression of bone marrow derived mononuclear cells (double stained endothelial progenitors,  
 
EPCs) in their offspring even if they were fed a HF or C diet in adulthood i.e. to study the role 
of prenatal and postnatal diet on EPCs. This work also studies the effect of pravastatin {both 
short-term (second half of pregnancy and lactation) and long-term (soon after weaning through 
to pregnancy and lactation)} treatment in dams on HF diet on the number of EPC colonies in 
their offspring even when these offspring are fed the HF diet.   
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The results demonstrate that (1) EPC numbers and expression (Figure-6.4) in female offspring 
exposed prenatally or postnatally (C/HF, HF/HF and HF/C) to the HF diet
 are significantly 
decreased;  (2)  treating  dams  with  pravastatin  (in  both  protocols)  proves  beneficial
  for 
improving EPC colony forming units in their offspring irrespective of their postnatal diet; (3) 
number of EPC is inversely correlated with total cholesterol and LDL-cholesterol levels (4) 
LDL-cholesterol  is  a  predictor  of  EPC  expression  and  (5)  maternal  hypercholesterolemia 
increases  CRP  levels  in  plasma  and  inhibits  number  of  EPC  colonies  expressed  in  adult 
offspring  (Figure  6.7).  Though  the  mechanism  behind  this  pathophysiology  still  remains 
elusive, improvement of EPC numbers observed in HF+S/HF offspring is probably related to
 
the blockade of CRP induced  excessive inflammation  and
  the improvement in  cholesterol 
profile. Previous studies have reported the role of statin in improving angiogenesis
359,639-640 but 
not directly in the context of DOHaD phenomenon. This is a very important and novel finding 
and has not been reported before.  
 
Figure-6.7:  The  plot  shows  the  linear  regression  results  in  HF/HF  offspring.  The  solid  line  illustrates  that 
increase in plasma CRP levels in offspring plasma correlates with decrease in number of bone marrow derived 
EPC colonies expression in adult offspring. Asterisks (*) where p<0.05, shows the level of significance. 
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Studies  and  laboratory  evidence  have  identified  that  EPCs  participate  in  postnatal 
neovascularization  and  reendothelialization.
318,360,620,623,626,362,642-645  However,  our  present 
findings have documented that hypercholesterolaemia can decrease EPC number and activity. 
Given the well-established role of EPCs in neovascularisation and re-endothelialization, our 
findings  may  establish  a  novel  pathophysiological  mechanism  of  hypercholesterolaemia: 
namely,  hypercholesterol  not  only  impairs  endothelial  cells  directly,  but  also  affects  EPC 
number  and  function  at  the  same  time.  Thus  hypercholesterolaemia  may  influence  the 
endothelial repair process and disturb the balance between the magnitude of injury and the 
capacity for repair, which leads to endothelial dysfunction, and promote the early progression 
of coronary artery disease in adult offspring.  
 
 
On  the  other  hand  statins  have  been  developed  as  lipid-lowering  drugs,  and  are  well 
established  to  reduce  morbidity  and  mortality  from  CAD.
646-647  Besides  lipid  lowering, 
primary and secondary prevention trials and laboratory investigations established, that statin 
possessed favourable effects independent of cholesterol reduction.
646-648 In particular, statins 
have recently been reported to promote EPC proliferation, migration, and cell survival in vitro. 
359-361,364 A recently performed clinical study demonstrated an increase in EPC number with 
enhanced migratory activity by statin treatment in patients with stable CAD.
360 Results of this 
work, together with the findings of other investigators suggested a novel mechanism of statins‘ 
action in augmentation and promotion of EPC functional activity. 
 
More  recently,  two  groups  have  documented  in  animals  and  human  subjects  that  EPCs 
contribute up to 25% of endothelial cells in newly formed vessels.
314,370 Thus, increasing the 
number of circulating EPCs by transplantation of hematopoietic stem cells or by injection of in 
vitro-differentiated  EPCs  has  been  shown  to  improve  neovascularization  of  ischemic 
hindlimbs
312,620 accelerate blood flow in diabetic mice
611, and improve cardiac function
643. 
More importantly, reports suggest that patients with CAD reveal reduced levels and functional 
impairment of EPCs, that correlate with risk factors for CAD.
648-649 Therefore, the stimulation  
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of mobilization and/or differentiation of EPCs by statin may provide a useful novel therapeutic 
tool to improve postnatal neovascularisation and reendothelialization in patients with CAD. 
 
There are several possible scenarios by which hypercholesterolaemia could have this effect. 
First, this might be due to increased apoptosis of premature progenitor cells, as CD34-positive 
EPCs have been shown to be very sensitive to apoptosis induction. Moreover, ox-LDL is 
known to induce apoptotic cell death. Secondly, hypercholesterolaemia may interfere with the 
signalling pathways regulating EPC differentiation or mobilization. Thirdly, the continuous 
endothelial  damage  or  dysfunction  may  lead  to  an  eventual  depletion  or  exhaustion  of  a 
presumed finite supply of EPCs. The mechanistic effects of statins on EPC in such settings 
may well be via increased regional perfusion of blood flow through increased endothelial NO 
production.
650-651 Or statin may induces EPC differentiation by reducing the CRP mediated 
inflammation via the PI 3-kinase/Akt (PI3K/Akt) pathway.
361-362.  
 
Evidence demonstrated by this study supports the notion that decrease in number of EPCs in 
HF/HF is heavily influenced by the maternal diet and thus contribute to the defect in postnatal 
vascular response i.e. EPCs mediated mobilization and endothelial function. It would have 
been  advantageous  to  conduct  fluorescence-activated  cell  sorting  (FACS)  for  cultured 
mononuclear cells to evaluate whether these cells progressed to an EPC-like phenotype rather 
than relying on the double staining alone to identify them.   
 
In  conclusion,  the  ability  of  maternal  hypercholesterolemia  to  reduce  EPC  numbers  and 
differentiation may represent an important mechanism in the developmental origins of CVD. 
Studies
  of  this  design  are  likely  to  be  valuable  to  our  understanding
  for  the  design  of 
intervention
 studies in human populations.
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When my inner landscape is full of beautiful and spiritual thoughts, 
everything then I do is an absolute pleasure. 
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CHAPTER-7 
General Discussion 
 
 
Overall this thesis provides evidence that offspring‘s prenatal environment is responsible for a 
cascade of pathogenic events (i.e. cardiovascular and metabolic disorders) later in life.  Current 
literature  so  far  lacks  details  of  how  we  humans  live  in  our  environments  and  how  the 
combination of genetics and developmental constraints affects our lives. Do our new emerging 
environments i.e. HF and over-nutrition, which we ourselves have created, answer the question 
of developmental origins of CVD/ metabolic syndrome in the fetus? Especially it is yet to be 
established whether maternal HF actually translates into fetal hypercholesterolemia and causes 
early CVD in its adult life. This aim led to the series of investigations in the thesis. 
 
Animal models have unequivocally shown that adverse prenatal nutrition, such as maternal 
diet  rich  in  fat  during  pregnancy,  enhances  susceptibility  of  the  offspring  to  metabolic 
syndrome and other features of the human CVD in adulthood.
247,249,250,253,254,287,652 However, 
previous experimental studies were confined to short-term modifications of the maternal diet 
during pregnancy and/or lactation periods, a situation uncommon in humans. Also in humans, 
the offspring may consume a HF diet, which may take them beyond the range to which their 
development adapts them to respond healthily. But it still remains unknown to what extent this 
contributes to CVD in humans. In this regard, the thesis is the first work investigating whether 
the effects of long-term consumption of a HF diet by the mother predisposes her offspring to 
developing a CVD/ metabolic syndrome-like phenotype in adult life. 
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In C57/BL6 mice, the effects on offspring of feeding their mothers  a  HF or  C diet from 
weaning through pregnancy and lactation were studied. Additive phenotypic effects of feeding 
these offspring a similar HF diet from weaning to adulthood (dam–offspring dietary group HF-
HF) were investigated. This group was compared with offspring from HF-fed dams fed a C 
diet from weaning to adulthood (HF-C) and offspring from C-fed mothers fed the C or HF diet 
(C-C and HF-C, respectively). HF-HF, HF-C and C-HF adult female offspring were observed 
to be heavier, fatter, and had raised serum cholesterol and BP compared with C-C female 
offspring. A similar trend was observed in male offspring except for the HF-C group which 
was not heavier or fatter than male C-C offspring. Liver histology demonstrated lipid vacuoles 
within  hepatocytes  in  the  HF-HF,  HF-C  and  C-HF  but  not  the  CC  offspring.  CRP  was 
observed to be elevated in female (C-HF and HF-HF) but not in male offspring. Elevated BP 
in the HF-C and C-HF groups was attenuated in the HF-HF group in males but not in females. 
The findings indicate that adverse effects on the offspring are induced during development and 
are not necessarily or completely reversed by either consumption of a postnatal C diet or a HF 
diet. The results from this study provide an experimental basis for investigating consequences 
of dietary transitions relevant to humans, where the woman‘s diet both before and during 
pregnancy and lactation may be a contributing factor to the development of metabolic and 
CVD in her children (Appendix- v).  
 
The  role  of  pharmacological  intervention  using  statins  in  late  pregnancy  to  alleviate  the 
detrimental effects of maternal HF diet on the health of the dams and their offspring was 
examined. This time pregnant C57/BL6 mice on HF diet were given pravastatin in the drinking 
water (5 mg/kg of body weight per day) in the second half of pregnancy and during lactation to 
lower cholesterol and improve post-weaning maternal BP. Weaned offspring were then fed HF 
diet until adulthood (generating dam/offspring dietary groups HF/HF and HF+S/HF). These 
groups were compared with offspring from C mothers, fed C diet as well to adulthood (C/C). 
Compared  with  HF/HF,  HF+S/HF  showed  significantly  reduced  total  cholesterol 
concentrations  and  reduced  SBP.  The  HF+S/HF  offspring  were  significantly  lighter,  less 
hypertensive, and more active compared with the HF/HF group. Total cholesterol and LDL 
concentrations were significantly lower, and HDL concentrations were increased in HF+S/HF  
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offspring,  compared  with  the  HF/HF.  The  findings  from  this  work  indicate  that  statin 
administration to
 HF-fed pregnant dams not only improves their cardiovascular
 and metabolic 
health but also gives postweaning protection
 to their offspring. This might allow time for other 
intervention
  strategies to be put  in  place to  protect  the offspring, which
  are  also  likely to 
consume  a  poor  post-weaning  diet.  This  new
  evidence  proposes  that  maternal 
hypercholesterolemia has a
 detrimental effect on the next generation and may necessitate a
 
reconsideration of present recommendations against the use of
 interventions during pregnancy 
(Appendix vi).  
 
Moreover, the effects of long-term pravastatin administration in the drinking water to HF-fed 
female  mice  from  the  time  they  were  weaned  until  weaning  of  their  offspring  were 
investigated. Weaned offspring were fed the HF diet until adulthood, generating dam/offspring 
dietary groups HF/HF and HF+S/HF. These groups were compared with offspring from C 
dams fed on C diet post-weaning to adulthood (C/C). HF+S dams demonstrated significantly 
reduced total cholesterol and SBP vs. HF dams. The HF+S/HF offspring were significantly 
lighter, with lower systolic blood pressure and serum cholesterol concentrations vs. HF/HF 
(P<0.001).    HF/HF  offspring  also  had  elevated  CRP  but  it  was  reduced  in  the  HF+S/HF 
animals to levels found in the C/C group. I conclude that long-term pravastatin administration 
to  dams  not  only  protects  them  from  the  deleterious  effects  of  a  HF  diet  but  completely 
protects their offspring from cardiovascular and metabolic risk factors in later life, even if 
these offspring consume a HF diet (Appendix-vii). 
 
These findings led to the study reported in chapter-6, where it was investigated whether any or 
all of the cardiovascular defects in female dams exposed to a long-term HF diet could have an 
impact  on  the  expression  of  bone  marrow  derived  mononuclear  cells  (double  stained 
endothelial progenitors; EPCs) in their offspring if they were fed a HF or C diet in adulthood. 
It was also investigated whether pravastatin treatment in dams either short-term or long-term  
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affect the EPC in offspring. Two study protocols were adopted with short term and long-term 
administration  of  pravastatin  to  dams  on  HF  diet.    The  results  suggest
  that  maternal 
hypercholesterolemia increases CRP and inhibits EPC whereas pravastatin treatment to these 
hypercholesterolemic dams improves EPC numbers and reduces CRP in their adult offspring 
(Appendices viii & ix).  
 
Although  the  cardiovascular  hazards  of  a  raised  intake  of  dietary  fat  in  adults  are  well 
recognised, it is yet not known whether a maternal diet containing a disproportionately HF 
content through the female life span (pre-pregnancy, pregnancy and lactation) is a threat to 
health  and  wellbeing  of  the  offspring,  even  into  adulthood.  The  evidence  presented  here 
suggests in animal model that this may be the case, though the mechanisms underlying this 
phenomenon are unknown. Therefore, in this final chapter I bring together a critical analysis of 
my approach, discuss at length the plausible mechanisms and review the possible limitations.  
 
7.1  HF diet & DOHaD-why it is important in cardiovascular medicine?  
 
A paradigm shift in how we perceive the early origins of many of the chronic diseases of adult 
life caused clinicians and scientists to focus on CVD at its earliest stages. Hence for those of 
us whose work centres on paediatric and adult cardiovascular medicine, this is an exciting 
subject to explore. It has of course been appreciated for many years that events before and 
soon  after  birth  have  important  implications  throughout  an  individual‘s  lifespan.  But  the 
impetus for many of the recent scientific advances in cardiovascular and metabolic medicine 
comes from the fact that current levels of nutrition in Western
 countries remain
 unbalanced
 and 
rich  in  HF  with  associated  high  birth  weight,  type-2  diabetes,  CVD  and  many  other 
components of metabolic syndrome in adult life.  
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Today, central to our understanding of predisposition to health and disease is the concept that 
a pregnant woman programs her fetus for the metabolic world in which she is living and in 
which it is assumed her offspring will also live. This explains the massive epidemic of CVD 
and obesity currently underway in many developing countries and in populations making a 
rapid transition to a Westernized lifestyle.
126,653 Today a pregnant woman lives a sedentary 
life, characterized by low levels of exercise, a high plane of HF intake and the adaptations in 
metabolism resulting in obesity, diabetes and a host of related conditions.
90;94,654 This process 
is relevant to the millions of people currently making rapid transitions from thrift to plenty, 
and  explains  why  such  individuals  are  so  particularly  prone  to  the  early  development  of 
diseases when compared with those whose ancestral line has made the transition over many 
generations.  
 
More recently, it has become evident that birth weights in the upper part of the range, in most 
cases as a result of exposure to fetal hyperglycemia from poorly controlled maternal diabetes, 
may also be an antecedent of metabolic syndrome and CVD.
123,655 Thus, these most important 
diseases of adult life have a U-shaped association with birth weight, with increased rates in 
both the lower and upper parts of the range, each reflecting different causal pathways.
656 In 
numerical terms, the epidemic of obesity, diabetes and related conditions currently underway 
across the world represents the greatest health challenge ever experienced by humans.
657 
 
This points our focus on the relationship between serum cholesterol levels and the risk of 
CVD
4-5 in the abundance of HF diet available in the 21
st century world. Indeed, experimental, 
clinical, and epidemiologic data capped by dramatic interventional results with statins and 
controlled  diet  had  established  hypercholesterolemia  as  a  major  causative  factor  in  CVD; 
clinically  manifested.  It  is  equally  clear  that  from  the  very  beginning  the  HF  induced 
hypercholesterolemic  related  phenotypic  changes  had  a  strong  inflammatory  component, 
characterized by ox-LDL generated in response to pro-oxidative changes in the CVD as a 
plausible candidate. Hence both phenomena could be intertwined. The nature of the persistent  
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changes in the fetus responsible for such increased adverse outcome and the mechanisms by 
which maternal hypercholesterolemia induce these changes requires to be investigated. This 
prompted me to choose this very thesis for research.  
 
7.2  Was the experimental model the best to use in this study? 
When  designed  within  the  context  of  evidence  obtained  from  human  populations,  animal 
models  are  able  to  test  specific  hypotheses  whilst  overcoming  the  major  limitations  of 
epidemiology study designs. Animal models have been absolutely essential in demonstrating 
the biological plausibility of the associations observed in human populations, providing proof 
of principle to the theory of DOHaD. Use of a C57BL/6 mouse model in this thesis gave 
control over confounding factors, and allows the measurement of invasive end points and the 
characterisation  of  downstream  events  across  the  full  life  span  and  into  subsequent 
generations. Its physical and biochemical phenotype greatly resembled human disease. It can 
thus be anticipated that this model will be helpful in providing new answers to a number of 
unresolved questions in this field. The homogeneous genetic background, rapid breeding, short 
growth phase, and short life-span of this mouse model accelerate the acquisition of knowledge 
that may take longer time to accumulate in the human disease situation. The use of C57BL6 
has exhibited circulating lipid profiles end points similar to those of human subjects.  
 
Literature demonstrates consistent evidence of moderate hyperglycemia, hyperinsulenemia and 
hypercholesterolemia  in  response  to  HF  feeding.
12  These  outcomes  are  associated  with 
increased number and size of adipocytes,
13-14 decreased skeletal muscle insulin sensitivity
15 
and  hepatic  steatosis
16  all  key  components  of  the  metabolic  syndrome.  It  was  therefore 
possible to induce a metabolic phenotype in my experimental model similar to that observed in 
the human subject, despite not exhibiting progression to an atherosclerotic state. Furthermore, 
the  model  permits  a  detailed  study  on  body  composition  and  tissue  characteristics  at  the 
histological,  histochemical,  and  molecular  levels—information  that  cannot  be  obtained  in  
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humans  for  ethical  and  technical  reasons.  Finally,  the  mouse  will  serve  as  a  useful  null 
hypothesis for future studies (discussed in chapter-8) on the impact of genes in a global or 
tissue-specific manner for physiological studies in the background of DOHaD.  
 
When comparing the outcomes of interventions such as statins during development in this 
model and when extrapolating conclusions to man, it is important to remember that the timing 
and trajectory of developmental processes differs between species. A particular limitation of 
the  mouse  model  is  that  they  are  generally  altrical  species  and  are  therefore  relatively 
immature at birth in comparison at with man and large animal models (e.g. sheep and pig). 
Mice are born with a poorly developed central nervous system and autocrine system and the 
development of organs implicated in the induction of disease (kidney and liver) continues into 
postnatal life. The periods of vulnerability of the developing systems therefore differ between 
species and therefore interventions directed at the same stage of gestation cannot be considered 
comparable. For example, nephrogensis is complete by 32-34 weeks of gestation in man and 
by 130 days of gestation in sheep. In contrast, nephrogenesis in the mice continues into the 
postnatal  period.  It  is  therefore  important  that  the  mechanisms  of  impact  of  interventions 
during  early  life  are  discussed  in  the  context  of  their  timing  in  relation  to  developmental 
processes rather than stage of gestation per se (discussed in chapter-2).  
 
The purified HF dietary pattern observed with my experimental diet more closely reflects that 
of the ‗non prudent‘ diet of human subjects
658-660 and avoids the very high intakes of specific 
and potentially biological active fatty acids {i.e. n-6 fatty acid, linoleic acid (LA), n-3 fatty 
acids, linolenic acid (LNA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)} 
that are observed in other models of HF feeding. It may be therefore be a useful tool for 
modelling the effects of non-prudent diets in human subjects. We now know through reported 
epidemiological and clinical studies that the n-6 fatty acid, LA, n-3 fatty acids, LNA, EPA and 
DHA  collectively  protect  against  CAD.  Such  fatty  acids  regulates  LDL-C  metabolism  by 
downregulating LDL-C production and enhancing its clearance in the blood. Further, these are 
critical factors determining the hyperlipemic effects of other dietary fat components, such as  
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saturated  and  trans-fatty  acids,  as  well  as  cholesterol  [discussed  in  Ref-660].  The  distinct 
functions of these two families make the balance between dietary n-6 and n-3 fatty acids an 
important consideration influencing cardiovascular health
661.  
 
7.3  Do the findings answer predictive adaptive response theory? 
The findings of the thesis demonstrate that a maternal HF diet alters plasma lipid levels, SBP 
and cause alterations in the activity levels in the offspring. The novel observation not only 
emphasizes the development of characteristics similar to the human metabolic syndrome in 
adult  mice,  the  programming  effects  of  maternal  diet,  but  further  provides  a  plausible 
explanation with regards to the developmental programming of CVD.  
 
We  now  know  that  fetus  constantly  ‗interprets‘  the  environment  created  by  the  maternal 
milieu.  Some  fetal  responses  are  homeostatic  or  immediately  adaptive;  others  reflect 
developmental  disruption  but  might  have  echoes  throughout  life  (e.g.  reduced  nephron 
numbers).  Still  others  have  little  immediate  adaptive  value,  but  confer  advantage  by 
establishing metabolic physiology appropriate for the postnatal environment predicted to exist 
(Figure 7.1)  
 
 
Gluckman & Hanson
95 explain in this figure the nature of the PAR that is determined by the 
predicted and actual postnatal environment. As explained earlier, the fetus sets a range of 
homeostatic settings appropriate for postnatal life according to the information it receives in 
utero. The postnatal range associated with health is narrowed if the fetal environment has been 
unbalanced simply because the plastic responses made during development may later act to 
limit the range of postnatal adaptive responses. The findings of the thesis support this concept 
in male offspring where the elevation of BP was less pronounced in the HF-HF group than in 
HF-C or C-HF groups. This supports the partially beneficial cardiovascular effect of reducing  
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Figure-7.1: Adopted from Gluckman & Hanson with permission. 
95 
 
 
the dietary mismatch in the HF/HF offspring. Khan et al
247 reported the same, but in his study 
(1) the dams were only fed the HF diet during pregnancy and weaning, and (2) endothelial 
dysfunction rather than elevated BP was observed to be attenuated when compared with the C 
fed offspring. These data are broadly in support of the PAR concept.
247-248,251 However, as 
outlined in the original exposition of the concept such an effect only operates within a range of 
postnatal environments, beyond which the risk of pathophysiology is increased. The upper 
limit of the postnatal nutritional environment tolerated without risk of CVD depends on the 
fetal prediction and this in turn depends on maternal physiology. As certain features of the  
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metabolic syndrome are acquired
 by mice offspring whose mothers consume a HF diet either
 in 
utero  and/or  during  suckling,  this  study  demonstrates  a  broad
  window  of  developmental 
susceptibility to dietary imbalance
 of a kind prevalent both among populations of developed 
countries
 and developing countries undergoing rapid economic
 transition. The data suggest that 
PAR
 occurs in utero to protect against a subsequent "dietary challenge"
 in the postnatal period.  
 
 
In
 addition, the results demonstrated that offspring of both sexes at weaning from HF dams and 
on HF diet (HF/HF) were heavier than those from C
 dams and on C diet (C/C). This greater 
weight was associated with hypercholesterolemia and hyperinsulinemia. Moreover, the relative 
accumulation of fat in hepatocytes reflects an early sign of the adverse effects of diets
 rich in 
saturated fatty acids.
661 Another
 example has been recently illustrated
 in Sprague-Dawley rats, 
with regards to hypertension, where it was not prevented in offspring raised on similar HF diet 
to their mothers.
 247-248, 251In agreement with the present study
 female offspring in this thesis 
are the most affected, which may indicate
 a similarity of underlying mechanism between these 
studies. 
247-248, 251 
 
 
7.4 Does the sex of the offspring need to be considered?  
The  thesis  demonstrates  subtle  offspring  gender  differences  in  food  intake,  BP  and  CRP 
levels.    Sex  differences  are  now  well  established  and  reports  have  suggested  female  sex 
hormones,
247,250,662-663 (estradiol exposure and
 somatosensory stimuli) partly associated with 
the sex difference.
662-664 However, the cardiovascular protective role of oestrogen discussed in 
literature still remains controversial. Peng et al
665 reported that young female spontaneously 
hypertensive rats (SHR) are relatively
 well protected from NaCl-sensitive hypertension, but 
depletion
  of  both  endogenous  and  dietary  estrogens  greatly  exacerbates
  NaCl-sensitive 
hypertension. The study tested the hypothesis
 that oestrogen also protected late middle-aged  
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female  SHR  from
  NaCl-sensitive  hypertension  and  that  this  effect  was  mediated
  by  an 
oestrogen-related effect on hypothalamic norepinephrine
 release.  
 
So far, no data has investigated the oestrogen response towards hypertension in females on HF 
diet. In the thesis hypertension and increased CRP levels in females were observed to be 
positively correlated with hypercholesterolemia. This relation could indirectly be deduced for 
the effect of HF diet on female hormones in downregaulating their protective effect on CVD; 
though the mechanism requires further studies (Figure 7.2).  
 
 
 
Figure 7.2: The plot shows the linear regression analysis in female HF/HF offspring. The solid line illustrates the 
level dependent increase in total cholesterol to increase in systolic blood pressure in 28 weeks old offspring. 
Similarly the dotted line demonstrates the rises in cholesterol levels positively correlate to increase in C-reactive 
protein values in same offspring (n=8). *p<0.001  
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Emerging studies have reported that HF offspring birth weight correlates with
665 both maternal 
weight gain and a high intake of HF
666 and is suggested to reflect abnormal fetal oestrogenic 
environment.
667 The daughters of women who suffered from pregnancy-induced hypertension 
(pre-eclampsia/eclampsia) have a 5-fold reduction with lower circulating oestrogen and PUFA 
levels.
668-669 These data, if extrapolated to humans, may explain the link among diet and CVD.  
 
7.5 Was tail-cuff method appropriate for BP measurement? 
The  suitability  of  any  research  methodology  is  largely  dependent  on  the  investigative 
objective. Thus, a particular technique for measuring BP may be well suited for one type of 
study but less useful for another. Accordingly, the advantages and disadvantages of various 
BP measurement
 methods with the goal of providing specific answers depend on the study 
objective.
 For example, if the primary objective is to determine whether
 a drug protects against 
atherosclerosis  or  cardiovascular
  damage  independent  of  any  effects  on  BP,  then  the 
investigator
 should use a monitoring technique that provides a comprehensive
 measure of the 
total BP load on the vasculature. For this kind
 of study objective, techniques that provide only 
sporadic measurements
 of BP would be less useful or even potentially misleading no
 matter 
how accurate those measurements might be.
  
 
Techniques for measuring BP in experimental animals can be divided
 into indirect method (tail 
cuff) and direct method (radiotelemetry). Most methods for measuring
 BP can be applied in a 
range of animals, although certain technical
 modifications may be required depending on the 
species  undergoing
  study.  In  most  cases,
  the  choice  of  method  should  be  driven  by  the 
investigative objective
 rather than the species of animal being studied. It should be
 emphasized 
that regardless of the method used for measuring
 BP, systemic anaesthesia should be avoided 
whenever feasible
 because of the well-documented effects of anaesthetics on cardiovascular
 
function.
670 It has long been recognized that commonly used anaesthetics
 can affect multiple   
 
      197 
 
 
aspects of circulatory system and that
 integrative cardiovascular responses often differ greatly 
in
 anaesthetized versus conscious animals.
670 
 
In animals, the most commonly used indirect method for monitoring
 BP is the cuff technique 
in which BP is measured in a tail or
 limb by determining the cuff pressure at which changes in 
blood
 flow occur during occlusion or release of the cuff. A variety
 of methods have been used 
for sensing the point at which some
 type of change in blood flow occurs during manipulation 
of cuff
 occlusion pressure, including, ut not limited to, photoelectric
 sensors, oscillometric 
sensors, doppler sensors, chamber volume
 sensors and acoustic sensors. Several improvements 
in sensor
 technology have occurred, but regardless of the type of sensor  used, all of these 
methods share certain advantages and disadvantages
 that should be carefully considered when 
deciding whether to
 use an indirect technique in a particular study.
  
 
Tail cuff method has served a valuable role in experimental
 hypertension research for many 
years and continues to be useful
 in certain kinds of study designs. This method used
 in the 
thesis shares some of the same advantages and
 disadvantages in blood pressure measurement. 
Tail cuff method has 4 main advantages
389,670,671: (1)
 It is noninvasive and does not require 
surgery; (2) it can be used to obtain repeated measurements of SBP in conscious
 animals 
during  studies  of  short  or  long  duration;  (3)  It  requires  less  expensive  equipment  than 
radiotelemetry
 and can also be less expensive to operate; and (4) it can
 be used to screen for 
systolic hypertension or substantial differences
 in SBP among large numbers of animals. Thus, 
I  preferred  this  method  to
  noninvasively  detect  or  confirm  the  presence  of  frank  systolic
 
hypertension, substantial differences in SBP between
 groups and substantial changes in SBP 
over time, particularly
 when dealing with large numbers of mice.  
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Although tail cuff method is clearly suitable for measuring
 BP for the thesis protocol, it has 3 
main disadvantages
; (1) it only measures BP in a very small sample
 of cardiac cycles and 
hence is incapable of assessing the average level of BP throughout
 the day and night over the 
course of a study. This
 problem limits the value of this method, regardless
 of how accurate this 
method is thought to be in measuring
 SBP during an individual cardiac cycle. Therefore to 
overcome this problem the BP measurements in this thesis were performed during only a very 
brief portion of the
 day. Although cuff devices for ambulatory BP monitoring
 are increasingly 
being used to indirectly measure BP over many
 cardiac cycles in humans, such approaches 
have not proven to
 be practical for measuring BP in animals.
 (2) Despite the noninvasive 
nature of indirect methods and
 well-intended efforts by investigators to train and acclimatize
 
animals to undergo the procedures, these methods impose significant
 stress though less then 
telemetry that disturbs multiple aspects of the cardiovascular
 system. The notion that one can 
truly acclimatize rodents to
 indirect tail-cuff procedures and effectively minimize the impact
 of 
the  procedural  stress  on  cardiovascular  and  endocrine  function
  is  doubtful.
672-674  Tail-cuff 
measurements of BP in rodents
 impose substantial amounts of thermal and restraint stress that
 
are known to affect BP, heart rate, and stress hormones.
672-675 In fact, acute restraint has been 
shown to lead to acute BP
 increases and activation of vascular wall mitogen-activated
 protein 
(MAP)  kinases  comparable  to  those  observed  after  acute
  infusions  of  angiotensin  II  or 
phenylephrine.
676 Moreover, the
 assumption that different experimental groups within a given
 
study would be expected to demonstrate similar quantitative
 responses to restraint stress may 
also not be valid.
677-679 Thermal stress is caused by increased body temperature required
 to 
dilate  the  tail  artery  and  allow  sufficient  blood  flow  into
  the  tail.  When  the  animals  are 
confined to the restraining cages,
 substantial increases in body temperature occur even without
 
intentional warming of the animal.
675 Tail-cuff measurements are
 also commonly performed 
during the day, which disrupts rodent
 sleep cycles.
 Therefore I trained/ conditioned the animals
 
for  5  to  14  days  before  commencing  tail-cuff  measurements,  yet  some
  investigators  have 
demonstrated that even 10 days of conditioning
 can fail to prevent the large changes in BP and 
heart rate induced
 by restraint stress.
672 (3) Several
 studies have been published purporting to 
validate cuff methods
 based on correlations between indirect cuff measurements of
 BP and 
direct  measurements  of  BP  simultaneously  or  subsequently
  obtained  with  arterial 
catheters.
388,675,680-684 Most such
 validation studies have relied on simple correlation/regression
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analyses that can be misleading and obscure large individual
 differences or even systematic 
differences between measurement
 methods.
685 When more appropriate analytical techniques 
have
 been used, such as agreement analysis, BP measurements obtained
 by indirect methods 
have  shown  poor  agreement  with  BP  measurements
  simultaneously  obtained  by  direct 
methods.
684,686 In some cases,
 tail-cuff measurements of systolic BP have appeared suspect
 
because they have shown large differences with direct measurements
 of systolic pressure
684 or 
because  they  have  shown  minimal  differences
  with  direct  measurements  of  mean  arterial 
pressures.
389 
 
As noted by Reddy et al, another major limitation of most tail-cuff
 methods is that they are not 
well suited to measuring diastolic
 pressure.
684 Diastolic BPs measured with a custom-made 
instrument
 incorporating a pulsed Doppler tail-flow sensor have been reported
 to show good 
agreement with directly measured diastolic pressures
684;
 however, this method requires the use 
of anaesthesia, which has
 obvious drawbacks in cardiovascular research. Based on a validation
 
protocol for evaluating automated sphygmomanometers that was
 developed by the Association 
for  the  Advancement  of  Medical
  Instrumentation,  Jamieson  et  al  compared  systolic  and 
diastolic
 BP results obtained with a commonly used tail-cuff instrument
 to those obtained by 
direct  arterial  recordings.
687  For  both
  systolic  and  diastolic  pressure  measurements,  the 
disagreement
  between  the  indirect  and  direct  methods  exceeded  clinically
  acceptable 
standards, and 74% of diastolic pressures showed
 disagreements >5 mm Hg.
687 Finally, even if 
an indirect method
 can be shown to provide an accurate measurement of BP during
 a particular 
moment in time, this does not validate the method
 for assessing an animal‘s true average BP or 
for detecting
 the extent to which BP exceeds certain thresholds during the
 course of a study.
  
 
Given  the  major  limitations  of  indirect  BP  measurement  methods
  and  particularly  their 
inability  to  determine  true  average  BP
  or  the  frequency  of  large  BP  fluctuations,  these 
techniques
 are not recommended for studies intended to quantify the relationship
 between BP  
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and other variables (eg, vascular damage, atherosclerosis, etc). This was not the case in my 
experiments.   
 
7.6 Maternal hypercholesterolemia and obesity programs disease risk  
The findings of the thesis provide evidence of metabolic imprinting of the progeny born to 
dams fed a long-term HF diet, that are overtly obese, hypercholesterolemic and hypertensive. 
The results also suggest that some of the effects of the HF diet in such offspring are adaptive 
in nature (discussed in section 7.3). This is in agreement with published literature.
118,688-693 
Long-term  HF  diet  induced  hypercholesterolemia  and  hypertension  prenatal  and  during 
pregnancy  in  dams  and  led  to  postnatal  hypertension  even  the  offspring  was  fed  C  diet. 
Lowering maternal cholesterol with statin reduced offspring cholesterol, LDL- cholesterol, 
CRP and hypertension. Studies have suggested that maternal treatment with a statin during 
pregnancy reduce atherogenic programming in mice.
254,288,435 The first indication that in utero 
exposure to cholesterol may program adult CVD came from the observation that maternal 
hypercholesterolemia, even if temporary and limited to pregnancy only, is associated with a 
marked increase in fatty streaks in the aorta of premature human fetuses.
278 The same study 
also showed that fetal cholesterol levels at the end of the second trimester were very high, 
even in fetuses of normocholesterolemic mothers, and declined linearly until term. This is 
consistent with the well-documented fact that in the absence of inherited genetic defects of 
lipid  metabolism  such  as  familial  hypercholesterolemia,  cholesterol  levels  of  term-born 
children  are  very  low,  even  if  their  mothers  are  hypercholesterolemic.  It  is  therefore 
conceivable  that  fetal  lesions  might  regress  towards  full  term.  Instead,  the  Fate  of  Early 
Lesions in Children (FELIC) study, a morphometric assessment of aortic atherosclerosis in 
normocholesterolemic children who died before the age of 14, demonstrated that maternal 
hypercholesterolemia was associated with greater atherogenesis throughout childhood
547. This 
observation could not be explained by conventional risk factors in mothers or children and 
suggested programming by maternal hypercholesterolemia.   
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7.7  HF diet plays a role in developmental programming of hepatic and renal 
metabolism  
An  understanding  of  the  mechanisms  contributing  to  disease  progression  from  hepatic 
steatosis to NAFLD is crucial in developing strategies to prevent chronic irreversible liver 
disease. Exposure to a HF diet in the developmental period could be an important factor that 
influences  the  offspring‘s  susceptibility  to  the  development  of  NAFLD  later  in  life  (see 
Chapter-3).  The work suggested that 27 week old offspring of dams fed a HF diet that were 
also fed a HF diet post-weaning (HF/HF), were predisposed to develop hepatic steatosis, a 
phenotype  similar  to  humans.  This  also  demonstrates  (1)  exposure  to  a  HF  diet  during 
development  and  post-weaning  is  worse  than  HF  exposure  post-weaning  alone  and  (2) 
maternal HF diet can lead to development of hepatic steatosis later in life, even if a C diet has 
been  adopted  in  the  adult  environment.  Further  studies  are  required  to  investigate  the 
underlying mechanisms that may lead to this developmental priming.  However it is plausible 
to speculate that this HF nutrition during the developmental period may alter the epigenetic 
profile  in  key  metabolic  genes,  subsequently  leading  to  persistent  modulations  in  gene 
transcription, and increases the risk of developing hepatic disorder in adulthood.
136 Our data 
indicates that exposure to a maternal HF diet primes an increased susceptibility to hepatic 
steatosis and inflammation in adult offspring.  
 
These  findings  highlight  a  public
  health  problem  which  coincides  with  the  obesity  and 
metabolic syndrome.
694-697 Reports
 of paediatric fatty liver disease and steatohepatitis in obese
 
children  have  been  increasing
698-700  and  include  cases  of
  cirrhosis
701-704  requiring  liver 
transplantation.
705 It is alarming to note that the prevalence of fatty liver in
 obese children in 
China, Italy, Japan, and the US
 stands between 10% and 77%.
706-710According to the ‗double-
hit‘  hypothesis,
439-440  HF  diet  leads  to  hepatocellular  lipid  accumulation  as  the  ‗first  hit‘, 
followed by a ‗second hit‘ in which proinflammatory mediators and reactive oxygen species  
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(ROS)  induced  inflammation,  hepatocellular  injury,  and  fibrosis.
711  While  this  is  a  useful 
conceptual  framework  with  knowledge  expanding  on  the  role  of  macrophages,  immune 
tolerance  and  lipid  homeostasis  (Figure-7.3
711),  our  understanding  of  the  cellular  and 
molecular mechanisms with regard to DOHaD phenomenon in  defining NAFLD and thereby 
guiding therapeutic approaches remains insufficient.   
 
 
Figure-7.3: Scheme for dysfunctional activation of Kupffer cells in NAFLD. Pattern recognition receptors of 
Kupffer cells such as TLR4 may be increasingly exposed to exogenous and endogenous danger signals (e.g., 
LPS, excess fatty acids, modified lipoproteins) via the portal circulation, enhanced by lack of hepatocellular 
clearance. Pattern recognition pathways may intensify due to altered sorting and signalling, impaired inhibitory 
circuits, or amplification of redox-sensitive signalling loops. Adipokine imbalance may contribute to these events 
including low adiponectin levels that fail to suppress intracellular ROS generation. Fat-laden hepatocytes may 
compromise sinusoid microcirculation leading to entrapment of inflammatory cells. Finally, steatosis may shift 
away  Kupffer  cells  from  alternative  activation.  Solid  lines,    pro-inflammatory  effects;  dotted  lines,  anti-
inflammatory mechanisms. Malfunction at one or more steps may promote ‗second hit‘ responses, while cellular 
targeting of these checkpoints has the potential for identifying novel treatment strategies in NAFLD.
711 
 
Moreover the findings in chapter-5 suggested that HF diet, fed for as little as 24 weeks in 
offspring from HF dams, could cause an increase in renal lipid accumulation in the glomerular  
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and  tubulointerstitial  cells  (Figure  5.5a).  It  is  noteworthy  that  relation  to  infer  causality 
between the maternal HF diet and risk for chronic kidney disease or microalbuminuria or 
glomerular filtration rates in offspring were not performed here. Yet the results of the thesis 
have important clinical and public health implications with regard to metabolic syndrome in 
the West.
712  
 
7.8 CRP and HF diet consumption 
Growing literature has
 drawn attention at CRP being an important predictor
 of subsequent risk 
of CVD, type-2 diabetes,
713 metabolic syndrome
714 and mortality.
715 Considerable insights into 
the  dynamics  of  disease  in  developmental  origins  of  CVD/  metabolic  disorder 
pathophysiology could be gained by investigating CRP levels in dams and their offspring. The 
present results demonstrate in HF dams at 52 weeks of age (1) reduction of serum CRP levels 
and  (2)  reduced  number  of  bone  marrow  derived  EPC.  Sex  specific  response  to  CRP  is 
observed i.e. in HF/HF female offspring CRP levels are raised and in HF/HF males CRP 
levels remain normal. Spearman‘s correlation coefficients between CRP and variables such as 
total cholesterol,  LDL and HDL show significant positive correlation (P<0.0001) between 
CRP and total cholesterol, LDL and a significant negative correlation with HDL (P<0.0001; 
Table 7.1). 
Table  7.1:  Spearman  rank  correlations  between  CRP  and  different  variables  in  female 
offspring. 
Variable  CRP  P 
Total cholesterol  0.19  <0.0001 
LDL  0.29  <0.0001 
HDL  -0.13  <0.0001  
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It  is  speculated  that  raised  CRP  in  offspring  may  lead  to  a  more  systemic  inflammatory 
reaction encompassing a wide range of organ systems, including hepatic production of CRP 
and  accumulation  of  fat  in  the  hepatocytes.
716-718  However,  little  is  known  about  this 
underlying mechanism and future
 studies are required to further test this hypothesis. 
 
7.9 Bone Marrow derived EPCs and increase CRP levels in offspring 
 
Given the importance of bone marrow derived EPC to postnatal vascular endothelial biology, 
the current work demonstrate that HF prenatal and postnatal diet and raised CRP exert direct 
effects  to  inhibit  EPC  expression  and  numbers  in  the  circulation.  Accumulating  evidence 
suggests that circulating CRP is one of the significant
 predictors of atherogenesis and vascular 
death in CVD pathology.
302,307,308, 309,348,442,350,719-724 CRP
 down-regulates eNOS
 transcription 
and destabilizes eNOS mRNA, which decreases both
 basal and stimulated NO release.
308 In 
addition,  CRP  stimulates  endothelin  release,  upregulate  adhesion  molecules  and  stimulate 
monocyte
  chemotactic  protein.  It  facilitate  macrophage  LDL  uptake,
350  EC  apoptosis
  and 
inhibit angiogenesis with upregulation  of NF-κB, a key nuclear factor for transcription
  of 
numerous proatherosclerotic genes.
725-726 It is hypothesized that the effects of maternal HF diet 
observed on offspring EPCs in the present work may involve this mechanistic interaction. 
  
 
7.10 Effects of maternal statin treatment on offspring phenotype 
The  present  work  demonstrates  that  statin  treatment  of  hypercholesterolemic  dams  during 
pregnancy  and  lactation  reduces  obesity,  hypertension  and  sedentary  behaviour  in  their 
offspring when fed on a similar diet. This effect is more permanent when the dams are given 
long-term statin from the time they were weaned.  Moreover, the novel effects
 of statin on  
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EPC numbers and on CRP levels in adult offspring in preventing the risk of later CVD is 
observed. It is plausible that statin specifically alters the expression of enhanced NO secretion 
by ECs  and suppresses  NF-κB  activity, outcomes  that may have favoured the developing 
offspring. Statins in dams appear to have a generalized
 antihypertensive effect by attenuating 
endothelial dysfunction
 and increasing NO production, inhibiting thrombin-induced endothelin
 
synthesis, and interfering with leukocyte-EC interactions. 
508-510,516,522,526,537,592-594 The
 results 
also suggest that part of the beneficial
 cardiovascular effects observed after treatment with 
statins
  may  be  due  to  the  favourable  effect  on  EPCs.  The  present  study  has  clinical 
implications  regarding  the  usefulness  of  statin  therapy  in  repairing  vascular  injury  by 
circulating  EPCs.  Our  findings  revealed  a  new  mechanism  of  statin  therapy  in  vascular 
disorders  involving  circulating  vascular  progenitor  cells.  Determination  of  the  relationship 
between EPC and timing of any stem cell intervention may contribute to establishment of 
vascular repair and atherosclerosis as new targets of treatment. 
 
A limitation to the present study is that the in vivo
 effects of CRP and statins on EPC number 
and vasculogenic
 function are not determined; however, such studies are the future work to 
elucidate  such  mechanisms.  The  present  data  add  to  the  growing  body
  of  evidence  that 
proposes the pleiotropic vasculoprotective
 effects of statins and their ability to increase
 EPC 
population  and  counteracting
  the  deleterious  effects  of  CRP.  To  summarise  the  possible 
mechanisms by which cholesterol lowering in dams by statins affects the offspring phenotype 
and protect it from future CVD is illustrated in Figure 7.4.  
 
 
7.11 Conclusions 
 
Considering that
 a typical Western diet is rich in dietary fat content,
 especially saturated fats, 
this thesis investigated
 the role of HF feeding in the concept of developmental
 origins of CVD  
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and  metabolic  syndrome.  These  studies  in  an  animal  model  indicate
  that  maternal  HF 
consumption during the life course can induce
 features of metabolic syndrome/ CVD including 
HMG-Co-A
EPC
Circulating EPC
Tissue EPC
EC
CD34 +/ AC133+/
KDR +/CD14+
TNF-α IL-6
-ve
-ve
CRP
Mevalonate Cholesterol
Reductase Enzyme
Liver
 
 
Figure 7.4: Hypercholesterolaemia plays a crucial role in the development of atherosclerotic diseases in general 
and CVD in particular. Statin, converts HMG-CoA to mevalonate. Inhibition of HMG-CoA reductase by statins 
decreases intracellular cholesterol biosynthesis, which then leads to transcriptionally upregulated production of 
microsomal  HMG-CoA  reductase  and  cell  surface  LDL  receptors.  This  resets  intracellular  cholesterol 
homeostasis in extrahepatic tissues. The liver is the target organ for the statins, since it is the major site of 
cholesterol  biosynthesis,  lipoprotein  production  and  LDL  catabolism,  inhibits  CRP  metabolism  and  exerts  a 
healthy effect on the bone marrow derived endothelial progenitor cells in the circulation. The beneficial effects of 
statin in offspring from HF dams on long term treatment may depend in part upon the degree to which statin act 
on extrahepatic tissues. (Adapted from references
508-510,516,522,526,537,592-594) 
 
obesity,  hypercholesterolemia,  hypertension,  increased  inflammation  and  decreased  bone 
marrow derived EPC numbers in offspring in their own adult life. The data, however, indicate 
the involvement
 of gender-associated mechanisms behind programming of dyslipidemia. The 
study design allowed investigating whether programming
 effects of the maternal diet could be   
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reversed by interventions in dams or with postnatal diet. The offspring obtained from HF 
mothers  continued  on  C  diet  postweaning  (HF/C)
  failed  to  show  a  phenotypic  benefit  as 
compared to
 C/C offspring. However, use of statin in dams reversed
 the programming effects 
of  the  maternal  HF  feeding  no  matter  what  diet  offspring  had  postnatally.
  Feeding  a  HF 
maternal diet caused a reduction in bone marrow derived endothelial progenitor cells, whereas 
given statins to mother positively affected EPC numbers and expression in adult offspring. 
Overall, it is observed that the relative risk of developing CVD and metabolic syndrome in 
dams on HF diet intake increased significantly (RR 1.47; 95% CI 1.11–1.96; p< 0.01) than 
their counterparts on C diet. This risk significantly reduced if dams on HF diet were given 
statins  (RR  1.63;  95%  CI  1.07–2.49;  p<  0.02).  The  novel  observations  in  the  offspring 
obtained from mothers fed
 HF diet, not only emphasize the programming effects of maternal
 
diet, but can further provide plausible mechanisms behind the
 developmental programming of 
CVD in the context of over-nutritional HF environment, presently encountered by developed 
and developing populations.  
 
On the basis of the presented work and the other large body of animal studies so far quoted in 
the  thesis,  it  is  clear  that  maternal  HF/  hypercholesterolemic  environment  could  exert  a 
programming effect on the fetus and increase its risk of metabolic syndrome and CVD. The 
situation is analogous to the description by Norbert Freinkel in a diabetic pregnancy discussed 
earlier in chapter-3. Therefore on the basis of the results, I would like to propose the term 
―Hypercholesterolemic-mediated Teratogenesis‖ for my animal model based work to describe 
these phenomena observed in my thesis. This is illustrated in Figure 7.5.  
 
7.12 Implications of this thesis to current population situation 
The  findings  of  the  thesis  that  HF  diet  mediates  hypercholesterolemia  in  young  female 
mammals may indicate a similar phenomenon in humans, a possible significant factor in the 
escalating epidemic of CVD/ metabolic syndrome. In a female, such a situation exposes her  
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fetus to multiple adverse programming influences, resulting in a complex phenotype including 
exaggerated tendency to develop  adiposity, obesity, hypertension, hypercholesterlomia and 
hyperinsulinemia at a young age.  
 
Figure  7.5:  The  hypothesized  “Hypercholesterolemic-mediated  Teratogenesis”  model  originating  from  this 
thesis. This model demonstrates on one extreme (right side) the risk of adult disease and on the other extreme 
(left side) range of postnatal physiological settings for survival fitness. At the x-axis (bottom) five different 
quality of prenatal environments from very poor to very rich are presented. The red line curve represents the 
environment that the fetus anticipates postnatally judged from the nutritional and related signals it receives from 
the mother through the placenta. Provided that the postnatal environment matches the range for which the fetus 
has  set  its  postnatal  physiology  by  the  processes  of  predictive  adaptive  responses,  the  disease  risk  is  low. 
However, when it lies outside that range then the postnatal environment turns bad (indicated by the red arrow) 
and the disease risk increases. The fetus perceives the more restricted environment and predicts a poorer postnatal 
survival.  But  maternal  high-fat  dietary  stress  worsens  the  situation.  Overnutritional  high  fat  environment 
prenatally and postnatally shifts the postnantal survival associated with increased disease risk further to the upper 
limit  (represented  with  curved  black  line).  Maternal  high  fat  diet  causes  hypercholesterolemic  mediated 
teratogenesis  with  deranged  lipid  profile,  increased  oxidative  stress  and  decreased  activity  of  endothelial 
progenitor  cells  in  the  circulation  of  the  offspring.  This  even  further  potentiates  the  CVD  risk  with  early 
manifestation of cardiovascular disease/ metabolic syndrome in its own adult life. From an adequate nutritional 
environment, the offspring then lies outside the band of rich and very rich environment that can be detrimental to 
its survival fitness. However, administration of statin to mothers on high fat diet, even at rich nutritional upper 
limit, can provide a good safeguard from the disease process and maintains the survival fitness even if increasing 
affluence raises the richness of the mature postnatal environment.    
 
      209 
 
 
Fueled by urbanization and the advent of the global economy, these changes in eating patterns 
are the most rapid and dramatic in the course of human history. Radical dietary shifts in many 
developed and developing nations are supplanting traditional patterns of eating with Western 
diet high in animal products and refined carbohydrates and low in whole grains, fruits, and 
vegetables. For example, in China, consumption of animal products increased by nearly 40% 
between 1989 and 1997 
727 and HF food sales more than doubled between 1999 and 2005.
727 
The term "Coca-colonization," a reference to the ubiquitous presence of Coca-Cola, Pepsi, and 
McDonald‘s, describes a world that is moving toward a common diet, one accompanied by the 
more sedentary lifestyles associated with increased risk of chronic disease.
728-729 
 
According to the World Health Organization‘s global database, countries like China, India and 
Pakistan has a preschool childhood obesity prevalence of about 1%. 
730 Childhood obesity 
increases the risk of obesity in adulthood and parental obesity interacts quite strongly to alter 
this risk.  There are several other interactive factors as well contributing to the increased 
prevalence of obesity in childhood. Societies like China, India and Pakistan, which are rapidly 
urbanising, demonstrate increases in energy intake, dramatic increases in fat intake along with 
increased  levels  of  sedentarianism.  Food  balance  data  from  the  Food  and  Agriculture 
Organization (FAO) show that the change in energy intake in Asian countries has been small, 
but there have been large changes in consumption of animal products, sugars and fats.
731 The 
net effect has been a marked shift in the diet with energy from fat (both animal and vegetable) 
increasing each year.
731 Data from India show that higher-income groups consumed a diet with 
32% of the energy from fat while the lower-income groups consumed only 17% energy from 
fat. 
732-735 
 
Therefore, nutritional history of current populations becomes an important determinant of their 
health. There is a growing recognition of the importance of environmental factors acting on  
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the genotype throughout the life cycle of an individual to progressively modify its phenotype. 
The periconceptional and intrauterine period seem to be the most crucial, when a small change  
 
in environment could have a large effect on the phenotype. . The slogan of the UN Expert 
Meeting  held  in  April  2008,  ―Woman's  Health  is  a  Nation's  Wealth‖  reflects  this 
philosophy.
736  
 
The basic principle of prevention of cardiovascular/metabolic syndrome events consists of the 
control of classical risk factors with specific interventions. This clinical approach has led to an 
improvement in prognosis, although still far below expectations. In other words, the mere 
control  of  hypertension,  hypercholesterolaemia,  or  obesity,  although  definitely  beneficial, 
leaves  a  residual  risk,  which  is  still  greater  than  that  reduced  by  treatment.  Thus,  it  is 
necessary to identify windows of time in the lifecycle when the susceptibility of the genome to 
such an influence is very high for different treatment targets, which could more successfully 
impact  on  CVD.  Any  preventive  intervention  will  therefore  have  to  start  in  utero,  and 
improving the health of young girls will be a very important aspect of such an approach.   
  
 
Today, we have to recognize that it may be still too early to test this hypothesis in the clinical 
setting, yet the animal model in the present work has established cause-effect relationships for 
some maternal factors and led to the identification of specific questions in a HF maternal 
environment. Further mechanistic studies, both in animals and in humans, are needed in order 
to achieve a better understanding of the role of maternal hf diet in the pathophysiology of 
CVD,  metabolic  syndrome  and  atherosclerosis.  Further  methods  that  allow  a  better 
characterization  of  the  vascular  milieu  in  humans  are  necessary.  Only  a  more  in-depth 
knowledge  of  these  important  pathophysiological  mechanisms  can  allow  identifying  and  
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testing  a  therapeutic  strategy  aimed  at  targetting  the  early  developmental  origins  of 
cardiovascular disease in the populations. 
 
 
 
 
 
 
 
The story of the Eagle always fascinates me. It has the longest life span of 70 years but to 
reach it takes hard decisions in life. Many a times, in order to survive the next step even in life 
one has to also start a change process. Only then one can take advantage of the present! 
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CHAPTER-8 
Future Work 
 
In  the  thesis,  we  have  learnt  about  the  effects  of  longterm  maternal  HF  diet  and  statin 
treatment  on  the  offspring  predisposition  to  early  cardiovascular  and  metabolic  disease. 
However, much of our understanding of the disorder is far from complete. Future research 
originating  from  present  work  could  focus  to  translate  unexplored  involved  signalling 
pathways in answering the central question- how such maternal HF diets affect the longterm 
cardiovascular health of offspring. I therefore, propose some mechanistic studies (currently 
ongoing or to be initiated) along the following lines: 
 
8.1. Effects of maternal HF diet on Genes Involved in Offspring Cardiac 
Development 
Throughout  fetal  development,  the  main  nutritional  source  for  the  fetus  comes  from  the 
mother. As a result, the quality of the maternal diet affects growth and development of the 
fetus  during  this  period, 
88,89,112,135,158,737  though  the  mechanisms  involved  are  poorly 
understood.  Nevertheless,  experimental  animal  models  whereby  the  maternal  diet  is 
manipulated  have  provided  insight  into  the  links  between  in-utero  environments  and 
susceptibility to disease in later life. Rodent offspring from dams that were fed a protein-
restricted diet during pregnancy later developed hypertension in adulthood.
377,433 However, 
developmental programming of CVD in adulthood is not limited to maternal dietary restriction 
alone. Ours and other groups have shown that feeding dams a HF diet during pregnancy and/or 
lactation  can  also  lead  to  the  offspring  developing  vascular  dysfunction  and  
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hypertension
247,248,251,435  and that changes in the maternal diet during pregnancy are linked 
with an increase in cardiomyocytes and fetal left ventricular mass.
738 Cardiomyocytes go  
 
through terminal differentiation at or after birth and this is characterised by the transition from 
hyperplastic growth to hypertrophic growth.
739-741 Many genes are reported to be involved in 
cell cycle progression and are associated with cardiac hypertrophy.
742 It remains however to be 
determined whether the hypercholesterolemic condition during pregnancy leads to any long 
term changes in these genes in the adult offspring heart; and whether the cholesterol-lowering 
effect of pravastatin given to pregnant dams consuming a HF diet influence the expression of 
these genes. In these settings particular pathways are of prime importance to explore.  
 
8.1.1 Cyclin dependent pathways 
Particular molecules involved in various stages of the cell cycle determine the progression of 
the normal cell cycle to assist with cell replication. Cyclins and cyclin dependent kinases 
(CDK) are a group of catalytic kinases that play a critical role in formation, activation and 
inactivation of the progression of cell from a quiescent state, G1 phase into the cycle.
743 Cyclin 
G1, one of the G1 phase cyclins, is up-regulated in nutrient restricted fetal heart and has been 
found to be involved with cardiac hypertrophy in adults. This gene is shown to encourage 
entry into the cell cycle therefore increasing cell numbers. Protein synthesis is initiated by 
cyclin G1 to cause cardiac hypertrophy, rather than DNA synthesis through entry into the cell 
cycle in an adult heart.
743 It seems that changes in this gene expression may be either a cardio-
protective  response  due  to  a  limited  nutrient  supply,  a  response  to  myocyte  stretch  from 
increased systemic vascular resistance or possibly a response to a changed endocrine situation. 
It may be interesting to find out how this gene behaves in a hypercholesterolemic state of 
mother and adult offspring as cyclin G1 is expressed in the only phase of the cell cycle that 
can be influenced by external stimuli; the G1 phase.
744 It is also advantageous to investigate 
the consequences of lowering maternal cholesterol with pravastatin on these HF-fed dams in  
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late  gestation  and  look  at  the  expression  level  of  cyclin  G1gene  involved  in  cell  cycle 
progression (Appendix-x Figures a & b).  
 
8.1.2 Brain natriuretic peptide 
Amongst the molecules which are considered vital in ventricular dysfunction, brain natriuretic 
peptide  (BNP)  is  an  important  marker  of  cardiac  function.  It  is  actually  an  indicator  of 
increased intra-cardiac pressure not taking into account whether the raised pressure is caused 
by LV systolic dysfunction, LV hypertrophy or valve disease.
745 However, BNP is secreted to 
a lesser degree in fetal life compared to adult life.
746 BNP is also thought to be a marker along 
with a modulator of cardiac hypertrophy
746-747 with a significantly increased expression of 
BNP in cardiac hypertrophy and cardiac stress. However, it remains to be determined whether 
BNP levels are affected by maternal HF diet and whether lowering maternal cholesterol with 
pravastatin on these HF-fed dams in late gestation plays a role in ventricular remodelling 
(BNP expression) in the offspring left ventricle (Appendix-x Figure-c).  
 
8.1.3 Small proline-rich repeat protein 1A 
Small proline-rich repeat protein 1A (SPRR 1A) is known to be a stress inducible cardio-
protective protein in cardiomyocytes responding to either ischemic or biochemical stress.
748 
Histological results discovered that SPRR1A induction after mechanical stress from pressure 
overload was  restricted  to  myocytes that surrounded necrotic lesions.  In post-infarcted rat 
hearts,  a  similar  expression  pattern  was  found.  In  vitro  and  in  vivo  over-expression  of 
SPRR1A protected cardiomyocytes from ischemic injury.
749 Therefore SPRR1A has a cardio-
protective effect against ischemic stress. A different role for SPRR1A may be its association 
with actin cytoskeleton. It has been reported that ectopic expression of SPRR1A may prevent 
disruption of myofibrils and accumulation of nuclear actin after ischemic stress.
750 It is further 
suggested that the cytoprotective action of SPRR1A may be due to mechanical stabilisation of 
myofilament/Z disc structure in cardiomyocytes, therefore preventing cells from permanent  
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damage.  However, the role of SPRR1A as a marker of cardiac stress in this experimental 
model still remains to be investigated. Moreover, it warrants investigations whether treating 
maternal  cholesterol  with  pravastatin  has  any  effect  on  the  SPRR  1A  expression  in  the 
offspring left ventricle (Appendix-x Figure-d).  
 
8.2 Effects of maternal HF on offspring bone structures 
Epidemiological studies suggest that skeletal growth is programmed during intrauterine and 
early postnatal life. It may be interesting to find out in this model, how hypercholesterolemic 
state of mother plays a role in the development of optimal peak bone mass, in fetus. Using the 
model,  femur  samples  were  taken  at  30  weeks  of  age  and  bone  structure,  adiposity  and 
strength analysed. Sample sizes were four to six for each sex and each diet group.  The results 
demonstrated that offspring from HF-fed dams showed increased adiposity in the femur in 
comparison to offspring from C-fed dams. Female offspring from HF dams exhibited altered 
trabecular structure indicative of in utero programming. This concludes that maternal HF diet 
during pregnancy increases bone marrow adiposity and alters bone structure in their offspring 
(For further readings see Appendix-xi). 
 
 
8.3 Mechanistic Studies 
8.3.1 Placental role in transplacental cholesterol transport 
The  CVD  programming  effect  of  maternal  hypercholesterolemia  and  the  observation  of 
strikingly high fetal cholesterol levels at the end of 2
nd trimester raise interest in maternal–fetal 
cholesterol transport. It is speculated that maternal cholesterol might cross the placental barrier 
such  as  in  Smith  Lemli  Opitz  syndrome  where  survival  of  fetus  depends  on  maternal 
cholesterol.
751  Identification  of  active  transport  mechanisms  on  the  maternal  side  of  the 
placenta in rabbits
752 and hamsters
753 has provided evidence for maternal–fetal cholesterol  
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transport. Transplacental cholesterol transport mechanism mediated by endothelial cells lining 
of the placental villi into the lumen of  fetal microvessels  has  recently  been elucidated.
754 
Results  indicate  that  regulation  of  these  mechanisms  by  increased  fetal  demand  for 
cholesterol,  differs  from  that  induced  by  maternal  hypercholesterolemia.
755  Increased 
cholesterol  transport,  at  least  during  parts  of  gestation,  may  therefore  constitute  one 
mechanism  by  which  maternal  hypercholesterolemia  affects  fetal  programming  and  hence 
requires further investigations.  
 
8.3.2 Maternal hypercholesterolemia and oxidative stress 
It is reported that hypercholesterolemia is associated with enhanced lipid peroxidation levels 
in fetal plasma and aortic lesions.
278,279,288,293,295 The first indication that increased oxidative 
stress plays a role in CVD programming is provided by a study in premature human fetuses 
that showed intracranial arteries with higher activities of antioxidant enzymes developed less 
atherosclerosis  in  response  to  maternal  hypercholesterolemia  than  extracranial  arteries.
278 
Given  that,  OxLDL  enhances  adult  atherogenesis  by  a  number  of  mechanisms,  including 
interference with many oxidation-sensitive nuclear signalling pathways,  it is plausible that 
oxidative  stress  is  an  important  element  in  the  developmental  programming  induced  by 
maternal HF nutrition. Hence the mechanism whereby maternal HF diet intake plays a role in 
inducing oxidative stress  mediated phenotypic  changes  in  the vasculature of the offspring 
requires further research in preventing atherogenic programming.  
 
8.3.2 Maternal HF diet and Epigenetic changesin the development 
Epigenetic changes associated with increased disease susceptibility such as obesity, type-2 
diabetes  and  cardiovascular  dysfunction  are  emerging  as  critical  components  of  enduring 
effects induced by early life experiences.  The available data are now beginning to provide a 
molecular basis for involvement of oxidative stress in modifying biological properties of DNA 
methylation and other epigenetic effects.
756 It is reported that in utero conditions result in  
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specific  epigenetic  change.
757-758  Developing  organisms  seem  to  have  a  wide  window  of 
susceptibility to epigenetic changes but the periconceptional period is particularly important 
towards  sensitivity  to  suboptimal  nutrition  during  this  developmental  stage  in  which 
widespread reprogramming of the epigenome occurs.
15,87,88,91-93,95,136-138,142 It is speculated that 
HF over-nutrition in pregnancy and/or postnatal could also lead to metabolic dysfunction in 
major organs such as kidneys and liver later in life.
150,208,211,215,222-226 These epigenetic changes 
within suboptimal nutrition can have long-lasting effects on epigenomic methylation patterns 
in  specific  gene  promoters.  Moroever,  the  study  of  epigenetics  will  further  guide  us  in 
understanding the hormonal regulation of enzymes controlling acetylation and methylation 
and sex differences across the epigenome. Therefore, the animal model used in this thesis will 
be  ideal  to  demonstrate  (1)  adverse  effects  of  impaired  early-life  maternal  HF  nutrition 
associated  epigenetic  changes  in  offspring  and  (2)  the  mechanisms/  impact  of  early 
interventions  such  as  statins  in  mothers  on  HF  diet  for  prevention  or  reversal  of  such 
epigenetic consequences during intrauterine development. 
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Appendices 
 
 
Appendix i: Ehrlich’s tissue histology protocol 
 
1.  Haematoxylin 
Haematoxylin          16 g 
Industrial methylated spirit       240 ml 
Potassium or ammonium alum    48 g 
Distilled water         240 ml 
Glycerol           240 ml 
Glacial acetic acid        24 ml 
Haematoxylin is dissolved in the alcohol with the aid of gentle heat (560C oven or water 
bath). The alum is then dissolved in the distilled water by using heat (hot plate) and whilst 
warm glycerol is added. Allow to cool. Alcoholic haematoxylin solution is added in small 
volumes  to  the  alum  glycerol  solution,  mixing  well.  Acetc  acid  is  added  and  mixed.The 
container is plugged with cotton wool and allowed to oxidise by exposure to light; this will 
take at least 6 weeks but ripening may be allowed to continue indefinitely beyond the period. 
Filter prior to use. Immediate oxidation may be achieved by adding 0.1 g of sodium iodate / 
100 ml of solution. Then mixing and allowing standing for at least 1 hour before use. 
 
2.  Eosin 
Eosin Yellowish        5 g 
Calcium chloride        5g 
Tap water          500 ml  
Added eosin and calcium chloride to the water, mixed thoroughly and filtered; the stain is 
ready for use immediately.  
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3.  1% Acid Alcohol 
Alcohol (IMS)         700 ml 
Distilled water         300 ml 
Concentrated hydrochloric acid    10 ml 
Alcohol is added to the water and mixed thoroughly, then hydrochloric acid is added and 
mixed again 
 
4.  Staining Method 
1.  Dewax sections in xylene, hydrate through graded alcohols to water 
2.  Stain in Ehrlich‘s Haematoxylin for 20 minutes 
3.  Wash in running tap water for 5 minutes 
4.  Differentiate in 1% acid alcohol for 5 seconds 
5.  ―Blue‖ in running tap water for 5 minutes 
6.  Stain in eosin for 5 minutes 
7.  Rinse briefly in water 
8.  Dehydrate through alcohols, clear in xylene and mount in DPX 
 
5.  Results 
Nuclei—Blue/ Black 
Cytoplasm—varying shades of pink 
Muscle fibres—deep pink red 
Red blood cells, eosinophils—orange red 
Fibrin--- deep red  
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Appendix  ii:  Reagents  and  materials  used  to  culture  and  stain 
bone marrow derived mononuclear cells 
1.  Fresh mononuclear cells derived from mice  
2.  D-MEM/F-12, Dulbecco‘s modified eagle medium. Nutrient Mixture F-12 (Ham) 1:1 
with glutamine + pyridoxine HCl without herpes buffer (Does not matter if it is with phenol 
red  or  not)  [Invitrogen  Corporation  GIBCO].  The  constitution  is  in  500  ml  of  bottle  add 
antibiotics (5mls), L-glutamine (5mls) and 5mls of fetal bovine serum (FBS). Turn upside 
down and save it in 2-80C. ▲Critical: Once prepared can stay in the fridge.  
3.  HANKS Buffered saline without phenol red. 
4.  Lymphoprep ™ (cat no: 1031966) is a ready made sterile and endotoxin tested solution 
for the isolation of pure lymphocuyte suspensions. The solution contains sodium diatrizoate 
(9.1%  w/v)  and  polysaccharide  (5.7%  w/v)  [AXIS-SHIELD  PoC  AS  Norway]  ▲Critical: 
Lymphoprep ™should be stored at room temperature. 
5.  Phosphate buffer solution (PBS) from Sigma 
6.  Lab-Tek ™ II Chamber slide ™ system (cat.no 154534) NUNC, UK. 
7.  Haemocytometer  
8.  Dil-Ac-LDL  catalogue  No:  BT-902,  concentration:  200  ug/L;  Lot  No:  9020506; 
Absorbance ratio= 5.6 ▲Critical: Dil-Ac-LDL is stable 3 months when kept sterile at 4oC. 
Never Freeze. 
9.   Lectin  from  Ulex  europaeus  (Sigma,  Cat.  No  L9006)  FITC  conjugate,  lyophilised 
powder, potency of <5 ug/mL agglutination activity. Storage temp. –20oC. 
10.  Citiflour  
11.  Kroeings wax (Pfaltz & Bauer, Wterbury, CT 06708. Cat No C25974) 
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Appendix-iii:   Pharmacokinetic properties of different statins (modified from references
70, 113-114) 
  Atorvastatin  Cerivastatin  Fluvastatin  Lovastatin  Pravastatin  Simvastatin  Rosuvastatin  Pitavastatin 
Optimal  timing  of 
dosing 
Anytime  of 
day 
Evening  Bedtime  With  meals 
morning  and 
evening 
Any  time  of 
day 
Evening  Anytime  of 
day 
na 
Bioavailability (%)  12  60  24  5  18  5  20  Nearly 80 
Solubility  Lipophilic  lipophilic  lipophilic  lipophilic  hydrophilic  lipophilic  hydrophilic  lipophilic 
Effect of food  Bioavailability  No effect  Bioavailability  Bioavailability  Bioavailability  No effect  No effect  na 
Protein binding (%)  98  >99  >98  >95  Nearly 50  95-98  90  96 
Active metabolites  √  √  x  √  x  √  minor  minor 
Elimination  of  half 
life (h) 
14  2.5  1.2  3  1.8  2  19  11 
CYP450  metabolism 
& isoenzyme 
√3A4  √3A4,2C8  √2C9  √3A4  X  √3A4  limited  limited 
Renal excretion  <5  30  6  10  20  13  10  na 
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Appendix iv: 
 
Mass spectrometry 
Mass spectrometry is performed using a Quattro LC™ tandem quadrupole mass spectrometer 
(Micromass, Manchester, UK) equipped with an ESI source. The capillary voltage is 4.0 kV, 
and the voltages of extractor and RF lens are 3.0 and 0.8 V, respectively. The entrance and 
exit energies of the collision cell are set at 15.0 V. The cone voltage is operated at an optimal 
value for each analyte in positive-ion mode. Nitrogen is used as the drying and nebulizing gas 
at flow rates of 500 and 70 l/h, respectively. The source and desolvation temperatures are 
optimized under LC–MS–MS operation, and were kept at 100 and 350 °C, respectively. 
During method development, individual standard solutions are infused through a syringe pump 
(Harvard Apparatus, Holliston, MA, USA) at a flow-rate of 10 μl/min into the mass analyzer. 
Following the selection of precursor ions by the first quadrupole mass analyzer, collision-
induced dissociation (CID) is carried out using 2.0ￗ10−3 mbar UHP argon (Praxair Products, 
Peterborough,  ON,  Canada)  in  the  hexapole  collision  cell.  Product  ion  mass  spectra  are 
obtained at a series of collision energies so as to characterize each compound‘s fragmentation 
behavior. When LC is used for analyte separation prior to tandem spectrometry, the mass 
spectrometer is operated in selected reaction monitoring (SRM) mode with 1.3 of low mass 
resolution  (LM  Res) and high mass resolution (HM  Res) on both  of the first  and second 
analyzers. A dwell time of 200 ms per ion pair is used, and the inter-channel delay was 10 ms. 
Liquid chromatography 
Analytes  are separated  using a Waters  2695 liquid  chromatograph (Waters,  Milford, MA, 
USA) with a Genesis C18 column (2.1ￗ50 mm, 3 μm) (Jones Chromatography, Hengoed, 
UK). The mobile phase solvents are acetonitrile and water, respectively, containing 2 mM 
methylamine with 0.1% acetate acid. The mobile phase gradient is started at 60% of A, which 
is increased linearly to 100% within 3 min and held for 2 min. The flow-rate of the mobile 
phase is 0.2 ml/min and the injection volume was 20 μl. 
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Appendix vii: 
Long-term  statin  treatment  in  hypercholesterolemic  pregnant 
mice reduces cardiovascular and metabolic risk in their offspring 
also fed a high fat diet post-weaning.  
M.M.Elahi1, F.Cagampang1, S.K.Ohri2, M.A.Hanson1 
1.Institute  of  Developmental  Sciences,  Developmental  Origins  of  Health  and  Disease 
Division, & 2.Wessex Cardiothoracic Centre, University of Southampton School of Medicine, 
Southampton General Hospital, Mailpoint 887, Southampton SO16 6YD, UK 
 
Introduction:  We  have  shown  that  long-term  maternal  high-fat  (HF)  feeding  during 
pregnancy and lactation predisposes offspring to hypertension, raised plasma lipids and fatty 
liver in mice1. Recently, we have also demonstrated that pharmacological intervention with 
statin  in  late  pregnancy  in  HF  fed  dams  reduces  cardiovascular  (CV)  and  metabolic  risk 
factors  in  their  offspring2.  In  this  study,  we  examined  the  effects  of  long-term  statin 
administration to HF-fed female mice on these risk factors when their offspring were also fed 
a  HF  diet.  Methods:  Pregnant  C57  mice  on  HF  diet  (45%  kcal  fat)  were  given  the 
3hydroxy3methylglutaryl-coenzyme A reductase inhibitor pravastatin in their drinking water 
(5 mg/kg of body weight per day) from the time they were weaned until weaning of their 
offspring.  Weaned  offspring  were  then  fed  the  HF  diet  until  adulthood  generating 
dam/offspring  dietary  groups  HF/HF  and  HF+S/HF.  These  groups  were  compared  with 
offspring  from  dams  fed  standard  chow  (C)  which  were  fed  chow  diet  post-weaning  to 
adulthood (C/C). All data were expressed as mean ± SEM. One way ANOVA followed by 
post-hoc  test  was  used.  Significance  was  assumed  if  the  P  value  was  <0.05.  Animal 
procedures  were  in  accordance  with  the  UK  Animals  (Scientific  Procedures)  Act  1986. 
Results:  HF+S  dams  showed  significantly  reduced  total  cholesterol  concentrations  and 
systolic blood pressure vs. HF dams (P<0.001). The HF+S/HF offspring were significantly 
lighter, with lower systolic blood pressure and serum cholesterol concentrations vs. HF/HF 
(P<0.001).  HF/HF offspring also had elevated C-reactive protein (CRP) levels and these were 
reduced in the HF+S/HF animals to levels found in the C/C group (P<0.001). Conclusions: 
Long-term pravastatin administration to dams  not  only protects  them from  the deleterious 
effects of a HF diet but also protects their offspring from CV and metabolic risk factors in 
later life, even if these offspring consume a HF diet.  
1.  M.M Elahi et al., Br J Nutr., 10:1-6, 2009. 
2.  M.M.Elahi et al., Hypertension., 51:939-44, 2008 
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Poster  presentation  (P-9A-387)  at  the  6th  World  Congress  on  Developmental  Origins  of 
Health and Disease, 19-22 November 2009, Santiago, Chile. J  Develop  Origins  Health & 
Disease, 2009; 1: 289. 
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Appendix viii: 
 
Statin  treatment  in  female  mice  has  sex  specific  effects  on 
cardiovascular risk factors and circulating endothelial progenitor 
cells in their offspring. 
Maqsood M Elahi,1 Felino R Cagampang,1 Dhia Mukhtar,1 Sunil K Ohri,2 Mark A Hanson.1 
1.  Institute  of  Developmental  Sciences,  Developmental  Origins  of  Health  and  Disease 
Division,  University  of  Southampton  School  of  Medicine,  Southampton  General  Hospital, 
Southampton,  United  Kingdom;  2.  Wessex  Cardiothoracic  Centre,  General  Hospital, 
Southampton, United Kingdom. 
Objectives: Recently we reported that, in dams consuming a high-fat high-cholesterol diet, 
statin administration during the 2nd half of pregnancy and lactation reduces cardiovascular 
risk factors in their offspring.  We have now examined the effects of statin administration to 
female  mice  from  the  time  they  were  weaned  until  weaning  of  their  offspring  on 
cardiovascular risk factors in their offspring. Materials and Methods: Virgin C57BL/6 mice 
(n=8/group) were fed either a high fat-high cholesterol diet (HF; fat-45% kcal) or standard 
chow (C; fat-21% kcal) from weaning through their pregnancy and lactation. Each group was 
given the HMG-Co-A reductase inhibitor pravastatin (S) in the drinking water (5 mg/kg body 
weight per day) throughout this period to create HF+S and C+S dam groups. Offspring from 
each group were fed HF or C diets from weaning to adulthood, generating dam/offspring 
dietary groups HF+S/HF, HF+S/C, C+S/HF and C+S/C. Body weight, blood pressure, serum 
lipid profile were measured in offspring at 27 weeks of age, and bone marrow cells were 
cultured  and  expression  of  marrow-derived  circulating  endothelial  progenitor  cells  (EPC) 
markers were assessed. Results: Compared with C+S/HF, HF+S/HF female offspring had 
lower  total  and  low-density  lipoprotein  cholesterol  concentrations,  were  less  obese  and 
hypertensive, and showed increased EPC expressing colony numbers (P<0.001). However, in 
male offspring the attenuation of EPCs and the increased cardiovascular risk factors brought 
about by prenatal or postnatal exposure to the HF diet was not blunted by prenatal statin 
therapy. Conclusion: Our results demonstrated  that statin administration in early life to dams 
fed a HF diet produce gender specific effects, which can influence responses of the offspring 
to the pre- or post-weaning HF diet.  
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Poster  Presentation  at  the  Society  for  Gynaecologic  Investigation  56th  Annual  Scientific 
Meeting, Reproductive Biology Session, 17-21 March, 2009. Reproductive Sciences, 2009; 
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High  Fat  High  Cholesterol  Diet  Consumption  in  Pregnancy 
attenuates  Bone  Marrow-derived  Circulating  Endothelial 
Progenitor  Cells  and  Increases  the  Risk  of  Cardiovascular 
Disorders in the Offspring. 
   Elahi M
1, Mukhtar D
1, Cagampang F
1, Ohri S
2, Hanson M
1 
Institute of Developmental Sciences, Developmental Origins of Health & Disease Division, 
Southampton  General  Hospital,  Mailpoint  887,  Southampton,  SO16  6YD  UK1;  Wessex 
Cardiothoracic Centre, General Hospital, Southampton, SO16 0YD, UK2. 
Abstract: 
Aims: We have previously shown that statin therapy in hypercholesterolemic dams during 
pregnancy and lactation alleviates the risk of adverse metabolic and cardiovascular disorders 
in  their  offspring.  Here  we  examine  C-reactive  protein  (CRP)  levels  and  expression  of 
endothelial  progenitor  cells  (EPCs)  in  bone  marrow  cultures  from  these  offspring.  Study 
Design & Subjects: Virgin C57BL/6 mice strain were fed either a high fat diet (HF; fat-45% 
kcal) or standard chow (C; fat-21% kcal) from weaning through to pregnancy and lactation. 
Half of the pregnant mothers in each group were given the Pravastatin (5mg/kg/day) in their 
drinking water from the second half of pregnancy through to lactation. Female offspring from 
each group were then weaned onto either HF or C diets to adulthood. Outcome Measures: 
Body weight, blood pressure, plasma lipid profile and serum CRP were measured in offspring 
at 27 weeks, bone marrow cells were cultured and expression of EPC markers was assessed. 
Results: Compared to offspring from C dams female offspring from hypercholesterolemic 
dams  had  significantly  (P<0.001)  elevated  CRP  and  fewer  EPC  expressing  colonies  in 
cultured bone marrow cells. Statin therapy in HF mothers resulted in their offspring having 
significantly  lower  CRP  and  increased  EPC  expressing  colonies  (P<0.001).  Conclusions: 
These  findings  suggest  that  EPC  expressing  cells  and  CRP  may  be  involved  in  the 
mechanisms  whereby  statin  therapy  to  hypercholesterolemic  dams  during  pregnancy  and 
lactation reduces the risk of adverse metabolic and cardiovascular function in their offspring. 
This work is supported by BUPA , HOPE Charity & BHF (UK) 
Oral presentation at the 5th International Congress on Developmental Origins of Health & 
Disease Perth, Western Australia. 6-9 November 2007. Early Human Development, 2007; 83: 
5-6, S74  
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Appendix x: Results 
 
a. Heart weight in adult male and female offspring  
The heart weights, expressed as % body weight, in the HF/HF females were heavier compared with 
C/C  group  (p<0.05).  Maternal  pravastatin  treatment  during  pregnancy  and  lactation  resulted  in 
reduction in heart weights in HF+S/HF female offspring (p<0.001 respectively vs HF/HF) to levels 
similar to the C/C group. There was no effect of prenatal and post weaning exposure to the HF diet and 
of maternal statin treatment on heart weight male offspring.  
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Figure-a: Heart weight, expressed as percent of body weight, in female and male adult offspring from HF-fed 
dams with or without pravastatin treatment during pregnancy and lactation (HF+S and HF, respectively) and fed 
post weaning a HF diet to adulthood (producing dam/offspring dietary groups HF+S/HF and HF/HF). The groups 
were compared to offspring from dams fed standard chow and fed post weaning the same chow diet (C/C). 
Values are expressed as meanSEM.  
 
b. Levels of mRNA expression for cyclin G1 in the adult offspring left ventricle  
Left ventricular (LV) mRNA levels for cyclin G1 were lower in HF/HF offspring vs C/C groups 
(p<0.05  for  both  sexes).  Maternal  statin  treatment  during  pregnancy  and  lactation  prevented  the 
reduction in cyclin G1 mRNA levels in HF+S/HF offspring compared to those found in the HF/HF 
group. 
  
 
      329 
 
 
 
 
 
 
 
Figure b. Levels of mRNA expression for cyclin G1 in the left ventricles of female and male adult offspring 
from  HF-fed  dams  with  or  without  pravastatin  treatment  during  pregnancy  and  lactation  (HF+S  and  HF, 
respectively) and fed post weaning a HF diet to adulthood (producing dam/offspring dietary groups HF+S/HF 
and HF/HF). The groups were compared to offspring from dams fed standard chow and fed post weaning the 
same chow diet (C/C). Values are expressed as meanSEM. 
c. Levels mRNA expression for BNP in the adult offspring left ventricle 
BNP mRNA levels in the LV (Figure 11) of female offspring remained unchanged following 
maternal and post weaning exposure to the HF diet, and following maternal statin treatment. In 
male offspring however, LV BNP levels were lower (p<0.05) in the HF/HF group vs C/C. 
Maternal statin treatment did not significantly change BNP gene expression in the HF+S/HF 
offspring compared with HF/HF group.   
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Figure c. Levels of expression for BNP in the left ventricles of female and male adult offspring from HF-fed 
dams with or without pravastatin treatment during pregnancy and lactation (HF+S and HF, respectively) and fed 
post weaning a HF diet to adulthood (producing dam/offspring dietary groups HF+S/HF and HF/HF). The groups 
were compared to offspring from dams fed standard chow and fed post weaning the same chow diet (C/C). 
Values are expressed as meanSEM. 
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d. Levels mRNA expression for SPRR 1A in the adult female offspring left ventricle 
SPRR 1A mRNA levels in the LV (Figure 12) were found to be similar in all groups. 
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Figure d. Levels of expression for SPRR 1A in the left ventricles of female adult offspring from HF-fed dams 
with or without pravastatin treatment during pregnancy and lactation (HF+S and HF, respectively) and fed post 
weaning a HF diet to adulthood (producing dam/offspring dietary groups HF+S/HF and HF/HF). The groups 
were compared to offspring from dams fed standard chow and fed post weaning the same chow diet (C/C). 
Values are expressed as meanSEM.  
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